

PCT/IB 04 / 04 239
(20.12.04)

PA 1223484

REC'D 20 DEC 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 14, 2004

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**


APPLICATION NUMBER: 60/533,761

FILING DATE: December 31, 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**




H. L. Jackson

H. L. JACKSON

Certifying Officer

15866 U.S. PTO
123103

Please type a plus sign (+) inside this box → 

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Stephen Sung Yong		Cho		Saline, MI United States	
Tracy Fay		Gregory		Parma, MI United States	
Peter R.		Guzzo		Niskayuna, NY United States	
<input checked="" type="checkbox"/> Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
N-SUBSTITUTED PIPERDINE AND PIPERAZINE DERIVATIVES					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number		<div></div>		<div>Place Customer Number Bar Code Label here</div>	
OR Type Customer Number here					
<input checked="" type="checkbox"/> Firm or Individual Name		Karen DeBenedictis			
Address		Warner-Lambert Company			
Address		2800 Plymouth Road			
City		Ann Arbor	State	Michigan	ZIP 48105
Country		U.S.A.	Telephone	734 622 3374	Fax 734 622 1553
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		<u>194</u>		<input type="checkbox"/> CD(s), Number <div></div>	
<input type="checkbox"/> Drawing(s) Number of Sheets		<div></div>		<input checked="" type="checkbox"/> Other (specify) <div>33 claims on 22 pages; Abstract on 1 page</div>	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		<u>23-0455</u>		<div>\$160.00</div>	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted
SIGNATURE Karen DeBenedictis
TYPED or PRINTED NAME Karen DeBenedictis
TELEPHONE 734 622 3374

Date 12/31/03
REGISTRATION NO. 32,977
(if appropriate)
Docket Number: PC25828

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

EXPRESS MAIL NO: EF220716648US
DOCKET NO. PC25858

15866 U.S. PTO
60533761
123103

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (8-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number	PC25828	Type a plus sign (+) inside this box →	+
---------------	---------	---	---

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Harry Ralph	Howard, Jr.	Bristol, CT United States
Sham Shridhar	Nikam	Ann Arbor, MI United States
Matthew D.	Surman	Albany, NY United States
Michael Anthony	Walters	Novi, MI United States

Number _____ of _____

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

EXPRESS MAIL NO: EF220716648US
DOCKET NO. PC25858

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Steven Cho, et al.

Docket No.

PC25828

Serial No.

Filing Date

Examiner

Group Art

Invention:

N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES

I hereby certify that this Provisional Application for Patent under 37 CFR 1.53(c)
(Identify type of correspondence)


Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

on

12/31/03
(Date)

KAREN DEBENEDICTIS

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

EF220716648US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing

EXPRESS MAIL NO: EF220716648US
DOCKET NO. PC25858

**EXOCYCLIC N-SUBSTITUTED HETEROCYCLIC ANALOGS FOR
THE TREATMENT OF SCHIZOPHRENIA**

BACKGROUND OF THE INVENTION

5 This invention relates to N-substituted piperidine and piperazine derivatives, pharmaceutical compositions containing them and their use for the treatment of schizophrenia and other central nervous system (CNS) disorders.

10 The N-substituted piperidine and piperazine derivatives of this invention exhibit activity as antagonists of dopamine D2 receptors and of serotonin 2A (5HT2A) receptors.


15 Other heterocyclic piperazine derivatives that are useful for the treatment of schizophrenia are referred to in United States patent 5,350,747, which issued on September 27, 1994, and in United States patent 6,127,357, which issued on October 3, 2000. These patents are incorporated herein by reference in their entirety.

20 Other piperazine and piperidine derivatives that have been stated to be useful as antipsychotic agents are those referred to in PCT patent publication WO 93/04684, which published on March 18, 1993, and European patent application EP 402644A, which was published on December 19, 1990. These patent applications are incorporated herein by reference in their entirety.

**EXPRESS MAIL NO: EF220716648US
DOCKET NO. PC25858**

SUMMARY OF THE INVENTION

The present invention relates to compounds of the formula 1



5 wherein U is sulfur, oxygen, SO, SO₂, CH₂ or NR³;

V is nitrogen or carbon;

Z is nitrogen or carbon;

A is -(CH₂)_mCH₂-; -(CH₂)_mO-; -(CH₂)_mNR⁴-; or -(CH₂)_mC(R⁵R⁶)-
 10 wherein R⁵ and R⁶ can independently be (C₁-C₄) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₄) alkoxy optionally substituted with from one to three fluorine atoms, hydroxy, aminoalkyl or R⁵ and R⁶ can together form a carbonyl, and wherein m is an integer from one to four;

R¹ and R² are independently selected from hydrogen, (C₁-C₄) alkyl
 15 optionally substituted with from one to three fluorine atoms, (C₁-C₄) alkoxy optionally substituted with from one to three fluorine atoms, halogen, nitro, cyano, amino, (C₁-C₄) alkylamino and di-(C₁-C₄) alkylamino;

R³ and R⁴ are independently selected from hydrogen, (C₁-C₄) alkyl
 20 optionally substituted with from one to three fluorine atoms or (C₁-C₄) alkoxy optionally substituted with from one to three fluorine atoms;

or, when U is NR³, one of R¹ and R² can form, together with the carbon to which it is attached, and together with R³ and the nitrogen to which it is attached, a heterocyclic ring containing from 4 to 7 ring members of which from 1 to 3 ring members can be heteroatoms selected
 25 from nitrogen, oxygen and sulfur, and of which the remaining ring

members are carbon, with the proviso that when R^3 forms a ring with one of R^1 and R^2 , the other of R^1 and R^2 is absent.

X is $(CH_2)_m$ wherein m is an integer from zero to three, with the proviso that when W is absent, m must be greater than or equal to 2;

5 W is $(CH_2)_p$ wherein p is an integer from zero to three, with the proviso that when X is absent, p is greater than or equal to 2;

R^7 and R^8 are selected, independently, from halo (e.g., chloro, fluoro, bromo or iodo), R^1 and $-OR^1$;

10 or R^7 , when attached to a carbon adjacent to one of the carbon atoms shared by both the phenyl ring to which R^7 is attached and the ring containing W, N and X forms, together with a carbon atom of X or a carbon atom of W, a saturated carbocyclic ring containing from three to six carbon atoms;

15 R^9 is selected from phenyl, phenoxy and phenylamino, wherein the phenyl moieties of said phenyl, phenoxy and phenylamino are optionally substituted with from 1-3 substituents independently selected from halo, (C_1-C_3) alkyl optionally substituted with from 1 to 3 fluorine atoms, (C_1-C_3) alkoxy optionally substituted with from 1 to 3 fluorine atoms, nitro, cyano, amino, and (C_1-C_3) alkylamino; or

20 R^9 is a pyrrolidine, piperidine or morpholine ring wherein the point of attachment to D, T or E is the ring nitrogen, and wherein said pyrrolidine, piperidine or morpholine ring can be optionally substituted with one or two substituents selected, independently, from methyl and amino; or

25 R^9 is (C_1-C_6) straight or branched alkyl or (C_3-C_6) cycloalkyl, wherein said straight, branched and cyclic alkyl moieties can be optionally substituted with from one to three halo atoms, (C_1-C_4) alkoxy optionally substituted with from one to three fluorine atoms; or

30 R^9 is halogen, nitro, cyano, amino, (C_1-C_4) alkylamino, di- (C_1-C_4) alkylamino or OR^1 , wherein the alkyl moieties of (C_1-C_4) alkylamino and di- (C_1-C_4) alkylamino can be optionally substituted with an amino group;

E is $-C(O)-$, $-S(O)-$ or $-SO_2-$;

T is $-C(O)-$, $-CO_2-$;

L is $-(CH_2)_n$ wherein n is an integer from 0-3;

D is $-(CH_2)_n$ wherein n is an integer from 1-3, or NR^{10} ;

R^{10} is hydrogen or straight or branched (C_1-C_3) alkyl;

and the pharmaceutically acceptable salts of such compounds.

5 Preferred compounds of the invention include compounds of the formula 1 wherein Z is nitrogen.

Other preferred compounds of the invention include compounds of the formula 1 wherein A is ethylene.

Other preferred compounds of the invention include compounds of the formula 1 wherein R^8 is chloro or methyl.

10 Other preferred compounds of the invention include compounds of the formula 1 wherein X is absent.

Other preferred compounds of the invention include compounds of the formula 1 wherein W is ethylene or propylene.

15 Other preferred compounds of the invention include compounds of the formula 1 wherein M is $C(O)R^9$ and R^9 is ($C_1 - C_4$)alkyl.

Other embodiments of this invention include compounds of the formula 1 wherein U is sulfur and V is nitrogen.

20 Other embodiments of this invention include compounds of the formula 1 wherein M is ER^9 , E is $-C(O)-$ and R^9 is optionally substituted phenyl or optionally substituted phenoxy.

Other embodiments of this invention include compounds of the formula 1 wherein M is TDR^9 , T is $-C(O)-$ and R^9 is optionally substituted phenyl or optionally substituted phenoxy.

25 Examples of specific preferred embodiments of this invention include the following compounds and their pharmaceutically acceptable salts:

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

30 1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

1-{7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;

1-{7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;

1-{6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

5 1-{7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;

1-{6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}-2-methyl-propan-1-one;

10 {7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-(4-fluoro-phenyl)-methanone;

1-{7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one;

{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-(4-fluoro-phenyl)-methanone;

15 {6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-(4-fluoro-phenyl)-methanone;

1-(7-{2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-ethanone;

20 1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-ethanone;

1-(7-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-ethanone;

25 1-(7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-propan-1-one;

1-(7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-2-methyl-propan-1-one;

30 {6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-(4-fluoro-phenyl)-methanone;

{6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-(4-fluoro-phenyl)-methanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-
isoindol-2-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-
isoindol-2-yl}-ethanone;

5 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-diethyl-
2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-
2,3-dihydro-indol-1-yl}-ethanone;

10 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-
2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-
3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

1-{6-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-
dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

15 1-{6-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-7-fluoro-
4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-
dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

20 1-{6-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-4,4-
dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{7-[2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-
2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-
trimethyl-1,2,3,4-tetrahydro-quinoline;

25 1-{7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-
1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone;

{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-
trimethyl-3,4-dihydro-2H-quinolin-1-yl}-cyclopropyl-methanone;

30 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-
4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-
4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-propan-1-one;

- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-(4-fluoro-phenyl)-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-(3-methoxy-phenyl)-ethanone;
- 5 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-thiophen-2-yl-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-phenoxy-propan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
10 2,3-dihydro-indol-1-yl}-(2,5-dimethyl-2H-pyrazol-3-yl)-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-butan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one;
- 15 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-m-tolyl-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-(4-chloro-phenoxy)-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
20 2,3-dihydro-indol-1-yl}-3-phenyl-propan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-(3,4-dimethoxy-phenyl)-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-(4-chloro-phenyl)-ethanone;
- 25 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-(4-methoxy-phenyl)-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indol-1-yl}-2-phenyl-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
30 2,3-dihydro-indol-1-yl}-2-(2,5-dimethoxy-phenyl)-ethanone;
- 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-
2,3-dihydro-indole-1-carboxylic acid phenyl ester;

- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-furan-2-yl-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one;
- 5 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-benzyloxy-ethanone;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-phenyl-methanone;
- 10 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-cyclopentyl-ethanone;
- 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline;
- 15 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;
- 20 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;
- 25 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-propan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-butan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one;
- 30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-pentan-1-one;

- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone;
- 5 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-cyclohexyl-methanone;
- 3-{4-[2-(6-Chloro-1-methanesulfonyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole;
- 1 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-ethanone;
- 10 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-propan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-butan-1-one;
- 15 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclopropyl-methanone;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-pentan-1-one;
- 20 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2,2-dimethyl-propan-1-one;
- 25 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclohexyl-methanone;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-phenyl-methanone;
- 30 {4-[2-(1-Methanesulfonyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

5 1-(6-Chloro-5-{2-[4-(5-methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(6-Chloro-5-{2-[4-(7-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

10 1-(6-Chloro-5-{2-[4-(7-methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperidin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

1-(6-Chloro-5-{2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

15 1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

20 1-(6-Chloro-5-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(6-Chloro-5-{2-[4-(5-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

25 1-(6-Chloro-5-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(6-Chloro-5-{2-[4-(7-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

30 1-{5-[2-(4-Benzo[b]thiophen-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

1-(6-Chloro-5-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(5-Methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3-dihydro-indol-1-yl)-ethanone;

5 1-(5-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(7-Methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3-dihydro-indol-1-yl)-ethanone;

10 1-(5-{2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-
indol-1-yl)-ethanone;

1-(5-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-
dihydro-indol-1-yl)-ethanone;

15 1-(5-{2-[4-(5-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-
dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-
dihydro-indol-1-yl)-ethanone;

20 1-(5-{2-[4-(7-Methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-
dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[b]thiophen-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-
indol-1-yl)-ethanone;

1-(5-{2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-
yl)-ethanone;

25 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-6-chloro-2,3-
dihydro-indol-1-yl)-2-pyrrolidin-1-yl)-ethanone;

3-(4-{2-[1-(4,5-Dihydro-oxazol-2-yl)-2,3-dihydro-1H-indol-5-yl]-ethyl}-
piperazin-1-yl)-benzo[d]isothiazole;

30 5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2,3-dihydro-
indole-1-carboxylic acid methylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2,3-dihydro-
indole-1-carboxylic acid ethylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid propylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid isopropylamide;

5 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid tert-butylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid cyclopentylamide;

10 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid phenylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid methylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid ethylamide;

15 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid propylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid isopropylamide;

20 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid tert-butylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid cyclopentylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid phenylamide;

25 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indole-1-carboxylic acid isopropylamide;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

30 1-(6-{2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-propan-1-one;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2,2-dimethyl-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-2-morpholin-4-yl-ethanone;

5 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-morpholin-4-yl-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-ethanone;

10 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-(3-dimethylamino-pyrrolidin-1-yl)-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-piperidin-1-yl-ethanone;

5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindole-2-carboxylic acid (4-fluoro-phenyl)-amide;

15 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-dimethylamino-ethanone;

{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-phenyl-methanone;

20 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-[(2-dimethylamino-ethyl)-methyl-amino]-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-diethylamino-ethanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

25 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-pyrrolidin-1-yl-ethanone;

30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-pyrrolidin-1-yl-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-diethylamino-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-3-diethylamino-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-2-dimethylamino-ethanone;

5 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-3-dimethylamino-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-2-morpholin-4-yl-ethanone;

10 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-3-morpholin-4-yl-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-2-piperidin-1-yl-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-3-piperidin-1-yl-propan-1-one;

15 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-4-fluoro-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl)-ethanone;

20 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl)-ethyl]-4-chloro-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl)-ethyl]-6-fluoro-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-6-fluoro-2,3-dihydro-indol-1-yl)-ethanone;

25 1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-4-chloro-2,3-dihydro-indol-1-yl)-ethanone;

1-(4-Fluoro-5-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl)-ethanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl)-ethanone;

{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-cyclopropyl-methanone;
1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-propan-1-one;
5 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-2,2-dimethyl-propan-1-one;
1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-pentan-1-one;
10 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-3-methyl-butan-1-one;
1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-2-methyl-propan-1-one;
1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-butan-1-one; and
15 {6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-phenyl-methanone.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof. Examples of "alkyl"
20 groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, iso- sec- and tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.

The term "alkoxy", as used herein, unless otherwise indicated, means "alkyl-O-", wherein "alkyl" is as defined above. Examples of
25 "alkoxy" groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy and pentoxy.

The term "alkenyl", as used herein, unless otherwise indicated, includes unsaturated hydrocarbon radicals having one or more double bonds connecting two carbon atoms, wherein said hydrocarbon radical
30 may have straight, branched or cyclic moieties or combinations thereof. Examples of "alkenyl" groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl.

The term "one or more substituents", as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites.

5 The terms "halo" and "halogen", as used herein, unless otherwise indicated, include, fluoro, chloro, bromo and iodo.

The term "treating", as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or preventing one or more symptoms of such condition or disorder.

10 The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.

The compounds of formula 1 and their pharmaceutically acceptable salts are also referred to herein, collectively, as the "novel compounds of this invention" and the "active compounds of this invention".

15 This invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 Compounds of formula 1 may contain chiral centers and therefore may exist in different enantiomeric and diastereomeric forms. This invention relates to all optical isomers and all stereoisomers of compounds of the formula 1, both as racemic mixtures and as individual enantiomers and diastereoisomers of such compounds, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined above that
25 contain or employ them, respectively. Individual isomers can be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the preparation of the final product or its intermediate. Individual enantiomers of the compounds of formula 1 may have advantages, as compared with the racemic mixtures of these
30 compounds, in the treatment of various disorders or conditions.

In so far as the compounds of formula 1 of this invention are basic compounds, they are all capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be

pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the base compound from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert to the free base compound by treatment with an alkaline reagent and thereafter convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bi-tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.

The present invention also includes isotopically labelled compounds, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as ^2H , ^3H , ^{13}C , ^{11}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labelled compounds of the present invention, for example those into which

radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of formula 1 of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

The compounds of formula 1 of this invention have useful pharmaceutical and medicinal properties.

This invention also relates to a method of treating a disorder or condition selected from the group consisting of single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic

disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising administering to a mammal in need of such treatment an amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

The compounds of formula 1 and their pharmaceutically acceptable salts are also referred to herein, collectively, as the "novel compounds of this invention" and the "active compounds of this invention".

This invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the

formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, 10 for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline 15 personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with 20 bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, 25 due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including 30

familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal in need of such treatment, including a human, comprising an amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

A more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from major depression, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthymia, cyclothymia and bipolar disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from schizophrenia, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, and schizophreniform disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from autism, pervasive development disorder, and attention deficit hyperactivity disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from generalized anxiety disorder, panic disorder, obsessive-

compulsive disorder, post-traumatic stress disorder, and phobias, including social phobia, agoraphobia, and specific phobias.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; and extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies.

Another more specific embodiment of this invention relates to the above method wherein the compound of formula 1 is administered to a human for the treatment of any two or more comorbid disorders or conditions selected from those disorders and conditions referred to in any of the above methods.

For the treatment of depression, anxiety, schizophrenia or any of the other disorders and conditions referred to above in the descriptions of the methods and pharmaceutical compositions of this invention, the novel compounds of this invention can be used in conjunction with one or more other antidepressants or anti-anxiety agents. Examples of classes of antidepressants that can be used in combination with the active compounds of this invention include norepinephrine reuptake inhibitors,

selective serotonin reuptake inhibitors (SSRIs), NK-1 receptor antagonists, monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, α -adrenoreceptor antagonists, and atypical antidepressants. Suitable norepinephrine reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics. Suitable tertiary amine tricyclics and secondary amine tricyclics include amitriptyline, clomipramine, doxepin, imipramine, trimipramine, dothiepin, butripyline, iprindole, lofepramine, nortriptyline, protriptyline, amoxapine, desipramine and maprotiline. Suitable selective serotonin reuptake inhibitors include fluoxetine, fluvoxamine, paroxetine and sertraline. Examples of monoamine oxidase inhibitors include isocarboxazid, phenelzine, and tranylcyclopramine. Suitable reversible inhibitors of monoamine oxidase include moclobemide. Suitable serotonin and noradrenaline reuptake inhibitors of use in the present invention include venlafaxine. Suitable CRF antagonists include those compounds described in International Patent Application Nos. WO 94/13643, WO 94/13644, WO 94/13661, WO 94/13676 and WO 94/13677. Suitable atypical anti-depressants include bupropion, lithium, nefazodone, trazodone and viloxazine. Suitable NK-1 receptor antagonists include those referred to in World Patent Publication WO 01/77100.

Suitable classes of anti-anxiety agents that can be used in combination with the active compounds of this invention include benzodiazepines and serotonin 1A (5-HT_{1A}) agonists or antagonists, especially 5-HT_{1A} partial agonists, and corticotropin releasing factor (CRF) antagonists. Suitable benzodiazepines include alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam. Suitable 5-HT_{1A} receptor agonists or antagonists include buspirone, flesinoxan, gepirone and ipsapirone.

This invention also relates to a method of treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic

depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute

dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal in need of such treatment, including a human, comprising administering to said mammal:

(a) a compound of the formula 1 or a pharmaceutically acceptable salt thereof; and

(b) another pharmaceutically active compound that is an antidepressant or anti-anxiety agent, or a pharmaceutically acceptable salt thereof;

wherein the active compounds "a" and "b" are present in amounts that render the combination effective in treating such disorder or condition.

A more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from major depression, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthymia, cyclothymia and bipolar disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from schizophrenia, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, and schizophreniform disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from autism, pervasive development disorder, and attention deficit hyperactivity disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is selected from generalized anxiety disorder, panic disorder, obsessive-

compulsive disorder, post-traumatic stress disorder, and phobias, including social phobia, agoraphobia, and specific phobias.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is
5 selected from movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; and extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism,
10 neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition that is being treated is
15 selected from delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma,
20 Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies.

Another more specific embodiment of this invention relates to the above method wherein the compound of formula 1 and the additional antidepressant or anti-anxiety agent are administered to a human for the
25 treatment of any two or more comorbid disorders or conditions selected from those disorders and conditions referred to in any of the above methods.

This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and
30 neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective

disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder;

5 anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders;

10 borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders

15 associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD),

20 Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as

25 akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive

30 dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and

behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal in need of such treatment, including a human, comprising:

(a) a compound of the formula 1 or a pharmaceutically acceptable salt thereof;

(b) another pharmaceutically active compound that is an antidepressant or anti-anxiety agent, or a pharmaceutically acceptable salt thereof; and


(c) a pharmaceutically acceptable carrier;

wherein the active compounds "a" and "b" are present in amounts that render the composition effective in treating such disorder or condition.


DETAILED DESCRIPTION OF THE INVENTION

The compounds of formula 1 of the present invention may be prepared as described in the following reaction schemes. Unless otherwise indicated, in the reaction schemes and discussion that follow, R¹ through R¹⁰, A, n, m, o, p, U, V, L, W, D, E, Y, Z and X are defined as above.

SCHEME A-1



1




2

[In compounds 1 and 2, one of the $-\text{CH}_2-$ groups of X or W is replaced by $-\text{C}(\text{O})-$]

5 The above scheme illustrates a method for preparing compounds of the formula 2 by reacting a compound of the formula 1 with a compound of formula $\text{X}^1\text{CO}(\text{CH}_2)_m\text{Q}$, wherein X^1 is either a halogen or OH and Q is either a halogen, mesylate, or tosylate. When X^1 is represented by a halogen, the reaction is typically carried out in the presence of a Lewis acid such as aluminum bromide (AlBr_3), aluminum chloride (AlCl_3), gallium trichloride (GaCl_3), ferric chloride (FeCl_3), zinc chloride (ZnCl_2), antimony pentachloride (SbCl_5), zirconium tetrachloride (ZrCl_4), tin tetrachloride (SnCl_4), boron trichloride (BCl_3), boron trifluoride (BF_3), or antimony trichloride (SbCl_3). The reaction can be carried out in nonpolar solvents such as chloroform, dichloromethane, or carbon disulfide, or in polar solvents such as nitrobenzene, or may be run neat in the presence of excess Lewis acid. The reaction is typically carried out at a temperature of 25°C to about 120°C for a period of about 1 hour to 6 hours. Where X^1 is represented by OH, the reaction is typically carried out in the presence of a proton acid such as polyphosphoric acid or sulfuric acid.


SCHEME A-2



[In compounds 2 and 3, one of the $-\text{CH}_2-$ groups of X or W is replaced by $-\text{C}(\text{O})-$]

The above scheme illustrates a method for preparing compounds of the formula 3. In compounds of the formulas 2 and 3, Q is defined as it is defined above in the description of Scheme A-1. The reaction illustrated in Scheme A-2 can be carried out using triethylsilane in trifluoroacetic acid at a temperature from about room temperature to the reflux temperature of the solvent for a period of up to about 24 hours. Alternatively, the reaction may be carried out using borane-tert-butylamine in the presence of a Lewis acid such as aluminum chloride or by using borane-dimethylamine in the presence of a Lewis acid such as titanium tetrachloride in an inert solvent such as dichloromethane, chloroform, or nitrobenzene under temperatures described.

SCHEME A-3



[In compounds 3, 4 and 5, one of the $-CH_2-$ groups of X or W is replaced by $-C(O)-$]


5

10

15

The above scheme illustrates a method for preparing compounds of the formula 4, by reacting a compound of the formula 3, as described in Scheme A-2, with a compound of formula 5. The reaction is typically run in the presence of a base such as potassium carbonate, sodium carbonate, triethylamine, or diisopropylethylamine. The solvent used may be water, acetonitrile, dioxane, benzene, toluene, tetrahydrofuran, methyl isobutyl ketone, or a combination of two of the formerly mentioned solvents. Inorganic salts such as a sodium or potassium halide (e.g., sodium iodide or potassium iodide) may be employed as catalysts in the reaction. The temperature of the reaction may vary from ambient to reflux temperature of the solvent used, preferably from about 80°C to 120°C, for a period of about 1 hour to about 96 hours, preferably from about 12 hours to 48 hours.


SCHEME A-4



5 [In compound 4, one of the $\text{-CH}_2\text{-}$ groups of W or X is replaced by -C(O)-]

10 The above scheme illustrates a method for preparing compounds of the formula 5 by reducing the amide carbonyl in the compound of the formula 4 with a reducing agent such as borane THF, or borane dimethyl sulfide. The reaction above can be carried out in a solvent such as methylene chloride, dichloroethane, benzene, or toluene. This reaction is typically carried out at a temperature from about -78°C to about the reflux temperature of the solvent, preferably from about -20°C to about 50°C ,
15 for a period of about 5 minutes to about 48 hours, preferably from about 0.5 to about 16 hours. The reaction is typically quenched with methanol, water, or a dilute base such as sodium carbonate or sodium bicarbonate. Preferably, the reaction is quenched with methanol or 10% sodium carbonate and the complexes are broken up by heating the reaction
20 mixture to a temperature from about 30°C to about the reflux temperature of the solvent, preferably to about 90°C , for about 0.5 to about 20 hours, preferably for about 2 hours.

Schem A-5




5 The above scheme illustrates a method for preparing compounds of the formula 1 by reacting compounds of the formula 5 with a compound of the formula R^9-G wherein G is $-COCl$, an acid or a suitably activated acid derivative such as the mixed anhydride, $-OCOCl$, $-N=C=O$, or $-SO_2Cl$, or wherein R^9-G is $ClSO_2N(Me)_2$. This reaction may be carried out in an inert solvent such as methylene chloride, dichloroethane, benzene, toluene, or

10 pyridine, preferably methylene chloride. Typically, it is carried out at a temperature from about $-78^\circ C$ to about the reflux temperature of the solvent, preferably from about $0^\circ C$ to about $25^\circ C$, for a period of about 5 minutes to 48 hours, preferably from about 0.5 to about 16 hours. This

reaction is generally performed in the presence of organic base such as diisopropylethylamine, pyridine, or triethylamine, preferably triethylamine, or in the presence of a polymer supported base such as tris-(2-aminoethyl)amine polystyrene.

5

Scheme B-1



10

[In compound 3, one of the $-\text{CH}_2-$ groups of W or X is replaced by $-\text{C}(\text{O})-$]


15

20

25


The above scheme illustrates a method for preparing compounds of the formula 6 by reducing the amide carbonyl in a compound of the formula 3 with a reducing agent such as borane THF, or borane dimethyl sulfide. The reaction above can be carried out in a solvent such as methylene chloride, THF, dichloroethane, benzene, or toluene. This reaction is typically carried out at a temperature from about -78°C to about the reflux temperature of the solvent, preferably from about -20°C to about 50°C , for a period of about 5 minutes to about 48 hours, preferably from about 0.5 to about 16 hours. The reaction is typically quenched with methanol, water, or a dilute base such as sodium carbonate or sodium bicarbonate. Preferably, the reaction is quenched with methanol or 10% sodium carbonate and the complexes are broken up by heating the reaction mixture to a temperature from about 30°C to about the reflux temperature of the solvent, preferably to about 90°C , for about 0.5 to about 20 hours, preferably for about 2 hours.

Schem B-2



5 The above scheme illustrates a method for preparing compounds of
 the formula 7 by reacting compounds of the formula 6 with a compound of
 the formula R^9-G wherein G is $-\text{COCl}$, an acid or a suitably activated acid
 derivative such as the mixed anhydride, $-\text{OCOCl}$, $-\text{N}=\text{C}=\text{O}$, or $-\text{SO}_2\text{Cl}$, or
 wherein R^9-G is $\text{ClSO}_2\text{N}(\text{Me})_2$. This reaction may be carried out in an inert
 solvent such as methylene chloride, dichloroethane, benzene, toluene, or
 10 pyridine, preferably methylene chloride. Typically, it is carried out at a
 temperature from about -78°C to about the reflux temperature of the
 solvent, preferably from about 0°C to about 25°C , for a period of about 5
 minutes to 48 hours, preferably from about 0.5 to about 16 hours. This
 reaction is generally performed in the presence of organic base such as
 15 diisopropylethylamine, pyridine, or triethylamine, preferably triethylamine,
 or in the presence of a polymer supported base such as tris-(2-
 aminoethyl)amine polystyrene.


Scheme B-3



The above scheme illustrates a method for preparing compounds of the formula 1 wherein A is $-(CH_2)_mCH_2-$ by reacting a compound of the formula 7, as described in scheme B-2, with a compound of formula 5. The reaction is typically run in the presence of a base such as potassium carbonate, sodium carbonate, triethylamine, or diisopropylethylamine. The solvent used may be water, acetonitrile, dioxane, benzene, toluene, tetrahydrofuran, methyl isobutyl ketone, or a combination of two of the formerly mentioned solvents. Inorganic salts such as a sodium or potassium halide (e.g., sodium iodide or potassium iodide) may be employed as catalysts in the reaction. The temperature of the reaction may vary from ambient to reflux temperature of the solvent used, preferably from about 80°C to 120°C, for a period of about 1 hour to about 96 hours, preferably from about 12 hours to 48 hours.

Examples 86 through 98 exemplify the syntheses described in Schemes B-1 through B-3.

Schem C



Examples 99 through 109 exemplify the syntheses described in Scheme C.

The preparation of other compounds of the formula 1 not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

5 In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e., about 1 atmosphere, is preferred as a matter of convenience.

10 The compounds of the formula 1, and the intermediates shown in the above reaction schemes can be isolated and purified by conventional procedures, such as recrystallization or chromatographic separation.

 The compounds of the formula 1 and their pharmaceutically acceptable salts can be administered to mammals via either the oral,
15 parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, buccal or intranasal routes. In general, these compounds are most desirably administered in doses ranging from about 3 mg to about 600 mg per day, in single or divided doses (i.e., from 1 to 4 doses per day), although variations will necessarily occur depending
20 upon the species, weight and condition of the patient being treated, the patient's individual response to said medicament, the nature and severity of the particular disorder being treated, as well as on the type of pharmaceutical formulation chosen and the overall time period and intervals over which such administration is carried out. However, a dosage level that
25 is in the range of about 25 mg to about 100 mg per day is most desirably employed. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such higher dose levels are first divided into several small doses for
30 administration throughout the day.

 The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously indicated, and such administration may be

carried out in single or multiple doses. More particularly, the novel therapeutic agents of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, 5 lozenges, troches, hard candies, suppositories, jellies, gels, pastes, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the 10 weight ratio of the novel compounds of this invention to the pharmaceutically acceptable carrier will be in the range from about 1:6 to about 2:1, and preferably from about 1:4 to about 1:1.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium 15 phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are 20 often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may 25 be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of a compound of the 30 present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for

intravenous injection purposes. The oily solutions are suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

This invention relates to methods of treating anxiety, depression, schizophrenia and the other disorders referred to in the description of the methods of the present invention, wherein a novel compound of this invention and one or more of the other active agents referred to above (e.g., an NK1 receptor antagonist, tricyclic antidepressant, 5HT1D receptor antagonist, or serotonin reuptake inhibitor) are administered together, as part of the same pharmaceutical composition, as well as to methods in which such active agents are administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy. The appropriate dose regimen, the amount of each dose of an active agent administered, and the specific intervals between doses of each active agent will depend upon the subject being treated, the specific active agent being administered and the nature and severity of the specific disorder or condition being treated. In general, the novel compounds of this invention, when used as a single active agent or in combination with another active agent, will be administered to an adult human in an amount from about 3 mg to about 600 mg per day, in single or divided doses, preferably from about 25 to about 100 mg per day. Such compounds may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day, especially 2 times per day and most especially once daily. Variations may nevertheless occur depending on the species, weight and condition of the patient being treated, the patient's individual response to said medicament, the nature and severity of the particular disorder being treated, as well as on the type of pharmaceutical formulation chosen and the overall time period and intervals over which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided

that such larger doses are first divided into several small doses for administration throughout the day.

5 A proposed daily dose of a 5HT reuptake inhibitor, preferably sertraline, in the combination methods and compositions of this invention, for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above, is from about 0.1 mg to about 2000 mg, preferably from about 1 mg to about 200 mg of the 5HT reuptake inhibitor per unit dose, which could be administered, for example, 1 to 4 times per day. A proposed daily dose of a 5HT1D receptor antagonist in the combination methods and compositions of this invention, 10 for oral, parenteral, rectal or buccal administration to the average adult human for the treatment of the conditions referred to above, is from about 0.01 mg to about 2000 mg, preferably from about 0.1 mg to about 200 mg of the 5HT1D receptor antagonist per unit dose, which could be administered, for example, 1 to 4 times per day. 15

For intranasal administration or administration by inhalation, the novel compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, 20 e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. 25 Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. Formulations of the active compounds of this invention for treatment of the conditions referred to above in the average adult human 30 are preferably prepared so that each metered dose or "puff" of aerosol contains 20 µg to 1000 µg of active compound. The overall daily dose with an aerosol will be within the range 100 µg to 10 mg. Administration may

be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

5 The ability of the compounds of this invention to bind to the dopamine D2 and serotonin 2A (5HT2A) receptors can be determined using conventional radioligand receptor binding assays. All receptors can be heterologously expressed in cell lines and experiments conducted in membrane preparations from the cell lines using procedures outlined below. IC₅₀ concentrations can be determined by nonlinear regression of concentration-dependent reduction in specific binding. The Cheng-10 Prussoff equation can be used to convert the IC₅₀ to Ki concentrations.

Dopamine D2 Receptor Binding:

[³H]Spiperone binding to a membrane preparation from CHO-hD2L cells is carried out in 250 µl of 50 mM Tris-HCl buffer containing 100 mM NaCl, 1 mM MgCl₂ and 1% DMSO at pH 7.4. Duplicate samples15 containing (in order of addition) the test compounds, 0.4 nM [³H]spiperone and approximately 12 µg protein are incubated for 120 minutes at room temperature. Bound radioligand is separated by rapid filtration under reduced pressure through Whatman GF/B glass fiber filters previously treated with 0.3% polyethyleneimine. Radioactivity retained on the filter is20 determined by liquid scintillation spectrophotometry.

The title compounds of Examples 1 – 220 were tested using the above assay, in which specific binding determined in the presence of 1 mM haloperidol was 95%. The title compounds of Examples 1 – 220 exhibited IC₅₀ values less than or equal to 10 µM. The title compound of25 Example 148 exhibited an IC₅₀ value of 6.5 nM. The title compound of Example 121 exhibited an IC₅₀ value of 23 nM.

Serotonin 2A Binding:

[³H] Ketanserin binding to Swiss-h5HT2A cell membranes can be carried out in 250 µl of 50 mM Tris-HCl buffer pH 7.4. Duplicate samples30 containing (in order of addition) test compounds, 1.0 nM [³H]ketanserin, and approximately 75 µg protein are incubated for 120 minutes at room

temperature. Bound radioligand is separated by rapid filtration under reduced pressure through Whatman GF/B glass fiber filters previously treated with 0.3% polyethyleneimine. Radioactivity retained on the filter is determined by liquid scintillation spectrophotometry.

5 The title compounds of Examples 1 – 220 were tested using the above assay, in which specific binding determined in the presence of 1 mM ketanserin was 90%. All of the title compounds of Examples 1 – 220 exhibited IC_{50} values less than or equal to 10 μ M. The title compound of Example 148 exhibited an IC_{50} value of 0.32nM. The title compound of
10 Example 121 exhibited an IC_{50} value of 0.42 nM.


The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million and are referenced to the deuterium lock signal from the sample solvent.

EXAMPLES

Examples 1 through 85 below exemplify the synthesis described above in Schemes A-1 through A-5.

EXAMPLE 1

5-(2-Chloroacetyl)-3,3-dimethyl-1,3-dihydroindol-2-one




25 A 12.5L 4-neck flask equipped with a mechanical stirrer, reflux condenser and two stoppers and heating mantle, was charged with $AlCl_3$ (633.29 g, 4.75 mol), 2 L of carbon disulfide and chloroacetyl chloride (87 ml, 1.09 mol) and this was stirred at room temperature during the portionwise addition of 3,3-dimethyl-1,3-dihydro-indol-2-one (123.5 g,
30 0.766 mol). This mixture was then heated to reflux for 3 hours, then cooled overnight. The solvent was decanted and the reaction was

quenched with addition of ice and water (8 L). The suspension was stirred vigorously for 1.5 hours, followed by filtration. The solids were washed with water (4.2 L) and then dried overnight in a vacuum oven at 50 degrees Celsius (192.19 g of 5-(2-chloroacetyl)-3,3-dimethyl-1,3-dihydroindol-2-one). 29.54 g of this material was taken up in hot acetone and purified by flash chromatography (250 g silica gel) eluting with acetone which provided >96% pure 5-(2-chloroacetyl)-3,3-dimethyl-1,3-dihydroindol-2-one by HPLC. Yield = 15.54g (52%); MS (APCI), (M + 1)⁺ = 238. CHN: calculated for C₁₂H₁₂ClNO₂, C: 60.64%, H: 5.09%, N: 5.89%; found, C: 61.04%, H: 5.15%, N: 5.38%.

EXAMPLE 2


5-(2-Chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one



A 5L 4-neck flask equipped with a mechanical stirrer, 1L addition funnel and two stoppers was charged with 5-(2-chloroacetyl)-3,3-dimethyl-1,3-dihydroindol-2-one (162.65 g, 0.684 mol) and this was taken up in trifluoroacetic acid (700 ml). The solution was cooled in an ice/water bath, followed by addition of triethylsilane (260 ml) over a 1 hour period. The reaction was stirred at room temperature overnight. The mixture as poured into a 12.5 L flask containing 8 L of rapidly stirring water. The reaction flask was washed with 1.5 L of water and 2 L of heptanes, both added to the 12.5 L flask. The mixture was again stirred over night. The suspension was vacuum filtered and the solids were washed with water (2 L) and heptanes (2 L) and dried over night in vacuum oven (73.2 g). The solid was purified by flash chromatography (550 g silica gel) eluting with acetone (2 L). Yield = 68.38g (45%); MS (APCI), (M + 1)⁺ = 224. CHN: calculated for C₁₂H₁₂ClNO₂, C: 64.43%, H: 6.31%, N: 6.29%; found, C: 64.35%, H: 6.36%, N: 5.84%.

EXAMPLE 3


5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-1,3-dihydro-indol-2-one



5
A 500ml round bottom (rb) flask was charged with 3-Piperazin-1-yl-
benzo[d]isothiazole (12.5g, 5.0 mol), 5-(2-chloroethyl)-3,3-dimethyl-1,3-
10 dihydroindol-2-one (11.5 g, 5.0 mol) and sodium carbonate (10.5 g, 10.0
mol), diluting with water (200ml). The stirring reaction was warmed to
reflux for 24 hours. The reaction was slowly cooled with vigorous stirring
and a solid formed. The tan solid was filtered washed with ether and dried
in a vacuum oven. Yield = 19.49 g (96%); ¹H NMR (400 MHz, DMSO-D₆)
15 δ ppm 1.20 (s, 6 H) 2.61 (m, 8 H) 3.42 (m, 5 H) 6.73 (d, J=7.82 Hz, 1 H)
7.00 (dd, J=7.82 Hz, 1 H) 7.14 (d, 1 H) 7.41 (t, J=7.69 Hz, 1 H) 7.53 (t,
J=7.45 Hz, 1 H) 8.03 (d, J=9.04 Hz, 2 H) 10.21 (s, 2 H)

EXAMPLE 4

20 **3-{4-[2-(3,3-Dimethyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-
benzo[d]isothiazole**




25 A solution of 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-
3,3-dimethyl-1,3-dihydro-indol-2-one (810 mg, 2.0 mmol) in toluene (15 ml)
with stirring at room temperature was treated with borane dimethyl sulfide
in toluene (2 ml, 4 mmol). The reaction was warmed to reflux for 1 hour.
The reaction was cooled and treated with a 10% aqueous solution of

sodium carbonate (10 ml) and warmed to reflux for 20 hours. The reaction was cooled and the layers were separated. The aqueous layers were extracted with ethyl acetate (2x 20 ml). The combined organics were dried over magnesium, filtered and the filtrate concentrated. The crude product was eluted through a flash column (silica gel 40, 230-400 mesh, methylene chloride (CH₂Cl₂) to 8% ethanol (EtOH) and 1% ammonium hydroxide (NH₄OH) in CH₂Cl₂) to give the title compound as a brown oily solid, yield = 620 mg (79%). ¹H-NMR (CDCl₃, δ): 7.91 (d, J=8.30 Hz, 1 H) 7.81 (d, J=8.30 Hz, 1 H) 7.47 (t, J=7.56 Hz, 1 H) 7.35 (t, J=7.56 Hz, 1 H) 6.89 (m, 2 H) 6.59 (d, J=8.30 Hz, 1 H) 3.61 (m, 4 H) 3.30 (s, 2 H) 2.69 (m, 8 H) 1.30 (s, 6 H).

EXAMPLE 5

{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-(4-fluoro-phenyl)-methanone




3-{4-[2-(3,3-Dimethyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-1,2-benzisothiazole was diluted to 0.20 M with anhydrous dichloromethane, then delivered to an 8 mL vial via pipette (0.20 mmol). To the amine solution was added PS-N-Methylmorpholine resin (0.40 mmol). Isoxazole-4-fluoro-benzoyl chloride was diluted to 0.20 M with dichloromethane, and added at room temperature (0.40 mmol). The solution was shaken overnight at room temperature. Polyamine scavenging resin was added (0.5 mmol). The solution was shaken overnight at room temperature, then filtered into an 8 mL vial. The filtrate

5

10

15

15




20

20

20

-48-




Isolated in 100% purity @ 254 nm; LCMS (APCI) 517 [M+H]⁺

5

EXAMPLE 8

1-{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-phenoxy-propan-1-one




Isolated in 96% purity @ 254 nm; LCMS (APCI) 541 [M+H]⁺

10

EXAMPLE 9

{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-(2,5-dimethyl-2H-pyrazol-3-yl)-methanone

-49-




Isolated in 100% purity @ 254 nm; LCMS (APCI) 515[M+H]⁺

5

EXAMPLE 10

1-{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-butan-1-one




10

Isolated in 100% purity @ 254 nm; LCMS (APCI) 463 [M+H]⁺

EXAMPLE 11

1-{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one

-50-




Isolated in 100% purity @ 254 nm; LCMS (APCI) 463 [M+H]⁺

5

EXAMPLE 12

{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-m-tolyl-methanone




10

Isolated in 98% purity @ 254 nm; LCMS (APCI) 511 [M+H]⁺

EXAMPLE 13

1-{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(4-chloro-phenoxy)-ethanone

-51-




Isolated in 100% purity @ 254 nm; LCMS (APCI) 562 [M+H]⁺

5

EXAMPLE 14

1-(5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl)-3,3-dimethyl-2,3-dihydro-indol-1-yl]-3-phenyl-propan-1-one




10

Isolated in 97% purity @ 254 nm; LCMS (APCI) 525 [M+H]⁺

EXAMPLE 15

1-(5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl)-3,3-dimethyl-2,3-dihydro-indol-1-yl]-2-(3,4-dimethoxy-phenyl)-ethanone


-52-



Isolated in 100% purity @ 254 nm; LCMS (APCI) 571 [M+H]⁺

EXAMPLE 16

5 1-{5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(4-chloro-phenyl)-ethanone




Isolated in 96% purity @ 254 nm; LCMS (APCI) 546 [M+H]⁺

10

EXAMPLE 17

{5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-(4-methoxy-phenyl)-methanone


-53-



Isolated in 100% purity @ 254 nm; LCMS (APCI) 527 [M+H]⁺

EXAMPLE 18

5 1-{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-phenyl-ethanone




Isolated in 100% purity @ 254 nm; LCMS (APCI) 511 [M+H]⁺

10

EXAMPLE 19

1-{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(2,5-dimethoxy-phenyl)-ethanone


-54-



Isolated in 100% purity @ 254 nm; LCMS (APCI) 571 [M+H]⁺

EXAMPLE 20

5 5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indole-1-carboxylic acid phenyl ester




Isolated in 90% purity @ 254 nm; LCMS (APCI) 513 [M+H]⁺

10

EXAMPLE 21

5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-furan-2-yl-methanone


-55-



Isolated in 100% purity @ 254 nm; LCMS (APCI) 487 [M+H]⁺

EXAMPLE 22

5 **1-{5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one**




Isolated in 100% purity @ 254 nm; LCMS (APCI) 477 [M+H]⁺

10

EXAMPLE 23

{5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone

-56-




Isolated in 100% purity @ 254 nm; LCMS (APCI) 489 [M+H]⁺

5

EXAMPLE 24

1-(5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl)-2-benzyloxy-ethanone




10

Isolated in 100% purity @ 254 nm; LCMS (APCI) 541 [M+H]⁺

EXAMPLE 25

{5-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-phenyl-methanone

-57-




Isolated in 100% purity @ 254 nm; LCMS (APCI) 497 [M+H]⁺

5

EXAMPLE 26

1-{5-[2-(4-1,2-Benzisothiazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-cyclopentyl-ethanone




10

Isolated in 100% purity @ 254 nm; LCMS (APCI) 503 [M+H]⁺

EXAMPLE 27

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone


15



3-{4-[2-(3,3-Dimethyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-1,2-benzisothiazole (0.81 mmol, 313 mg) was diluted with anhydrous THF (5 ml) and triethylamine (0.225 ml) then treated with acetyl chloride (0.711 ml) and allowed to stir for 72 hours ("h" or "hr"). The reaction was filtered and the filtrate was concentrated. The crude solid was washed with sodium carbonate (10 ml) and extracted with methylene chloride (25 ml) dried and concentrated to oily solid. The solid was crystallized from ether to yield pure 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone : Yield; 182 mg (52%). ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.34 (s, 6 H) 2.19 (s, 3 H) 2.76 (m, 8 H) 3.60 (s, 4 H) 3.75 (s, 2 H) 6.98 (s, 1 H) 7.05 (d, J =8.06 Hz, 1 H) 7.34 (t, J =7.57 Hz, 1 H) 7.46 (t, J =7.57 Hz, 1 H) 7.80 (d, J =8.30 Hz, 1 H) 7.90 (d, J =8.30 Hz, 1 H) 8.08 (d, J =8.06 Hz, 1 H) MS (APCI) = 435.2 [M+H]⁺.

EXAMPLE 27

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indole-1-carboxylic acid isopropylamide




A solution of 3-{4-[2-(3,3-Dimethyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-1,2-benzisothiazole (0.4 mmols, 160 mg) in THF (5ml) was treated by dropwise addition with Isopropyl isocyanonate at room temperature (RT or rt) and allowed to stir for 4 days. The reaction was

concentrated to dryness, diluted with H₂O and extracted with CH₂Cl₂. The organics were placed through a phase separator and dried down in a 100X16mm tube, resulting in a solid. The solid was then recrystallized from ACN to yield pure 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indole-1-carboxylic acid isopropylamide. Yield: 112 mg (58%). ¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.07 (d, J=6.59 Hz, 6 H) 1.22 (s, 6 H) 2.60 (m, 8 H) 3.40 (s, 4 H) 3.57 (s, 2 H) 3.80 (m, 1 H) 6.14 (d, J=7.81 Hz, 1 H) 6.90 (d, J=8.05 Hz, 1 H) 6.98 (s, 1 H) 7.38 (t, J=7.69 Hz, 1 H) 7.51 (t, J=7.81 Hz, 1 H) 7.65 (d, J=8.05 Hz, 1 H) 8.00 (d, J=8.78 Hz, 2 H).

EXAMPLE 28

6-(2-Chloro-acetyl)-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one




A rb flask was charged with 60 mL dichloroethane and AlCl₃ (11.5 g, 86 mmol, 3 eq) and cooled on an ice-bath. To this solution was added, portionwise, 5.0 g (29 mmol, 1 eq) of the known 2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one (Protiva, M.; Sedivy, Z.; Holubek, J.; Svatek, E.; Nemec, J. *Collection of Czechoslovak Chemical Communications* **1985**, *50*, 1888-98, Clark, R. D.; Muchowski, J. M.; Fisher, L. E.; Flippin, L. A.; Repke, D. B.; Souchet, M. *Synthesis* **1991**, 871-8). After 20 min, 2.8 mL (34 mmol, 1.2 eq) of chloroacetylchloride was added and the solution was allowed to warm slowly to rt. After 30 hours at rt the solution was poured carefully into 500 mL of iced-water and the resulting ppt was filtered and washed with chloroform. The white solid was oven dried overnight at 60 °C under vacuum to give 6.0 g (83 % yield) of the desired product as a beige solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.1 (m, J=12.3, 12.3, 12.1, 3.3 Hz, 1 H) 1.7 (m, 1 H) 2.0 (m, J=10.4, 7.2, 3.7, 1.7 Hz, 1 H) 2.1

(ddd, $J=12.0, 8.7, 3.4$ Hz, 1 H) 2.7 (m, 1 H) 3.1 (dd, $J=19.0, 7.1$ Hz, 1 H) 3.3 (s, 1 H) 3.4 (dd, $J=12.1, 5.2$ Hz, 1 H) 5.0 (m, 2 H) 6.7 (d, $J=8.3$ Hz, 1 H) 7.8 (dd, $J=8.3, 1.0$ Hz, 1 H) 10.6 (s, 1 H). MS (APCI), $(M+1)^+ = 250$.

5

EXAMPLE 29

6-(2-Chloro-ethyl)-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one




10 A rb flask was charged with 5.85 g (23 mmol, 1 eq) 6-(2-Chloro-acetyl)-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one, 18 mL (10 eq) trifluoroacetic acid and 11 mL (3 eq) triethylsilane and heated to 60 °C for 4 hr. The reaction mixture was then quenched carefully into 300 mL of iced water and extracted with 400 mL of CH₂Cl₂. The aqueous layer was
15 extracted with an additional 200 mL CH₂Cl₂, dried over MgSO₄ and concentrated in vacuo to give 11 g of a semi-solid. This material was triturated with 200 mL of 1:1 diethylether:hexanes and the resulting solid dried in vacuo to give 4.68 g (86 % yield) of the desired material as a pale yellow solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.1 (m, 1 H) 1.8 (m, 1 H)
20 2.0 (m, 1 H) 2.1 (m, 1 H) 2.5 (m, 1 H) 2.7 (dd, $J=17.6, 7.3$ Hz, 1 H) 2.9 (td, $J=14.8, 6.6$ Hz, 2 H) 3.3 (m, 1 H) 3.7 (m, 2 H) 6.5 (d, $J=7.6$ Hz, 1 H) 6.9 (d, $J=7.8$ Hz, 1 H) 10.1 (s, 1 H). MS (APCI), $(M+1)^+ = 236$.

EXAMPLE 30

25 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one


-61-



A 20 mL reaction vial was charged with 0.47 g (2 mmol, 1 eq) 6-(2-Chloro-ethyl)-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one, 0.51 g 3-Piperazin-1-yl-benzo[d]-iso-thiazole hydrochloride, and 5 mL of 1 M aqueous sodium carbonate (Na_2CO_3) and heated to 100°C for 60 h. The solid was filtered, washed with water and dried in vacuo overnight. The resulting solid was purified by medium pressure liquid chromatography (MPLC) (ethyl acetate (EtOAc) eluant) to give 0.36 g (43 % yield) of the desired material as a white solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 1.3 (qd, $J=12.3, 3.5$ Hz, 1 H) 1.9 (m, 1 H) 2.2 (m, 1 H) 2.4 (dt, $J=12.2, 4.4$ Hz, 1 H) 2.6 (m, 3 H) 2.8 (m, 6 H) 3.3 (dd, $J=11.8, 5.0$ Hz, 1 H) 3.6 (s, 4 H) 6.6 (d, $J=7.6$ Hz, 1 H) 7.0 (d, $J=7.8$ Hz, 1 H) 7.3 (m, 1 H) 7.5 (m, 1 H) 7.8 (d, $J=8.1$ Hz, 1 H) 7.9 (d, $J=8.1$ Hz, 1 H) 8.2 (s, 1 H). MS (APCI), $(\text{M}+1)^+ = 292, 419$.

EXAMPLE 31

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,2a,3,4,5-hexahydro-benzo[cd]indole




A rb flask was charged with 5.0 g (12 mmol, 1 eq) 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one and 50 mL tetrahydrofuran (THF) and cooled on an ice bath. The reaction was treated dropwise with 48 mL (48 mmol, 4 eq) 1

M borane-THF (BH₃-THF) in THF over 0.5 h and then allowed to warm slowly to rt. After 24 h the reaction was quenched with 20 mL methanol (MeOH) (gas evolution) and heated at 50°C for 15 h. The reaction was cooled, partitioned between CH₂Cl₂ and brine. The organic extracts were dried over magnesium sulfate (MgSO₄), filtered, and concentrated to give 4.7 g of a yellow foam that was a mixture of indole and indoline products by ¹H NMR. This mixture was taken on without purification.

A rb flask was charged with 4.38 g of the above mixture and 43 mL acetic acid (HOAc). This mixture was treated with 1.8 g (27 mm, 2.5 eq) sodium cyanoborohydride (NaCNBH₃) and stirred at rt for 15 h. The reaction solvent was removed in vacuo and the resulting solid was dissolved in 200 mL CH₂Cl₂ and washed with 1 M sodium bicarbonate (NaHCO₃). The aqueous layer was back-extracted with 100 mL CH₂Cl₂. The combined organic layers were washed with brine, separated, and dried over MgSO₄. Concentration in vacuo gave 4.0 g of a yellow foam that was purified by MPLC to give 1.65 g (33 % yield) of the desired material as a slightly yellow foam. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.3 (d, J=10.5 Hz, 1 H) 1.7 (s, 1 H) 2.1 (m, 2 H) 2.6 (dd, J=10.3, 5.4 Hz, 4 H) 2.8 (m, 7 H) 3.1 (m, 2 H) 3.6 (m, 5 H) 6.5 (d, J=7.6 Hz, 1 H) 6.8 (d, J=7.6 Hz, 1 H) 7.3 (dd, J=8.1, 7.1 Hz, 1 H) 7.5 (m, 1 H) 7.8 (m, 1 H) 7.9 (d, J=8.3 Hz, 1 H). MS (APCI), (M+1)⁺ = 403.

EXAMPLE 32

1-{6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-ethanone




A solution of 1.0 g (2.0 mmol, 1 eq) 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,2a,3,4,5-hexahydro-benzo[cd]indole was treated with 0.689 mL (4.9 mmol, 2 eq) triethylamine (Et₃N) and then 0.263 mL (3.7 mmol, 1.5 eq) acetyl chloride and stirred at rt for 20 h. The reaction was quenched with 1 M NaHCO₃, filtered through 5 μm PTFE (phase-separating filter), and concentrated in vacuo to give 1.19 g (quantitative yield) of a pale-yellow foam. ¹H NMR (400 MHz, CDCl₃) (Integration does not take into account a 3:1 mixture of rotamers, the presence of which is most pronounced at the peaks labeled major/minor.) ppm 1.1 (m, 3 H) 1.2 (m, 1 H) 1.3 (m, 1 H) 1.8 (m, 1 H) 2.1 (m, 5 H) 2.4 (s, 1 H) 2.6 (m, 5 H) 2.8 (m, 7 H) 2.9 (t, J=7.3 Hz, 1 H) 3.3 (m, 1 H) 3.5 (dd, J=11.2 Hz, 1 H) 3.6 (m, 4 H) 4.2 (major, t, J=9.2 Hz, 1 H) 4.6 (minor, 1 H) 6.8 (minor, d, J=8.1 Hz, 1 H) 7.0 (major, m, 1 H) 7.3 (m, 1 H) 7.4 (t, J=7.6 Hz, 1 H) 7.8 (d, J=8.1 Hz, 2 H) 7.9 (d, J=8.1 Hz, 1 H). MS (APCI), (M+1)⁺ = 447.


The title compounds of Examples 33 through 40 were prepared from 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,2a,3,4,5-hexahydro-benzo[cd]indole in a fashion similar to that reported above. R_t (min) reported is for the following high pressure liquid chromatography (HPLC) conditions: 60:40 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Purity for each compound reported is > 90% by UV (254 nM).

EXAMPLE 33

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-cyclopropyl-methanone



-64-




HPLC: $R_t = 3.005$; MS (APCI), $(M+1)^+ = 473$

5

EXAMPLE 34

1-(6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl)-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl]-propan-1-one




10

HPLC: $R_t = 2.898$; MS (APCI), $(M+1)^+ = 461$

EXAMPLE 35

1-(6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl)-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl]-2,2-dimethyl-propan-1-one


15



HPLC: $R_t = 3.885$; MS (APCI), $(M+1)^+ = 489$

EXAMPLE 36


1-[6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl]-pentan-1-one



HPLC: $R_t = 3.935$; MS (APCI), $(M+1)^+ = 489$

EXAMPLE 37

1-[6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl]-3-methyl-butan-1-one




HPLC: $R_t = 3.753$; MS (APCI), $(M+1)^+ = 489$

EXAMPLE 38

1-[6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl]-2-methyl-propan-1-one

-66-




HPLC: $R_t = 3.218$; MS (APCI), $(M+1)^+ = 475$

5

EXAMPLE 39

1-[6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl]-butan-1-one



10


HPLC: $R_t = 3.302$; MS (APCI), $(M+1)^+ = 475$

EXAMPLE 40

{6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-phenyl-methanone

15

-67-




HPLC: $R_t = 3.441$; MS (APCI), $(M+1)^+ = 509$

5

EXAMPLE 41

3-[4-[2-(6-Chloro-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl]-benzo[d]isothiazole



10

A solution of borane dimethyl sulfide in THF (9.6 ml, 19.2 mmol) was added dropwise to a suspension of 3.17g (7.7 mmols) of known 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one (Howard, Harry R.; Lowe, John A. III; Seeger, Thomas F.; Seymour, Patricia A.; Zorn, Stevin H.; Maloney, Patrick R.; Ewing, Frank E.; Newman, Michael E.; Schmidt, Anne W.; et al., "3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents", Journal of Medicinal Chemistry (1996), 39(1), 143-8) in THF (15 ml), with stirring at 0°C. The reaction was warmed to reflux for 2 hours.

The reaction was cooled and treated with a 30% aqueous solution of sodium carbonate (10 ml). The layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 20 ml). The combined organics were dried over magnesium, filtered and the filtrate concentrated. The crude product was eluted through a flash column (silica gel 40, 230-400 mesh, CH₂Cl₂ to 8% EtOH and 1% NH₄OH in CH₂Cl₂) to give the title compound

20


25

-68-

as a solid, yield = 348 mg (11%). ¹H NMR (400 MHz, DMSO-D₆) δ ppm
3.01 (m, 2 H) 3.16 (m, 2 H) 3.31 (m, 4 H) 3.51 (m, 4 H) 3.67 (d, J=11.72
Hz, 2 H) 4.07 (d, J=13.68 Hz, 2 H) 7.04 (s, 1 H) 7.28 (s, 1 H) 7.45 (t,
J=8.30 Hz, 1 H) 7.56 (t, J=8.06 Hz, 1 H) 8.10 (m, 2 H) 11.32 (s, 1 H): MS
(APCI), (M+1)⁺ = 399.0.

EXAMPLE 42


1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3- dihydro-indol-1-yl}-ethanone



A solution of 3-{4-[2-(6-Chloro-2,3-dihydro-1H-indol-5-yl)-ethyl]-
piperazin-1-yl}-benzo[d]isothiazole (500 mg, 1.25 mmols) in THF (10ml)
with triethylamine (0.262 ml, 1.88 mmols) was treated with acetyl chloride
0.088 ml, 1.25 mmols) and stirred for 16 hours at room temperature. The
reaction was quenched with water, extracted with methylene chloride and
filtered through 5 μm PTFE (phase-separating filter), and concentrated in
vacuo, followed by a crystallization from isopropyl alcohol to yield : 510 mg
(93%) of 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-
2,3-dihydro-indol-1-yl}-ethanone. ¹H NMR (400 MHz, DMSO-D₆) δ ppm
2.91 (m, 2 H) 3.07 (m, 2 H) 3.23 (m, 1 H) 3.49 (t, J=8.43 Hz, 1 H) 3.84 (m,
2 H) 4.49 (t, J=8.55 Hz, 1 H) 7.64 (s, 1 H) 7.81 (m, 1 H) 7.94 (m, 1 H) 8.43
(m, 1 H); MP = 160.2-162.3 °C: MS (APCI), (M+1)⁺ = 441.1.

EXAMPLE 43

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3- dihydro-indol-1-yl}-propan-1-on




A solution of 3-{4-[2-(6-chloro-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole (375 mg, 0.94 mmols) in THF (2.0ml) with triethylamine (0.196 ml, 1.41 mmols) was treated with Propionyl chloride (0.083 ml, 0.95 mmols) and stirred for 16 hours at room temperature. The reaction was quenched with sodium hydroxide (1N, 5 ml), extracted with methylene chloride and filtered through 5 μ m PTFE (phase-separating filter), and concentrated in vacuo, followed by a crystallization from isopropyl alcohol to yield: 207 mg (48%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 455.2 [M+H]⁺.

The title compounds of Examples 44 through 50 were prepared from 3-{4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole in a fashion similar to that reported above using the appropriate commercially available acid chloride.

EXAMPLE 44


1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-butan-1-one



Treating with butyryl chloride; yield: 265 mg (60%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 469.2 [M+H]⁺.

EXAMPLE 45


1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one



5 Treating with isobutyryl chloride; yield: 136 mg (31%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 469.3 [M+H]⁺.

EXAMPLE 46


1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-pentan-1-one



15 Treating with valeryl chloride; yield: 310 mg (67%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 483.3 [M+H]⁺.

EXAMPLE 47


1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one



20 Treating with isovaleryl chloride; yield: 198 mg (44%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 483.2 [M+H]⁺.

EXAMPLE 48


{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-6-chloro-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone



Treating with cyclopentane carbonyl chloride; yield: 332 mg (72%)
Isolated in 100% purity @ 254 nm; LCMS (APCI) 495.2 [M+H]⁺.

EXAMPLE 49


{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-6-chloro-2,3-dihydro-indol-1-yl}-cyclohexyl-methanone



Treating with cyclohexane carbonyl chloride; yield: 166 mg (35%)
Isolated in 100% purity @ 254 nm; LCMS (APCI) 509.3 [M+H]⁺.

EXAMPLE 50


3-{4-[2-(6-Chloro-1-methanesulfonyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole



Treating with methane sulfonyl chloride; yield: 83 mg (18%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 477.2 [M+H]⁺.

EXAMPLE 51

5 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid methylamide



10 A solution of 3-{4-[2-(6-Chloro-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole (160 mg, 0.4 mmols in THF (5ml) was treated by dropwise addition with above methyl isocyanate at room temperature and allowed to stir for 72 hours. The reaction was concentrated to dryness, diluted with H₂O and extracted with methylene
15 chloride and filtered through 5 μm PTFE (phase-separating filter), and concentrated in vacuo, followed by a crystallization from acetonitrile to yield: 164 mg (90%). R_t (min) reported is for the following HPLC conditions: 65:35 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 4.856; MS (APCI), (M+1)⁺ =
20 456.1


The title compounds of Examples 52-56 were prepared from 3-{4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole in a fashion similar to that reported above using the appropriate commercially available isocyanate.

25

EXAMPLE 52

5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid ethylamide


-73-



Treating with ethyl isocyanate; yield: 170 mg (90%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 6.216$; MS (APCI), $(M+1)^+ = 470.1$.

EXAMPLE 53


5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl-6-chloro-2,3-dihydro-indole-1-carboxylic acid propylamide



Treating with n-propyl isocyanate; yield: 178 mg (92%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 8.880$; MS (APCI), $(M+1)^+ = 484.1$.

EXAMPLE 54


5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl-6-chloro-2,3-dihydro-indole-1-carboxylic acid isopropylamide



Treating with isopropyl isocyanate; yield: 100 mg (52%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 8.862$; MS (APCI), $(M+1)^+ = 484.1$.

EXAMPLE 55


5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-thyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid tert-butylamide



5 Treating with t-butyl isocyanate; yield: 94 mg (47%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 17.330$; MS (APCI), $(M+1)^+ = 498.2$.

EXAMPLE 55


5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid cyclopentylamide



15 Treating with cyclopentyl isocyanate; yield: 200 mg (98%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 15.499$; MS (APCI), $(M+1)^+ = 510.1$.

EXAMPLE 56


5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid phenylamide



25 Treating with phenyl isocyanate; yield: 120 mg (58%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 13.190$; MS (APCI), $(M+1)^+ = 518.1$.

EXAMPLE 57

6-Chloro-5-(3-chloro-propionyl)-1,3-dihydro-indol-2-one




5

A 500ml rb flask equipped with a stirrer, reflux condenser and heating mantle, was charged with aluminum chloride (AlCl_3) (14.76 g, 0.11 mol), 75 mL of carbon disulfide and 3-chloropropionyl chloride (2.21 ml, 0.023 mol) and this was stirred at room temperature during the portionwise addition of 6-chloro oxindole (3.0 g, 0.0179 mol). This mixture was then heated to reflux for 3 hours, then cooled. The solvent was decanted and the reaction was quenched with addition of ice and water. The suspension was stirred vigorously for 0.5 hours, followed by filtration. The solids were washed with water and then dried overnight in a vacuum oven. Yield = 4.23 g (92%); MS (APCI), $(M + 1)^+ = 259.1$.

15

EXAMPLE 58

6-Chloro-5-(3-chloro-propyl)-1,3-dihydro-indol-2-one



20


6-Chloro-5-(3-chloro-propyl)-1,3-dihydro-indol-2-one was prepared in a similar fashion to that of Example 2 from scheme 1. Yield = 1.15 g (82%); MS (APCI), $(M + 1)^+ = 244.1$.

25

EXAMPLE 59

5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-1,3-dihydro-indol-2-one


-76-



5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-1,3-dihydro-indol-2-one was prepared in a similar fashion to that of Example 3 from scheme 1. Yield: 155 mg (16%) MS (APCI), $(M + 1)^+ = 427.1$.

EXAMPLE 60


3-{4-[3-(6-Chloro-2,3-dihydro-1H-indol-5-yl)-propyl]-piperazin-1-yl}-benzo[d]isothiazole



A solution of 5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-1,3-dihydro-indol-2-one (1.0 g, 2.34 mmol) in THF (40 ml) with stirring at 0°C was treated with $BH_3 \cdot THF$ complex (9.4 ml, 9.4 mmol). The reaction was warmed to reflux for 16 hour. The reaction was cooled and treated with a 10% aqueous solution of sodium carbonate (10 ml) and warmed to reflux for 5.0 hours. The reaction was cooled and the layers were separated. The aqueous layers were extracted with ethyl acetate. The combined organics were dried over magnesium, filtered and the filtrate concentrated. The crude product was eluted through a flash column (1:1 Ethyl acetate:methylene chloride) to give the title compound. Yield = 70 mg (7%). MS (APCI), $(M + 1)^+ = 413.1$.

EXAMPLE 61


1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone



5 A solution of 3-{4-[3-(6-chloro-2,3-dihydro-1H-indol-5-yl)-propyl]-
piperazin-1-yl}-benzo[d]isothiazole (69 mg) in THF (1.0ml) with
triethylamine (0.03 ml) was treated with acetic anhydride (0.03 ml) and
stirred for 4 hours at reflux. The reaction was quenched with water,
extracted with ethyl acetate and filter and concentrated in vacuo. Yield: 34
10 mg (45%) MS (APCI), $(M+1)^+ = 455.1$.

EXAMPLE 62

3-Methyl-but-2-enoic-acid o-tolylamide




15

To a cold 0.25M solution of o-toluidine (5.0ml, 46.85mmole, 1eq) in
dry THF and pyridine (2eq) was added dropwise neat 3,3-dimethyl-acryloyl
chloride and stirred vigorously. The reaction was filtered and the filtrate
20 diluted with EtOAc (equal volume) and washed with H₂O (3x), 1N HCl (2x),
sat. Na₂CO₃ (1x), brine (1x), dried (MgSO₄), and concentrated to a solid. A
mixture of the titled product and its terminal olefin isomer were isolated as
a 1:1 mixture. MS (APCI) = 190.1 $[M+H]^+$.

25

EXAMPLE 63


4,4,8-Trimethyl-3,4-dihydro-1H-quinolin-2-one



To a solution of 3-Methyl-but-2-enoic-acid o-tolylamide (7.27g, 38.41mmole, 1eq) in 1,2-dichlorobenzene (50ml) was added AlCl_3 (30.73g, 230.49mmole, 6eq) and the whole heated to 50-70°C. As the reaction reached about 50°C vigorous gaseous hydrogen chloride (HCl(g)) was released. After the HCl evolution appeared to cease, the reaction was allowed to continue for an additional 10min before cooling. The reaction was cooled and poured into cold H_2O . The heterogeneous mix was extracted with CH_2Cl_2 (3x100ml), dried (MgSO_4) and concentrated to an orange oil which was purified by MPLC (30% EtOAc /hexanes) to give the above titled compound (5.357g, 28.31mmole, 74% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.43 (s, 1H), 7.16 (d, $J = 7.5\text{Hz}$, 1H), 7.04 (d, $J = 7.5\text{Hz}$, 1H), 6.96 (t, $J = 7.5\text{Hz}$, 1H), 2.48 (s, 2H), 2.30 (s, 3H), 1.32 (s, 6H).

EXAMPLE 64


6-(2-Chloro-acetyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one



To a solution of 4,4,8-Trimethyl-3,4-dihydro-1H-quinolin-2-one (3.545g, 18.71mmole, 1eq) in CS_2 (200ml) was added chloroacetyl chloride (2.23ml, 28.06mmole, 1.5eq), followed by aluminum chloride (9.98g, 74.84mmole, 4eq) in one portion. The reaction was heated to reflux for 1h after which thin layer chromatography (TLC) and mass spectroscopy (MS) indicated complete reaction. After cooling, the solvent was decanted and the remaining residue was carefully hydrolyzed with cold H_2O . The resulting precipitate was filtered and dried at 50°C under hivaac to give titled compound as a tan solid (4.79g, 18.03mmole, 96% yield). 100% purity at 254nm; LCMS (APCI) 266.3 $[\text{M}+\text{H}]^+$; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (bs, 1H), 7.81 (s, 1H), 7.67 (s, 1H), 4.65 (s, 2H), 2.52 (s, 2H), 2.32 (s, 3H), 1.36 (s, 6H).

EXAMPLE 65

6-(2-Chloro-ethyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one



5

To a solution of 6-(2-Chloro-acetyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one (4.79g, 18.03mmole, 1.0eq) in trifluoroacetic acid (100ml) was added triethylsilane (7.20ml, 45.08mmole, 2.5eq) and the whole heated to 60°C. After 2h TLC (30% EtOAc/hexanes) and MS indicated complete reaction. The reaction was cooled and poured over ice. After extracting with CH₂Cl₂ (3x100ml), drying (MgSO₄) and concentrating to an oil, the crude was purified by MPLC (30% EtOAc/hexanes) to give the titled compound as a white solid (3.23g, 12.84mmole, 71% yield). 100% purity at 254nm; LCMS (APCI) 252.2 [M+H]⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.41 (bs, 1H), 6.99 (s, 1H), 6.89 (s, 1H), 3.67 (t, J = 7.3Hz, 2H), 2.98 (t, J = 7.3Hz, 2H), 2.46 (s, 2H), 2.21 (s, 3H), 1.30 (s, 6H).


10

15

EXAMPLE 66

2-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one

20




25

A heterogeneous mix of 6-(2-Chloro-ethyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one (2.200g, 8.739mmole, 1.0eq), sodium carbonate (1.158g, 10.924mmole, 1.25 eq), and added 3-Piperazin-1-yl-benzo[d]isothiazole hydrochloride (3.353g, 13.110mmole, 1.5eq) in water (20ml) was heated to 175°C under microwave assistance for 10min. The reaction was diluted with H₂O (100ml), CH₂Cl₂ (100ml) and the layers

separated. The aqueous layer was extracted with CH₂Cl₂ (2x, 50ml) and the organic dried (MgSO₄), concentrated, and the residue purified by MPLC (25%EA/CH₂Cl₂ ----- 50%EA gradient over 20min and hold for 20min ---- 100%EA gradient over 20min). Titled product was obtained as a white crystalline solid in 63% yield. 100% purity at 254nm; LCMS (APCI) 435.2 [M+H]⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, 1H, J = 7.94Hz), 7.80 (d, 1H, J = 7.94Hz), 7.46 (t, 1H, J = 7.94Hz), 7.34 (t, 1H, J = 7.94Hz), 7.02 (s, 1H), 6.91 (s, 1H), 4.78 (s, 1H), 3.69-3.55 (m, 4H), 2.86-2.59 (m, 8H), 2.45 (s, 2H), 2.21 (s, 3H), 1.30 (s, 6H).

EXAMPLE 67

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline




To a stirring solution of 2-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one (0.500g, 1.150mmole) in dry THF (50ml) was added Borane THF complex (1M in THF, 2eq) and the reaction heated to reflux for 3h. Upon cooling the reaction was quenched with MeOH and 1ml acetic acid. The reaction was concentrated to a residue and stripped from MeOH (3x, 50ml). The residue was taken up in DCM, washed with water and the organics dried (MgSO₄) and concentrated to a residue. The residue was taken up in dioxane and the HCl salt was precipitated from HCl dioxane treatment. The salt was collected by filtration and then converted to its free base by treatment with NaOH and extraction with EtOAc to give titled product (0.421g, 1.000mmole, 87% yield). 100% purity at 254nm; LCMS (APCI) 421.2 [M+H]⁺; ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.29 (s, 6 H) 1.73 (m, 2 H) 2.06 (s, 3 H) 3.05 (m, 6 H) 3.28 (m, 2 H) 3.35 (m, 2 H) 3.72 (d, J=13.43 Hz, 2 H) 3.98 (m, 2 H) 6.74 (s, 1 H) 6.93 (d, J=0.98 Hz, 1 H)

Hz, 1 H) 7.37 (t, J=7.69 Hz, 1 H) 7.48 (t, J=7.57 Hz, 1 H) 7.84 (dd, J=11.72, 8.30 Hz, 2 H).

EXAMPLE 68

5 **1-[6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl]-ethanone hydrochloride salt**




To a solution of 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline (0.499g, 1.000mmole) in dry THF (5ml) was added sodium hydride (NaH) (60% dispersed in oil, 1.1 eq). After stirring for 10 min. at room temperature, acetyl chloride was added dropwise. The reaction was stirred for 30 min. and was then diluted with H₂O/EtOAc and the layers separated. The organics were dried and concentrated and the residue subjected to MPLC (EtOAc). The HCl salt was precipitated by treatment of an ether solution of freebase with 1N HCl in ethyl ether (Et₂O) to give titled product (0.125g, 0.270mmole). 100% purity at 254nm; LCMS (APCI) 463.2 [M+H]⁺; ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.14 (s, 2 H) 1.25 (s, 2 H) 1.32 (d, J=8.30 Hz, 3 H) 1.55 (ddd, J=13.31, 7.57, 7.45 Hz, 1 H) 1.90 (s, 3 H) 2.11 (s, 1 H) 2.21 (s, 2 H) 2.27 (s, 1 H) 2.68 (m, 2 H) 2.80 (m, 7 H) 3.02 (ddd, J=13.00, 7.75, 5.37 Hz, 1 H) 3.59 (m, 4 H) 4.66 (m, 1 H) 6.95 (d, J=15.14 Hz, 1 H) 7.03 (dd, J=7.82, 1.71 Hz, 1 H) 7.34 (td, J=7.57, 0.98 Hz, 1 H) 7.45 (m, 1 H) 7.79 (m, 1 H) 7.90 (d, J=8.06 Hz, 1 H).

25

EXAMPLE 69


3-Methyl-but-2-enoic acid (3-chloro-2-methyl-phenyl)-amide



3,3-Diethylacryoyl chloride (21.0 mL, 0.189 mol) was slowly added to a solution of 3-chloro-2-methylaniline (20.0 mL, 0.167 mol) and pyridine (17.0 mL, 0.210 mol) in dichloromethane (210 mL) at 0 °C. After 1.5 h, the reaction was quenched by slow addition of saturated sodium bicarbonate solution (60 mL). The solution was transferred to a separatory funnel and the layers separated. The aqueous layer was back-extracted with dichloromethane (2 x 100 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The resulting purple solid was used directly without purification. MS (APCI): (M+1)⁺ = 224.1.

EXAMPLE 70

7-Chloro-6-(2-chloro-acetyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one




To a solution of 3-methyl-but-2-enoic acid (3-chloro-2-methyl-phenyl)-amide in dichloromethane (167 mL) was slowly added aluminum chloride (91.5 g, 0.686 mol) at a rate to maintain gentle reflux. Upon complete addition of the aluminum chloride, a reflux condenser was attached and the reaction was heated to reflux. After 1.5 h, TLC showed no remaining starting material. Chloroacetyl chloride (20.0 mL, 0.250 mol) was slowly added and the mixture was refluxed for an additional 4 h. The reaction mixture was cooled to ambient temperature, poured into ice water (1000 mL) and extracted with dichloromethane (4 x 300 mL). The organic extracts were combined, washed with saturated sodium chloride solution (200 mL), dried over anhydrous sodium sulfate, filtered and the solvent

removed under reduced pressure. The resulting solid was used directly without purification. MS (APCI): $(M+1)^+ = 300.1$, $(M+3)^+ = 302.1$.

EXAMPLE 71


5 **7-Chloro-6-(2-chloro-ethyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one**



10 To a solution of 7-chloro-6-(2-chloro-acetyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one in trifluoroacetic acid (168.0 mL) was added triethylsilane (59.0 mL, 0.369 mol). The reaction mixture was heated to 60 °C under nitrogen. After 5.5 h, the reaction was cooled to ambient temperature and the reaction was stirred overnight. The reaction mixture
15 was poured into ice water (350 mL). The reaction flask was rinsed with methanol (50 mL). The mixture was vigorously stirred resulting in formation of a precipitate. The solid was filtered and then triturated with hexanes. The solid was recrystallized from hot methyl-*tert*-butyl ether (MTBE) (600 mL) to product as a light tan solid. Yield: 36.0345 g (0.126
20 mol, 75% yield over four steps). MS (APCI): $(M+1)^+ = 288.1$. ^1H NMR (400 MHz, CDCl_3 , δ): 7.50 (br s, 1 H), 7.06 (s, 1 H), 3.71 (t, $J=7.2$ Hz, 2 H), 3.16 (t, $J=7.2$ Hz, 2 H), 2.45 (s, 2 H), 2.30 (s, 3 H), 1.30 (s, 6 H).

EXAMPLE 72


25 **6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one**



A mixture of the product from step C above (5.0016 g, 17.476 mmol), 3-piperazin-1-yl-benzo[d]isothiazole hydrochloride (4.4811 g, 17.520 mmol), potassium carbonate (4.8299 g, 34.946 mmol) and potassium iodine (0.2903 g, 1.749 mmol) were reacted in acetonitrile (29.0 mL) in a microwave reactor for 1 h at 200 °C. The reaction was cooled to room temperature, diluted with H₂O and filtered. The solid was washed with H₂O and hexanes. The resulting solid was eluted through a flash column (silica gel 60, 230-400 mesh, 0-3% MeOH in CH₂Cl₂ gradient over 1 h) to give an off-white solid. Yield: 5.6591 g (12.065 mmol, 69%). CHN: Calculated for C₂₅H₂₉ClN₄OS•0.02 CH₂Cl₂: C, 63.84; H, 6.22; N, 11.90. Found: C, 63.49, H, 6.13; N, 11.72. LC-MS (APCI): (M+1)⁺ = 471.0. ¹H NMR (400 MHz, CDCl₃, δ): 7.90 (d, J=8.2 Hz, 1 H), 7.80 (d, J=8.0 Hz, 1 H), 7.58 (s, 1 H), 7.45 (ddd, J=8.0, 7.1, 1.0 Hz, 1 H), 7.34 (ddd, J=8.2, 7.1, 1.0 Hz, 1 H), 7.08 (s, 1 H), 3.61 (m, 4 H), 2.98 (m, 2 H), 2.80 (s, 4 H), 2.68 (m, 2 H), 2.44 (s, 2 H), 2.31 (s, 3 H), 1.30 (s, 6 H).

EXAMPLE 73

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline




To a solution of 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one (2.5024 g, 5.335 mmol) in anhydrous THF (18 mL) under a nitrogen atmosphere was added borane-THF complex (1.0 M, 6.4 mL, 6.4 mmol). The reaction was refluxed overnight. Additional borane-THF complex (1.0 M, 6.4 mL, 6.4 mmol) was added and the reaction was refluxed for an additional 4 h then cooled to ambient temperature. The excess reagent was quenched by

slow addition of methanol (MeOH, 20.0 mL). The reaction mixture was heated to reflux overnight then cooled to ambient temperature. The organic solvents were removed *in vacuo* to give a white residue. The residue was dissolved in MeOH (20 mL) and removed *in vacuo*. The residue was dissolved in methylene chloride (CH₂Cl₂) and washed with saturated sodium bicarbonate solution (NaHCO₃, 2 x 30 mL) and the organic layer was dried over anhydrous sodium sulfate (Na₂SO₄), filtered and concentrated to an oil. The oil was eluted through a flash column (silica gel 60, 230-400 mesh, 0-5% MeOH in CH₂Cl₂ gradient over 1 h) to give an off-white solid. Yield = 1.6876 g (3.709 mmol, 70%). CHN: Calculated for C₂₅H₃₁ClN₄S•0.05 CH₂Cl₂: C, 65.50; H, 6.82; N, 12.20. Found: C, 65.14, H, 6.91; N, 11.91. MS (APCI), (M+1)⁺ = 456. ¹H-NMR (400 MHz, CDCl₃, δ): 7.91 (d, J=8.2 Hz, 1 H), 7.80 (d, J=8.2 Hz, 1 H), 7.45 (t, J=7.4 Hz, 1 H), 7.34 (t, J=7.4 Hz, 1 H), 7.00 (s, 1 H), 3.76 (br s, 1 H), 3.60 (m, 4 H), 3.36 (m, 2 H), 2.90 (m, 2 H), 2.80 (m, 4 H), 2.65 (m, 2 H), 2.17 (s, 3 H), 1.71 (m, 2 H), 1.28 (s, 6 H).

EXAMPLE 74

1-{6-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-7-chloro-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone methane sulfonate




To a stirred solution of 6-[2-(4-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-7-chloro-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline (0.4497 g, 0.988 mmol) in THF (10 mL) under a nitrogen atmosphere was added acetyl chloride (77.4 μL, 1.089 mmol). The reaction was stirred O.N. Additional acetyl chloride (0.0250 mL, 0.351 mmol) was added to try to drive the reaction to completion. After 0.5 h, there was no change in TLC.

The reaction was quenched by slow addition of sat. NaHCO_3 solution (10 mL) and ethyl acetate (EtOAc, 10 mL). The layers were separated and the organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. The residue was eluted through a flash column (silica gel 60, 230-400 mesh, 25-75% EtOAc in hexanes gradient over 1 h) to a clear oil. Attempts to crystallize using CH_2Cl_2 and CH_2Cl_2 /hexanes were unsuccessful. The oil was taken up in THF (9.5 mL) and heated to 40 °C. Methanesulfonic acid (61.5 μL , 0.948 mmol) was added and after 5 min, the reaction was allowed to cool to ambient temperature. The product was allowed to crystallize overnight. Hexanes were added to the reaction mixture and the solid was filtered and washed with hexanes. The wet solid was dried in a vacuum oven at 60 °C to give a white/off-white crystalline solid as the mesylate salt. Yield: 0.4576 g (0.771 mmol, 78%). CHN: Calculated for $\text{C}_{27}\text{H}_{33}\text{ClN}_4\text{OS}\cdot\text{CH}_4\text{O}_3\text{S}\cdot 0.34 \text{ H}_2\text{O}$: C, 56.11; H, 6.34; N, 9.35. Found: C, 55.72, H, 6.01; N, 8.97. MS (APCI), $(\text{M}+1)^+ = 498$. ^1H -NMR (400 MHz, CDCl_3 , δ): 11.60 (br s, 0.6 H), 11.47 (br s, 0.4 H), 7.84 (m, 2 H), 7.51 (m, 1 H), 7.40 (m, 1 H), 7.35 (s, 0.6 H), 7.32 (s, 0.4 H), 4.65 (m, 0.6 H), 4.16 (m, 1.4 H), 3.97 (m, 2 H), 3.70 (m, 1 H), 3.32 (m, 4 H), 3.01 (m, 1 H), 2.90 (s, 3 H), 2.28 (s, 1.2 H), 2.25 (s, 1.8 H), 2.11 (s, 1 H), 1.90 (m, 1.2 H), 1.85 (s, 2.4 H), 1.81 (s, 3.6 H), 1.75 (m, 1.2 H), 1.55 (m, 0.6 H), 1.35 (s, 1.8 H), 1.33 (s, 1.2 H), 1.25 (s, 1.2 H), 1.14 (s, 1.8 H).

EXAMPLE 75

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-propan-1-one methane sulfonate



To a stirred solution of 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline (0.4500g, 0.989 mmol) in THF (10 mL) under a nitrogen atmosphere was added propionyl chloride (94.6 μ L, 1.089 mmol). The reaction was stirred O.N.

5 Additional propionyl chloride (31.0 μ L, 0.357 mmol) was added to try to drive the reaction to completion. After 0.5 h, there was no change in TLC. The reaction was quenched by slow addition of sat. NaHCO_3 solution (10 mL) and EtOAc (10 mL). The layers were separated and the organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. The

10 residue was eluted through a flash column (silica gel 60, 230-400 mesh, 25-75% EtOAc in hexanes gradient over 1 h) to a clear oil. Attempts to crystallize using CH_2Cl_2 and CH_2Cl_2 /hexanes were unsuccessful. The oil was taken up in THF (9.0 mL) and heated to 40 $^\circ\text{C}$. Methanesulfonic acid (59.0 μ L, 0.909 mmol) was added and after 5 min, the reaction was


15 allowed to cool to ambient temperature. The product was allowed to crystallize overnight. Hexanes were added to the reaction mixture and the solid was filtered and washed with hexanes. The wet solid was dried in a vacuum oven at 60 $^\circ$ to give a white/off-white crystalline solid as the mesylate salt. Yield: 0.4484 g (0.738 mmol, 75%). CHN: Calculated for

20 $\text{C}_{28}\text{H}_{35}\text{ClN}_4\text{OS}\cdot\text{CH}_4\text{O}_3\text{S}$: C, 57.36; H, 6.47; N, 9.23. Found: C, 57.01, H, 6.23; N, 8.90. MS (APCI), $(\text{M}+1)^+ = 512$. ^1H -NMR (400 MHz, CDCl_3 , δ): 11.58 (br s, 0.6 H), 11.45 (br s, 0.4 H), 7.84 (m, 2 H), 7.51 (m, 1 H), 7.40 (m, 1 H), 7.34 (s, 0.6 H), 7.31 (s, 0.4 H), 4.66 (m, 0.6 H), 4.16 (m, 1.4 H), 3.98 (m, 2 H), 3.71 (m, 1 H), 3.36 (m, 2 H), 3.26 (m, 1 H), 3.00 (m, 0.6 H),

25 2.90 (s, 3 H), 2.60 (m, 0.4 H), 2.48 (m, 0.4 H), 2.23 (s, 1.8 H), 2.16 (m, 0.6 H), 2.08 (s, 1.2 H), 1.89 (m, 1.4 H), 1.75 (s, 6 H), 1.54 (m, 0.6 H), 1.34 (s, 1.8 H), 1.32 (s, 1.2 H), 1.24 (s, 1.2 H), 1.23 (t, $J=7.5$ Hz, 1.2 H), 1.13 (s, 1.8 H), 1.04 (t, $J=7.5$ Hz, 1.8 H).

EXAMPLE 76


6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-cyclopropylmethanone



To a stirred solution of 6-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline (0.4496g, 0.988 mmol) in THF (10 mL) under a nitrogen atmosphere was added cyclopropanecarbonyl chloride (98.8 μ L, 1.089 mmol). The reaction was stirred O.N. Additional propionyl chloride (31.0 μ L, 0.342 mmol) was added to try to drive the reaction to completion. After 0.5 h, there was no change in TLC. The reaction was quenched by slow addition of sat. NaHCO_3 solution (10 mL) and EtOAc (10 mL). The layers were separated and the organic layer was dried over anhydrous sodium sulfate (Na_2SO_4), filtered and concentrated *in vacuo*. The residue was eluted through a flash column (silica gel 60, 230-400 mesh, 25-75% EtOAc in hexanes gradient over 1 h) to give a white foam. The foam was dried overnight under high vacuum. Yield: 0.4477 g (0.856 mmol, 87%). CHN: Calculated for $\text{C}_{29}\text{H}_{35}\text{ClN}_4\text{OS}\cdot 0.07 \text{CH}_2\text{Cl}_2$: C, 65.99; H, 6.69; N, 10.49. Found: C, 65.87, H, 6.50; N, 10.19. MS (APCI), $(\text{M}+1)^+ = 524$. $^1\text{H-NMR}$ (400 MHz, CDCl_3 , δ): 7.91 (d, $J=8.1$ Hz, 1 H), 7.81 (d, $J=8.1$ Hz, 1 H), 7.46 (ddd, $J=8.1, 7.0, 1.0$ Hz, 1 H), 7.35 (ddd, $J=8.1, 7.0, 1.0$ Hz, 1 H), 7.14 (s, 0.9 H), 7.08 (s, 0.1 H), 4.65 (m, 1 H), 3.60 (m, 4 H), 3.04 (m, 2 H), 2.81 (m, 4 H), 2.71 (m, 2 H), 2.34 (s, 2.7 H), 2.10 (s, 0.3 H), 1.91 (m, 1 H), 1.58 (m, 3 H), 1.37 (m, 3 H), 1.21 (s, 0.3H), 1.17 (s, 2.7 H), 1.05 (m, 2 H), 0.83 (m, 1 H), 0.55 (m, 1 H).

EXAMPLE 77

7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-1,3,4,5-tetrahydro-benzo[b]azepin-2-one



A. 1,3,4,5-tetrahydro-benzo[b]azepin-2-one

Beilstein Registry Number 137258; CAS Registry Number 4424-80-0

Horning, E. C.; Stromberg, V. L.; Lloyd, H. A. *J. Am. Chem. Soc.* **1952**, *74*, 5153-5155.

B. 7-(2-Chloro-acetyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

To a 1-L round-bottom flask was added AlCl_3 (83.4 g, 626 mmol), CS_2 (500 mL), chloroacetyl chloride (12.0 mL, 156.4 mmol), and azepinone (from step A) [16.79 g, 104.3 mmol]. The reaction was stirred to a thick gummy deposit, refluxed for 3 h and cooled to 0°C . The solvent was decanted and ice water (300 mL) was added very slowly (CAUTION: exotherm and HCl gas produced) until a solid suspension was formed. The solid was collected by filtration and washed with H_2O (50 mL) to produce a brown solid. This material was recrystallized in methanol/ H_2O to give the title compound (19.2 g, 78%) as a dark tan solid: ^1H NMR (300 MHz, CDCl_3) δ 8.50 (s, 1H), 7.87-7.81 (m, 2H), 7.10 (d, $J = 9.0$ Hz, 1H), 4.68 (s, 2H), 2.89 (t, $J = 7.2$ Hz, 2H), 2.42 (t, $J = 7.2$ Hz, 2H), 2.36-2.25 (m, 2H).

C. 7-(2-Chloro-ethyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

Into a 250-mL round-bottom flask was placed the ketone from step B (5.00 g, 21.1 mmol) and TFA (25 mL). The solution was cooled to 0°C and triethylsilane (10.2 mL, 63.2 mmol) was added dropwise over a 5 min period. The reaction was warmed to 50°C and stirred for 18 h. The


mixture was cooled to room temperature, diluted with H₂O (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over Na₂SO₄, and concentrated under high vacuum to produce the title compound (5.1 g, >99%): ¹H NMR (300 MHz, CDCl₃) δ 9.19 (s, 1H), 7.17-7.12 (m, 2H), 7.00 (d, *J* = 9.0 Hz, 1H), 3.72 (t, *J* = 9.0 Hz, 2H), 3.06 (t, *J* = 7.2 Hz, 2H), 2.80 (t, *J* = 7.2 Hz, 2H), 2.41-2.28 (m, 4H).

D. 7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

A suspension of the compound from step C (1.00 g, 4.48 mmol) in CH₃CN (40 mL) was treated with 3-piperazin-1-yl-benzo[d]isoxazole • HCl (1.20 g, 4.98 mmol), NaI (744 mg, 4.96 mmol), and potassium carbonate (K₂CO₃) (1.87 g, 13.5 mmol). The mixture was heated to reflux under nitrogen (N₂) for 44 h, then allowed to cool. The mixture was diluted with H₂O (100 mL) and extracted with CH₂Cl₂ (4 x 100 mL). The combined organic layers were dried over Na₂SO₄, decanted, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, EtOAc) to give the title compound (0.95 g, 54%) as a white powder: mp 199-200 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, *J* = 8.1 Hz, 1H), 7.45-7.52 (m, 2H), 7.19-7.25 (m, 1H), 7.18 (s, 1H), 7.08-7.11 (m, 2H), 6.88 (d, *J* = 8.4 Hz, 1H), 3.61-3.64 (m, 4H), 2.65-2.86 (m, 10H), 2.35 (t, *J* = 7.5 Hz, 2H), 2.23 (m, 2H); ESI MS *m/z* 391 [C₂₃H₂₆N₄O₂ + H]⁺; R_f 0.41 (silica gel, 95:5 EtOAc/MeOH); HPLC 97.0% (AUC), *t*_R = 11.36 min. Anal. Calc'd for C₂₃H₂₆N₄O₂: C, 70.75; H, 6.71; N, 14.35. Found: C, 70.71; H, 6.72; N, 14.28.

EXAMPLE 78

1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone methanesulfonate



A. 7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-2,3,4,5-tetrahydro-1H-benzo[b]azepine



5 A suspension of the title compound of Example 77 (0.36 g, 0.92 mmol) in THF (8 mL) was treated with a solution of BH_3 in THF (4.0 mL, 1.5 M, 6.0 mmol). The resulting clear solution was heated to reflux for 3 h, then allowed to cool. The reaction was quenched with 6N HCl until gas evolution subsided. The mixture was heated to reflux for 1 h, allowed to cool, and then made basic (pH 8) with solid sodium hydroxide (NaOH) and
10 a 1N NaOH solution. The biphasic mixture was diluted with H_2O (50 mL) and extracted with CH_2Cl_2 (3 x 50 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 hexanes/EtOAc) to give the title compound (0.22 g, 63%) as a colorless oil: ^1H NMR (300 MHz, CDCl_3) δ 7.70 (d, J = 8.1 Hz, 1H), 7.44-7.52 (m, 2H), 7.19-7.25 (m, 1H), 6.96 (d, J = 1.7 Hz, 1H), 6.89 (dd, J = 7.9, 2.0 Hz, 1H), 6.67 (d, J = 7.8 Hz, 1H), 3.71 (bs, 1H), 3.61-3.64 (m, 4H), 3.02 (t, J = 5.3 Hz, 2H), 2.62-2.78 (m, 10H), 1.76-1.83 (m, 2H), 1.60-1.67 (m, 2H); ESI
15 MS m/z 377 [$\text{C}_{23}\text{H}_{28}\text{N}_4\text{O} + \text{H}$] $^+$; R_f 0.52 (silica gel, 1:1 hexanes/EtOAc).
20

B. 1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone methanesulfonate

25 A solution of the title compound from step A (0.22 g, 0.58 mmol) in CH_2Cl_2 (12 mL) was treated with acetic anhydride (Ac_2O) (55 μL , 0.58 mmol). After stirring at room temperature under N_2 for 15 h, the reaction was quenched with saturated NaHCO_3 (30 mL) and extracted with CH_2Cl_2 (3 x 50 mL). The combined organic layers were dried over Na_2SO_4 , decanted,

and the solvent was removed in vacuo. The residue was purified by flash column chromatography (Silica gel, 2:1 EtOAc/hexanes) to give a white solid residue (0.21 g, 0.50 mmol, 86%). The residue was dissolved in EtOAc (15 mL) and treated with methanesulfonic acid (CH₃SO₃H) (2M in Et₂O, 0.25 mL, 1 mmol). After stirring for 5 min, the resulting precipitate was isolated by filtration, washed with Et₂O (3 x 6 mL), and dried in a vacuum oven at 50°C for 4 d to give the title compound (228 mg, 88%) as a white powder: mp 234-235 °C (dec); ¹H NMR (300 MHz, CDCl₃) δ 11.99 (s, 1H), 7.51-7.63 (m, 3H), 7.27-7.33 (m, 1H), 7.13-7.17 (m, 2H), 7.08 (d, *J* = 7.8 Hz, 1H), 4.68 (m, 1H), 4.20 (d, *J* = 14.5 Hz, 2H), 3.99 (t, *J* = 12.3 Hz, 2H), 3.72 (d, *J* = 12.2 Hz, 2H), 3.08-3.33 (m, 6H), 2.90 (s, 3H), 2.68-2.74 (m, 2H), 2.50-2.59 (m, 1H), 1.74-1.99 (m, 3H), 1.83 (s, 3H), 1.32-1.40 (m, 1H); ESI MS *m/z* 419 [C₂₅H₃₀N₄O₂ + H]⁺; R_f 0.47 (silica gel, 95:5 EtOAc/MeOH); HPLC >99% (AUC), *t*_R = 12.12 min. Anal. Calc'd for C₂₅H₃₀N₄O₂ • CH₃SO₃H: C, 60.68; H, 6.66; N, 10.89. Found: C, 60.62; H, 6.57; N, 10.82.

EXAMPLES 79A and 79B



7-{2-[4-(5-Fluoro-b nzo[d]isothiazol-3-yl)-pip razin-1-yl]-ethyl}-1,3,4,5-tetrahydro-b nzo[b]azepin-2-one (Ex. 79A)

A suspension of 7-chloroethylazepin-2-one (1.71 g, 7.64 mmol) and 5-fluoro-3-piperazin-1-yl-benzo[d]isothiazole (1.99 g, 8.39 mmol) in CH₃CN (80 mL) was treated with NaI (1.27 g, 8.47 mmol), and K₂CO₃ (2.12 g, 15.3 mmol). The mixture was heated to reflux under N₂ for 3 days (d), then allowed to cool. The mixture was diluted with H₂O (200 mL) and extracted with CH₂Cl₂ (3 x 200 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 EtOAc/hexanes) to give an off-white solid (2.58 g, 79%). The solid was recrystallized from EtOAc/hexanes to give the title compound as a white fluffy solid: mp 168-169 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.75 (dd, *J* = 8.9, 4.6 Hz, 1H), 7.54 (dd, *J* = 9.3, 2.2 Hz, 1H), 7.23-7.29 (m, 2H), 7.09-7.12 (m, 2H), 6.89 (d, *J* = 8.4 Hz, 1H), 3.54-3.57 (m, 4H), 2.67-2.85 (m, 10H), 2.34-2.36 (m, 2H), 2.21-2.26 (m, 2H); ESI MS *m/z* 425 [C₂₃H₂₅FN₄OS + H]⁺; *R*_f 0.31 (silica gel, EtOAc); HPLC >99% (AUC), *t*_R = 12.28 min. Anal. Calcd for C₂₃H₂₅FN₄OS: C, 65.07; H, 5.94; N, 13.20. Found: C, 64.94; H, 5.97; N, 13.13.


7-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-1,3,4,5-tetrahydro-benzo[b]azepin-2-one (Ex. 79B)

A suspension of 7-chloroethylazepin-2-one (1.49 g, 6.66 mmol) and 7-fluoro-3-piperazin-1-yl-benzo[d]isothiazole • HCl (2.00 g, 7.31 mmol) in CH₃CN (70 mL) was treated with NaI (1.10 g, 7.34 mmol), and K₂CO₃ (2.77 g, 20.0 mmol). The mixture was heated to reflux under N₂ for 3 d, then allowed to cool. The mixture was diluted with H₂O (200 mL) and extracted with CH₂Cl₂ (3 x 200 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 4:1 EtOAc/hexanes) to give the title compound (2.54 g, 90%) as an off-white solid: mp 180-181 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, *J* = 8.1 Hz,

1H), 7.31-7.37 (m, 1H), 7.09-7.17 (m, 4H), 6.88 (d, $J = 8.5$ Hz, 1H), 3.59-3.62 (m, 4H), 2.66-2.87 (m, 10H), 2.34-2.36 (m, 2H), 2.21-2.25 (m, 2H); ESI MS m/z 425 [$C_{23}H_{25}FN_4OS + H$] $^+$; R_f 0.22 (silica gel, EtOAc); HPLC >99% (AUC), $t_R = 12.79$ min. Anal. Calc'd for $C_{23}H_{25}FN_4OS$: C, 65.07; H, 5.94; N, 13.20. Found: C, 64.86; H, 5.86; N, 13.01.

EXAMPLE 80

1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one



A. 9-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-1,2,4,5,6,7-hexahydro-azepino[3,2,1-*h*]indole

A suspension of the title compound of Example 79A (1.46 g, 3.44 mmol) in THF (10 mL) was treated dropwise with a solution of BH_3 in THF (22 mL, 1.0 M, 22 mmol). The mixture was heated at reflux for 3 h, then allowed to cool. The reaction was quenched with 6N HCl until gas evolution subsided. The mixture was heated at reflux for 30 min, allowed to cool, and then made basic (pH ~8-9) with solid NaOH and 1 N NaOH. The biphasic mixture was extracted with CH_2Cl_2 (3 x 100 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, gradient from 2:1 to 1:1 hexanes/EtOAc) to give the title compound (0.53 g, 38%) as a colorless oil: 1H NMR (300 MHz, $CDCl_3$) δ 11.56 (bs, 1H), 7.82-7.86 (m, 2H), 7.49-7.54 (m, 1H), 7.40-7.43 (m, 1H), 6.88 (s, 1H), 6.75 (s, 1H), 4.03-4.11 (m, 4H), 3.46-3.70 (m,


2H), 3.04-3.36 (m, 8H), 2.91-2.97 (m, 4H), 2.89 (s, 3H), 2.69-2.73 (m, 2H), 1.86 (bm, 2H), 1.70 (bm, 2H); ESI MS m/z 419 [$C_{25}H_{30}N_4S + H$]⁺; R_f 0.34 (silica gel, 1:1 EtOAc/hexanes).

5 **B. 1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one**

A solution of the title compound from step A (0.53 g, 1.29 mmol) in CH_2Cl_2 (15 mL) was treated with acetic anhydride (0.13 mL, 1.4 mmol) under N_2 . After stirring at room temperature overnight, saturated $NaHCO_3$ (30 mL)
10 was added, and the mixture was extracted with CH_2Cl_2 (3 x 50 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, gradient from 2:1 to 3:1 EtOAc/hexanes) to give a white semi-solid (0.53 g, 91%). The semi-solid (0.53 g, 1.2 mmol)
15 was dissolved in EtOAc (30 mL) and treated with CH_3SO_3H (2M in Et_2O , 0.59 mL, 1.2 mmol). After stirring for 30 minutes (min), the resulting precipitate was isolated by filtration, washed with Et_2O (3 x 10 mL), and dried in a vacuum oven at 55°C overnight to give the title compound (0.49 g, 76%) as a white powder: mp 188-191 °C (dec); 1H NMR (300 MHz, $CDCl_3$) δ 11.86 (s, 1H), 7.50-7.64 (m, 3H), 7.28-7.33 (m, 2H), 7.15 (dd, J = 7.9, 1.9 Hz, 1H), 7.01 (d, J = 7.9 Hz, 1H), 4.73-4.77 (m, 1H), 4.21 (d, J = 14.6 Hz, 2H), 3.95-4.04 (m, 2H), 3.74 (d, J = 11.4 Hz, 2H), 3.10-3.35 (m, 6H), 2.91 (s, 3H), 2.47-2.57 (m, 1H), 2.14-2.26 (m, 2H), 1.85-1.95 (m, 1H), 1.45-1.74 (m, 3H), 1.42 (s, 3H), 1.17 (s, 3H), 1.07 (t, J = 7.4 Hz, 3H); ESI
20 MS m/z 461 [$C_{28}H_{36}N_4O_2 + H$]⁺; R_f 0.66 (silica gel, 2:1 EtOAc/hexanes); HPLC 98.4% (AUC), t_R = 13.67 min. Anal. Calc'd for $C_{28}H_{36}N_4O_2 \cdot CH_3SO_3H \cdot 1.2H_2O$: C, 60.23; H, 7.39; N, 9.69. Found: C, 60.24; H, 7.40; N, 9.49.
25

30 **EXAMPLE 81**

1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one



A. 9-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,4,5,6,7-hexahydro-azepino[3,2,1-h]indole

A suspension of the title compound from Example 79B (1.02 g, 2.40 mmol) in THF (10 mL) was treated dropwise with a solution of BH₃ in THF (15 mL, 1.0 M, 15 mmol). The mixture was heated at reflux for 2.5 h, then allowed to cool. The reaction was quenched with 1N HCl until gas evolution subsided. The mixture was heated at reflux for 30 min, allowed to cool, and then made basic (pH ~8-9) with 1 N NaOH. The biphasic mixture was extracted with CH₂Cl₂ (3 x 100 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 1:1 hexanes/EtOAc) to give the title compound (0.79 g, 80%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ 11.56 (bs, 1H), 7.82-7.86 (m, 2H), 7.49-7.54 (m, 1H), 7.40-7.43 (m, 1H), 6.88 (s, 1H), 6.75 (s, 1H), 4.03-4.11 (m, 4H), 3.46-3.70 (m, 2H), 3.04-3.36 (m, 8H), 2.91-2.97 (m, 4H), 2.89 (s, 3H), 2.69-2.73 (m, 2H), 1.86 (bm, 2H), 1.70 (bm, 2H); ESI MS *m/z* 419 [C₂₅H₃₀N₄S + H]⁺; *R*_f 0.34 (silica gel, 1:1 EtOAc/hexanes).


B. 1-[7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-propan-1-one

A solution of the title compound from step A (0.72 g, 1.75 mmol) in CH₂Cl₂ (20 mL) was treated with acetic anhydride (0.17 mL, 1.8 mmol) under N₂. After stirring at room temperature overnight, the reaction mixture was diluted with CH₂Cl₂ (50 mL) and washed with saturated NaHCO₃ (50 mL). The aqueous layer was extracted with CH₂Cl₂ (2 x 50 mL), and the combined organic layers were dried over Na₂SO₄, filtered, and the solvent

was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 4:1 EtOAc/hexanes) to give a white semi-solid (0.60 g, 76%). The semi-solid (0.60 g, 1.3 mmol) was dissolved in EtOAc (20 mL) and treated with CH₃SO₃H (2M in Et₂O, 0.66 mL, 1.3 mmol). After stirring for 10 min, the clear solution was diluted with Et₂O (20 mL) to give a gummy precipitate. After stirring for 10 min, the solvent was removed in vacuo to give a gummy residue. The residue was suspended in Et₂O (40 mL), and the mixture was stirred until the residue became particulate. The solid was isolated by filtration, washed with Et₂O (4 x 20 mL), and dried in a vacuum oven at 45 °C overnight to give the title compound (0.62 g, 85%) as a white powder: mp 188-191 °C (dec); ¹H NMR (300 MHz, CDCl₃) δ 11.86 (s, 1H), 7.50-7.64 (m, 3H), 7.28-7.33 (m, 2H), 7.15 (dd, *J* = 7.9, 1.9 Hz, 1H), 7.01 (d, *J* = 7.9 Hz, 1H), 4.73-4.77 (m, 1H), 4.21 (d, *J* = 14.6 Hz, 2H), 3.95-4.04 (m, 2H), 3.74 (d, *J* = 11.4 Hz, 2H), 3.10-3.35 (m, 6H), 2.91 (s, 3H), 2.47-2.57 (m, 1H), 2.14-2.26 (m, 2H), 1.85-1.95 (m, 1H), 1.45-1.74 (m, 3H), 1.42 (s, 3H), 1.17 (s, 3H), 1.07 (t, *J* = 7.4 Hz, 3H); ESI MS *m/z* 461 [C₂₈H₃₆N₄O₂ + H]⁺; *R*_f 0.66 (silica gel, 2:1 EtOAc/hexanes); HPLC 98.4% (AUC), *t*_R = 13.67 min. Anal. Calcd for C₂₈H₃₆N₄O₂ • CH₃SO₃H • 1.2H₂O: C, 60.23; H, 7.39; N, 9.69. Found: C, 60.24; H, 7.40; N, 9.49.

EXAMPLE 82

9-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,4,5,6,7-hexahydro-azepino[3,2,1-*h*]indole methanesulfonate



A. 9-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,4,5,6,7-hexahydro-azepino[3,2,1-*h*]indole methanesulfonate

A solution of 7-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-1,3,4,5-tetrahydro-benzo[b]azepin-2-one (5.27 g, 13.0 mmol) in THF (50 mL) was treated dropwise with a solution of BH₃ in THF (80 mL, 1.0 M, 80 mmol). The mixture was heated at reflux for 3 h, then allowed to cool. The reaction was quenched with 1N HCl until gas evolution subsided. The mixture was heated at reflux for 30 min, allowed to cool, and then made basic (pH ~8-9) with 1 N NaOH. The biphasic mixture was separated and the organic layer was washed with brine (100 mL). The combined aqueous layers were extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 hexanes/EtOAc) to give the title compound (2.94 g, 58%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ 11.56 (bs, 1H), 7.82-7.86 (m, 2H), 7.49-7.54 (m, 1H), 7.40-7.43 (m, 1H), 6.88 (s, 1H), 6.75 (s, 1H), 4.03-4.11 (m, 4H), 3.46-3.70 (m, 2H), 3.04-3.36 (m, 8H), 2.91-2.97 (m, 4H), 2.89 (s, 3H), 2.69-2.73 (m, 2H), 1.86 (bm, 2H), 1.70 (bm, 2H); ESI MS *m/z* 419 [C₂₅H₃₀N₄S + H]⁺; *R_f* 0.34 (silica gel, 1:1 EtOAc/hexanes).

B. 1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one methanesulfonate

A solution of the compound from step A (0.93 g, 2.4 mmol) in CH₂Cl₂ (25 mL) under N₂ was cooled in an ice bath, treated with Et₃N (0.37 mL, 2.6 mmol) and propionyl chloride (0.41 mL, 4.7 mmol), and warmed to room temperature. After stirring at room temperature overnight, the reaction mixture was diluted with CH₂Cl₂ (25 mL) and washed with saturated NaHCO₃ (50 mL). The aqueous layer was extracted with CH₂Cl₂ (2 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, gradient from 1:1 to 2:1 EtOAc/hexanes) to give a colorless residue (0.79 g, 74%). The residue


(0.65 g, 1.4 mmol) was dissolved in EtOAc (10 mL) and treated with CH₃SO₃H (2M in Et₂O, 0.72 mL, 1.4 mmol). After stirring for 30 min, the resulting precipitate was isolated by filtration, washed with Et₂O, and dried in a vacuum oven at 55 °C overnight to give the title compound (0.66 g, 83%) as a white powder: mp 188-191 °C (dec); ¹H NMR (300 MHz, CDCl₃) δ 11.86 (s, 1H), 7.50-7.64 (m, 3H), 7.28-7.33 (m, 2H), 7.15 (dd, *J* = 7.9, 1.9 Hz, 1H), 7.01 (d, *J* = 7.9 Hz, 1H), 4.73-4.77 (m, 1H), 4.21 (d, *J* = 14.6 Hz, 2H), 3.95-4.04 (m, 2H), 3.74 (d, *J* = 11.4 Hz, 2H), 3.10-3.35 (m, 6H), 2.91 (s, 3H), 2.47-2.57 (m, 1H), 2.14-2.26 (m, 2H), 1.85-1.95 (m, 1H), 1.45-1.74 (m, 3H), 1.42 (s, 3H), 1.17 (s, 3H), 1.07 (t, *J* = 7.4 Hz, 3H); ESI MS *m/z* 461 [C₂₈H₃₆N₄O₂ + H]⁺; *R*_f 0.66 (silica gel, 2:1 EtOAc/hexanes); HPLC 98.4% (AUC), *t*_R = 13.67 min. Anal. Calc'd for C₂₈H₃₆N₄O₂ • CH₃SO₃H • 1.2H₂O: C, 60.23; H, 7.39; N, 9.69. Found: C, 60.24; H, 7.40; N, 9.49.

C. 9-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,2,4,5,6,7-hexahydro-azepino[3,2,1-*h*]indole methanesulfonate

A solution of the compound from step B (free base, 0.24 g, 0.53 mmol) in THF (5 mL) was treated dropwise with a solution of BH₃ in THF (3.5 mL, 1.0 M, 3.5 mmol). The mixture was heated to reflux for 3 h, then allowed to cool. The reaction was quenched with 1N HCl until gas evolution subsided. The mixture was heated to reflux for 30 min, allowed to cool, and then made basic (pH ~8-9) with 1 N NaOH. The biphasic mixture was diluted with H₂O (25 mL) and extracted with CH₂Cl₂ (3 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 4:1 hexanes/EtOAc) to give a colorless residue (0.15 g, 65%). The residue (0.15 mg, 0.34 mmol) was dissolved in EtOAc (5 mL) and treated with CH₃SO₃H (2M in Et₂O, 0.17 mL, 0.34 mmol). The mixture was diluted with EtOAc (2 mL) and Et₂O (5 mL). After stirring for 15 min, the solid was isolated by filtration, washed with Et₂O, and dried in a vacuum oven at 55 °C overnight to give the title compound (0.13 mg,

71%) as a white powder: mp 188-189 °C (dec); ¹H NMR (300 MHz, CDCl₃) δ 11.56 (bs, 1H), 7.82-7.86 (m, 2H), 7.49-7.54 (m, 1H), 7.40-7.43 (m, 1H), 6.88 (s, 1H), 6.75 (s, 1H), 4.03-4.11 (m, 4H), 3.46-3.70 (m, 2H), 3.04-3.36 (m, 8H), 2.91-2.97 (m, 4H), 2.89 (s, 3H), 2.69-2.73 (m, 2H), 1.86 (bm, 2H), 1.70 (bm, 2H); ESI MS *m/z* 419 [C₂₅H₃₀N₄S + H]⁺; *R_f* 0.34 (silica gel, 1:1 EtOAc/hexanes); HPLC 96.4% (AUC), *t_R* = 10.52 min. Anal. Calc'd for C₂₅H₃₀N₄S • CH₃SO₃H • 0.4H₂O: C, 59.84; H, 6.72; N, 10.74. Found: C, 59.90; H, 6.65; N, 10.49.

EXAMPLE 82




1-{7-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl-propan-1-one methanesulfonate

A solution of 7-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-1,3,4,5-tetrahydro-benzo[b]azepin (0.91 g, 2.3 mmol) in CH₂Cl₂ (25 mL) under N₂ was cooled in an ice bath, treated with Et₃N (0.36 mL, 2.6 mmol) and isobutyryl chloride (0.50 mL, 4.8 mmol), and warmed to room temperature. After stirring at room temperature overnight, the reaction mixture was washed with saturated NaHCO₃ (50 mL), and the aqueous layer was extracted with CH₂Cl₂ (2 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 1:1 EtOAc/hexanes) to give a colorless residue (1.01 g, 94%). The residue (1.01 g, 2.2 mmol) was dissolved in EtOAc (20 mL) and treated with CH₃SO₃H (2M in Et₂O, 1.1 mL, 2.2 mmol). The resulting clear solution was treated with Et₂O (20 mL) to give a cloudy mixture with gummy precipitate. After stirring for 5 min, the solvent was

removed in vacuo. The residue was dissolved in CH₂Cl₂ and the solvent was removed in vacuo to give a white foam. The foam was dried in a vacuum oven at 50 °C for 5 h to give the title compound (0.76 g, 62%) as a white powder: mp 88-93 °C dec; ¹H NMR (300 MHz, CDCl₃) δ 11.53 (s, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.85 (d, *J* = 8.1 Hz, 1H), 7.51-7.56 (m, 1H), 7.40-7.45 (m, 1H), 7.14-7.18 (m, 2H), 7.07 (d, *J* = 7.8 Hz, 1H), 4.67-4.72 (m, 1H), 4.18 (d, *J* = 15.3 Hz, 2H), 3.93-4.01 (m, 2H), 3.71 (d, *J* = 11.6 Hz, 2H), 3.18-3.36 (m, 6H), 2.92 (s, 3H), 2.69-2.74 (m, 2H), 2.46-2.57 (m, 2H), 1.78-1.95 (m, 3H), 1.28-1.35 (m, 1H), 1.10 (d, *J* = 6.6 Hz, 3H), 0.91 (d, *J* = 6.8 Hz, 3H); ESI MS *m/z* 463 [C₂₇H₃₄N₄OS + H]⁺; *R*_f 0.51 (silica gel, EtOAc); HPLC 97.9% (AUC), *t*_R = 13.93 min. Anal. Calc'd for C₂₇H₃₄N₄OS • CH₃SO₃H • 0.15CH₃CO₂C₂H₅ • 1.3H₂O: C, 57.70; H, 7.08; N, 9.41. Found: C, 57.90; H, 7.02; N, 9.11.

EXAMPLE 83

7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one



A. 4,4-Dimethyl-3,4-dihydro-2H-naphthalen-1-one

Beilstein Registry Number 1818110; CAS Registry Number 2979-69-3
Endo, Y.; Takehana, S.; Ohno, M.; Driedger, P. E.; Stabel, S.; Mizutani, M. Y.; Tomioka, N.; Itai, A.; Shudo, K. *J. Med. Chem.* **1998**, *41*, 1476-1496.

B. 4,4-Dimethyl-3,4-dihydro-2H-naphthalen-1-one oxime

Beilstein Registry Number 1818110; CAS Registry Number 2979-69-3
Woods, G. F.; Heying, T. L.; Schwartzman, L. H.; Grenell, S. M.; Gasser, W. F.; Rowe, E. W.; Bolgiano, N. C. *J. Org. Chem.* **1954**, *19*, 1290-1295.
Into a 1-L round-bottom flask was placed the tetralone from step A (8.94 g,

51.4 mmol), hydroxylamine hydrochloride (4.29 g, 61.7 mmol), sodium acetate (8.43 g, 103 mmol), and 50% aqueous ethanol (350 mL). The mixture was refluxed for 16 h, cooled to room temperature and made alkaline by the addition of 10% aqueous NaHCO₃. The reaction was extracted with CH₂Cl₂ (3 x 100 mL) and the combined organic layers were dried over Na₂SO₄ and concentrated under vacuum to produce the title oxime (8.37 g, 84%) as an orange solid.

C. 5,5-Dimethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

Into a 500-mL round-bottom flask equipped with a mechanical stirrer was placed polyphosphoric acid (90 g). The reaction was heated to 125°C, the title compound from step B (8.37 g, 44.3 mmol) was added in one portion, and the reaction was stirred for 5 min. The mixture was poured into ice water (300 mL), stirred until the polyphosphoric acid was dissolved and extracted with CH₂Cl₂ (3 x 100 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum to produce the title benzazepinone (7.76 g, 93%) as a tan solid: ¹H NMR (300 MHz, CDCl₃) δ 7.45 (bs, 1H), 7.42 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.13-7.25 (m, 2H), 6.91 (dd, *J* = 7.6, 1.6 Hz, 1H), 2.40 (t, *J* = 7.0 Hz, 2H), 2.11 (t, *J* = 7.0 Hz, 2H), 1.42 (s, 6H); ESI MS *m/z* 190 [C₁₂H₁₅NO + H]⁺.

D. 7-(2-Chloro-acetyl)-5,5-dimethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

Into a 500-mL round-bottom flask equipped with a mechanical stirrer was placed aluminum chloride (33.6 g, 252 mmol), anhydrous dichloromethane (230 mL), chloroacetyl chloride (4.87 mL, 61.05 mmol), and the title compound from step C (7.69 g, 40.7 mmol). The reaction was slowly heated to reflux and stirred for 15 h. The mixture was cooled to 0°C and ice water (200 mL) was slowly added (CAUTION: exotherm). The two layers were separated and the aqueous layer was extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with H₂O (150 mL), dried over Na₂SO₄, concentrated under

vacuum, and chromatographed (silica, 4:1 hexanes/ethyl acetate) to produce the title compound (3.82 g, 35%) as a yellow solid: ^1H NMR (300 MHz, CDCl_3) δ 9.07 (s, 1H), 8.09 (d, $J = 1.9$ Hz, 1H), 7.80 (dd, $J = 8.2, 2.0$ Hz, 1H), 7.10 (d, $J = 8.3$ Hz, 1H), 4.68 (s, 2H), 2.49 (t, $J = 6.5$ Hz, 2H), 2.15 (t, $J = 8.3$ Hz, 2H), 1.46 (s, 6H).

E. 7-(2-Chloro-ethyl)-5,5-dimethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

Into a 100-mL round-bottom-flask was placed the ketone from step D (2.23 g, 8.4 mmol) and TFA (16 mL). The solution was cooled to 0°C and triethylsilane (4.07 mL, 25.2 mmol) was added dropwise over a 5 min period. The reaction was warmed to 50°C and stirred for 15 h. The mixture was cooled to room temperature, diluted with H_2O (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over Na_2SO_4 , and concentrated under high vacuum and chromatographed (silica, 4:1 hexanes/ethyl acetate) to produce the title compound (1.58 g, 75%) as a white solid: ^1H NMR (300 MHz, CDCl_3) δ 7.83 (s, 1H), 7.24 (d, $J = 1.8$ Hz, 1H), 7.08 (dd, $J = 8.0, 2.0$ Hz, 1H), 6.89 (d, $J = 8.0$ Hz, 1H), 3.71 (t, $J = 7.3$ Hz, 2H), 3.06 (t, $J = 7.3$ Hz, 2H), 2.39 (t, $J = 6.8$ Hz, 2H), 2.11 (t, $J = 7.4$ Hz, 2H), 1.40 (s, 6H).


F. 7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-5,5-dimethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

A suspension of the title compound from step E (2.55 g, 10.1 mmol) in CH_3CN (100 mL) was treated with 3-piperazin-1-yl-benzo[d]isoxazole \cdot HCl (2.68 g, 11.2 mmol), NaI (1.68 g, 11.2 mmol), and K_2CO_3 (4.22 g, 30.5 mmol). The mixture was heated to reflux under N_2 for 87 h, then allowed to cool. The mixture was diluted with H_2O (250 mL) and extracted with CH_2Cl_2 (4 x 200 mL). The combined organic layers were dried over Na_2SO_4 , decanted, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, EtOAc) to give the title compound (3.09 g, 73%) as a white powder: mp $193\text{--}194^\circ\text{C}$ (dec);

¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, *J* = 8.0 Hz, 1H), 7.44-7.52 (m, 2H), 7.20-7.28 (m, 2H), 7.15 (s, 1H), 7.08 (dd, *J* = 7.9, 1.9 Hz, 1H), 6.82 (d, *J* = 7.9 Hz, 1H), 3.61-3.65 (m, 4H), 2.82-2.87 (m, 2H), 2.73-2.76 (m, 4H), 2.65-2.70 (m, 2H), 2.39 (t, *J* = 7.0 Hz, 2H), 2.10 (t, *J* = 7.0 Hz, 2H), 1.41 (s, 6H);
 5 ESI MS *m/z* 419 [C₂₅H₃₀N₄O₂ + H]⁺; R_f 0.55 (silica gel, EtOAc); HPLC 96.4% (AUC), *t_R* = 12.12 min. Anal. Calc'd for C₂₅H₃₀N₄O₂ • 0.2H₂O: C, 71.13; H, 7.26; N, 13.27. Found: C, 71.11; H, 7.30; N, 13.06.

EXAMPLE 84

10 7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-(4-fluoro-phenyl)-methanone
methanesulfonate



15

A. 7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine

A suspension of 7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one (3.09 g, 7.38 mmol) in THF (50 mL) was treated with borane (1.5M in THF, 35.0 mL, 52.5 mmol)
 20 over 10 min. The resulting clear solution was heated to reflux under N₂ for 3.5 h, then allowed to cool. The reaction was quenched with 6N HCl until gas evolution subsided. The mixture was heated to reflux for 45 min, allowed to cool, and then made basic with solid NaOH and a 1N NaOH solution (50 mL).
 25 The biphasic mixture was extracted with CH₂Cl₂ (4 x 50 mL), and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 hexanes/EtOAc) to

give the title compound (2.42 g, 81%) as a colorless oil: ^1H NMR (300 MHz, CDCl_3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.45-7.48 (m, 2H), 7.18-7.24 (m, 1H), 7.16 (d, J = 1.9 Hz, 1H), 6.88 (dd, J = 7.8, 2.0 Hz, 1H), 6.62 (d, J = 7.8 Hz, 1H), 3.61-3.64 (m, 4H), 3.00 (t, J = 5.6 Hz, 2H), 2.62-2.81 (m, 8H), 1.82-1.90 (m, 2H), 1.60-1.64 (m, 2H), 1.38 (s, 6H); ESI MS m/z 405 [$\text{C}_{25}\text{H}_{32}\text{N}_4\text{O} + \text{H}$] $^+$; R_f 0.39 (silica gel, 2:1 hexanes/EtOAc).

B. 1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone methanesulfonate


A solution of the title compound from step A (0.90 g, 2.2 mmol) in CH_2Cl_2 (20 mL) was treated with Ac_2O (0.21 mL, 2.2 mmol). After stirring at room temperature under N_2 for 18 h, the reaction was quenched with saturated NaHCO_3 (30 mL) and extracted with CH_2Cl_2 (3 x 50 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 EtOAc/hexanes to 3:1 EtOAc/hexanes to EtOAc) to give a white solid residue (0.58 g, 1.30 mmol, 58%). The residue was dissolved in EtOAc (6.5 mL) and treated with $\text{CH}_3\text{SO}_3\text{H}$ (2M in Et_2O , 0.65 mL, 1.3 mmol). After stirring for 45 min, the oily, precipitous mixture was diluted with EtOAc (6.5 mL). After stirring for an additional 19 h, the resulting precipitate was isolated by filtration, washed with Et_2O (3 x 20 mL), and dried in a vacuum oven at 60°C overnight to give the title compound (595 mg, 84%) as a white powder: mp $227\text{-}229^\circ\text{C}$ (dec); ^1H NMR (300 MHz, CDCl_3) δ 11.94 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.50-7.59 (m, 2H), 7.27-7.33 (m, 2H), 7.16 (dd, J = 7.9, 1.9 Hz, 1H), 7.02 (d, J = 7.9 Hz, 1H), 4.71-4.75 (m, 1H), 4.21 (d, J = 14.6 Hz, 2H), 3.96-4.04 (m, 2H), 3.74 (d, J = 11.7 Hz, 2H), 3.12-3.35 (m, 6H), 2.90 (s, 3H), 2.48-2.52 (m, 1H), 2.15-2.20 (m, 1H), 1.86 (s, 3H), 1.47-1.74 (m, 3H), 1.43 (s, 3H), 1.20 (s, 3H); ESI MS m/z 447 [$\text{C}_{27}\text{H}_{34}\text{N}_4\text{O}_2 + \text{H}$] $^+$; R_f 0.64 (silica gel, EtOAc); HPLC >99% (AUC), t_R = 12.97 min. Anal. Calc'd for $\text{C}_{27}\text{H}_{34}\text{N}_4\text{O}_2$ •

CH₃SO₃H • 0.3H₂O: C, 61.36; H, 7.10; N, 10.22. Found: C, 61.42; H, 7.13; N, 10.17.

C. {7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-(4-fluorophenyl)-methanone methanesulfonate

A solution of the title compound from step B (0.90 g, 2.2 mmol) in CH₂Cl₂ (20 mL) under N₂ was cooled in an ice bath, treated Et₃N (0.34 mL, 2.42 mmol) and *p*-fluorobenzoyl chloride (0.26 mL, 2.2 mmol), and warmed to room temperature. After stirring at room temperature for 17 h, the reaction was quenched with saturated NaHCO₃ (30 mL) and extracted with CH₂Cl₂ (3 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 7:3 hexanes/EtOAc) to give a colorless residue (0.74 g, 1.40 mmol, 63%). The residue (0.71 g, 1.35 mmol) was dissolved in EtOAc (13 mL) and treated with CH₃SO₃H (2M in Et₂O, 0.67 mL, 1.34 mmol). After stirring for 21 h, the clear solution was treated with Et₂O (20 mL). After stirring for 45 min, the oily, precipitous mixture was treated with Et₂O (10 mL) and stirred for an additional 27 h. The mixture was concentrated in vacuo, and the resulting oily solid was suspended in Et₂O. The solid was isolated by filtration, washed with Et₂O, and dried in a vacuum oven at 60°C for 4 d to give the title compound (629 mg, 75%) as a white powder: mp 135-140°C; ¹H NMR (300 MHz, CDCl₃) δ 11.91 (s, 1H), 7.50-7.62 (m, 4H), 7.21-7.36 (m, 3H), 6.78-6.85 (m, 3H), 6.50 (d, *J* = 7.9 Hz, 1H), 5.02-5.06 (m, 1H), 4.19 (d, *J* = 13.9 Hz, 2H), 3.98 (t, *J* = 13.4 Hz, 2H), 3.69 (d, *J* = 11.2 Hz, 2H), 3.05-3.26 (m, 6H), 2.88 (s, 3H), 2.72 (t, *J* = 11.7 Hz, 1H), 2.23-2.28 (m, 1H), 1.77-1.90 (m, 2H), 1.55-1.64 (m, 1H), 1.50 (s, 3H), 1.49 (s, 3H); ESI MS *m/z* 527 [C₃₂H₃₅FN₄O₂ + H]⁺; R_f 0.77 (silica gel, 2:1 EtOAc/hexanes); HPLC >99% (AUC), *t*_R = 15.23 min. Anal. Calc'd for C₃₂H₃₅FN₄O₂ • CH₃SO₃H • H₂O: C, 61.86; H, 6.45; N, 8.74. Found: C, 61.89; H, 6.40; N, 8.67.

EXAMPLE 85




1-{7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one methanesulfonate

A solution of 7-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine (0.45 g, 1.1 mmol) in CH₂Cl₂ (10 mL) under N₂ was cooled in an ice bath, treated with Et₃N (0.17 mL, 1.2 mmol) and propionyl chloride (0.10 mL, 1.1 mmol), and warmed to room temperature. After stirring at room temperature for 23 h, additional propionyl chloride (0.10 mL, 1.1 mmol) was added. After stirring for an additional 8 h, the reaction was quenched with saturated NaHCO₃ (20 mL) and extracted with CH₂Cl₂ (3 x 20 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 EtOAc/hexanes) to give a colorless residue (0.40 g, 0.87 mmol, 79%). The residue (0.40 g, 0.87 mmol) was dissolved in EtOAc (10 mL) and treated with CH₃SO₃H (2M in Et₂O, 0.43 mL, 0.86 mmol). After stirring for 15 min, the clear solution was treated with Et₂O (30 mL). After stirring for 20 min, the oily, precipitous mixture was concentrated in vacuo, and the resulting oily solid was suspended in Et₂O (15 mL). After stirring for 16 h, the solid was isolated by filtration, washed with Et₂O (3 x 10 mL), and dried in a vacuum oven at 60°C for 24 h to give the title compound (416 mg, 86%) as a white powder: mp 188-191°C (dec); ¹H NMR (300 MHz, CDCl₃) δ 11.86 (s, 1H), 7.50-7.64 (m, 3H), 7.28-7.33 (m, 2H), 7.15 (dd, J = 7.9, 1.9 Hz, 1H), 7.01 (d, J = 7.9 Hz, 1H), 4.73-4.77 (m, 1H), 4.21 (d, J = 14.6 Hz, 2H), 3.95-4.04 (m, 2H), 3.74 (d, J = 11.4 Hz, 2H), 3.10-

3.35 (m, 6H), 2.91 (s, 3H), 2.47-2.57 (m, 1H), 2.14-2.26 (m, 2H), 1.85-1.95 (m, 1H), 1.45-1.74 (m, 3H), 1.42 (s, 3H), 1.17 (s, 3H), 1.07 (t, $J = 7.4$ Hz, 3H); ESI MS m/z 461 $[C_{28}H_{36}N_4O_2 + H]^+$; R_f 0.66 (silica gel, 2:1 EtOAc/hexanes); HPLC 98.4% (AUC), $t_R = 13.67$ min. Anal. Calc'd for $C_{28}H_{36}N_4O_2 \cdot CH_3SO_3H \cdot 1.2H_2O$: C, 60.23; H, 7.39; N, 9.69. Found: C, 60.24; H, 7.40; N, 9.49.

EXAMPLE 86


6-(2-Chloroacetyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one



3,3-Dimethyl-3,4-dihydro-1H-quinolin-2-one was prepared according to the procedure in *J. Med. Chem.*, 1986, 29, 1832, and underwent a Friedel-Crafts acylation with chloroacetyl chloride according to the procedure described in Example 1 to give the title compound as a solid. MS (APCI): $(M + 1)^+ = 252$.

EXAMPLE 87


6-(2-Chloroethyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one



To a mixture of the title compound of Example 86 (6.52 g, 0.026 mol) and trifluoroacetic acid (20 ml, 0.26 mol), cooled to 0°C under nitrogen, was added portionwise triethylsilane (9.57 ml, 0.059 mol). The reaction mixture was heated at 40-45°C for 20 minutes and then stirred at room temperature for 16 hours. The solution was poured into ice water layered with hexane and vigorously stirred for several hours. The precipitate that formed was collected and washed with water and hexanes to give the title compound as a solid. MS (APCI): $(M + 1)^+ = 238$.

EXAMPLE 88

6-(2-Chloro ethyl)-3,3-dimethyl-1,2,3,4-tetrahydroquinoline



5


To a solution of 6-(2-chloroethyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one (1.0 g, 4.21 mmol) in anhydrous THF (75 ml) under nitrogen was added 1.0 M borane-THF complex (14.3 ml, 14.3 mmol). The reaction mixture was refluxed for 1.5 hours and cooled to ambient temperature. The excess reagent was quenched with water and the organic solvent was removed *in vacuo*. The aqueous residue was extracted with methylene chloride and the organic extract was dried over magnesium sulfate, filtered, and concentrated to an oil. Yield = 942 mg (100%); MS (APCI), $(M + 1)^+ = 224$. $^1\text{H-NMR}$ (CDCl_3 , δ): 6.80 (d, 1H, $J = 8.1$ Hz), 6.75 (s, 1H), 6.43 (d, 1H, $J = 8.1$ Hz), 3.87 (br s, 1H), 3.62 (t, 2H, $J = 7.6, 8.1$ Hz), 2.88 (m, 4H), 2.45 (s, 2H), 0.99 (s, 6H).

10

15

EXAMPLE 89

1-[6-(2-Chloroethyl)-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]-ethanone



20


25

A mixture of 6-(2-chloroethyl)-3,3-dimethyl-1,2,3,4-tetrahydroquinoline (942 mg, 4.21 mmol) and acetyl chloride (0.317 ml, 4.44 mmol) in dry acetone (15 ml) was refluxed for 2 hours. The reaction

mixture was poured into dilute aqueous HCl (100 ml) and the whole extracted with chloroform. The organic extract was dried over magnesium sulfate, filtered, and concentrated. The product was washed with hexane to give an off-white, crystalline solid. Yield = 791 mg (71%); MS (APCI), (M + 1)⁺ = 266. ¹H-NMR (CDCl₃, δ): 7.25 (s, 1H), 7.00 (d, 1H, J = 7.1 Hz), 6.94 (s, 1H), 3.68 (t, 2H, J = 7.6, 7.3 Hz), 3.52 (br s, 2H), 3.00 (t, 2H, J = 7.3, 7.3 Hz), 2.57 (s, 2H), 2.27 (s, 3H), 0.99 (s, 6H).

EXAMPLE 90


1-(6-{2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone



A mixture of 3-piperazin-1-yl-1H-indazole hydrochloride (520 mg, 2.60 mmol), 1-[6-(2-chloroethyl)-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]-ethanone (791 mg, 2.98 mmol), anhydrous potassium carbonate (791 mg, 5.70 mmol) and potassium iodide (75 mg) in acetonitrile (50 ml) was refluxed for 72 hours. The reaction mixture was concentrated and the residue was partitioned between water and methylene chloride. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The crude product was eluted through a flash column (silica gel 60, 230-400 mesh, 5% MeOH in EtOAc) and taken up in methylene chloride. Treatment with 4.0 N HCl solution in dioxane precipitated the dihydrochloride salt. Yield = 496 mg (38%); CHN: Calculated for C₂₆H₃₃N₅O 2HCl; C, 61.90%, H, 6.99%, N, 13.88%; found; C, 61.50%, H, 7.27%, N, 13.45%. MS (APCI), (M + 1)⁺ = 432; (M - 1)⁺ = 430. ¹H-NMR (dmso-d₆, δ): 12.18 (s, 1H), 10.75 (br s, 1H), 7.75 (d, 1H, J = 8.3 Hz), 7.34 (m, 3H), 7.02 (m, 3H), 3.92 (br d, 2H, J = 10.5 Hz), 3.61-3.22 (m, 10H), 3.00 (m, 2H), 2.46 (s, 2H), 2.16 (s, 3H), 0.89 (s, 6H).

EXAMPLE 91

1-{6-[2-(4-B nzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl}-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}ethanone
methanesulfonate



A. 7-Chloro-6-(2-chloroethyl)-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one

Triethylsilane (10.0 mL, 62.6 mmol) was added to a stirred solution of 7-chloro-6-(2-chloroacetyl)-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (5.03 g, 17.6 mmol) in trifluoroacetic acid (25 mL) at 0°C under nitrogen (N₂). After stirring for 5 min, the cooling bath was replaced with a heating bath, and the thermostat set for 50°C. After stirring for 15 hours (h), the mixture was allowed to cool, poured into H₂O (150 mL), then extracted twice with EtOAc (150 mL). The extracts were combined, washed with H₂O (150 mL), saturated NaHCO₃, and saturated sodium chloride (NaCl), dried over Na₂SO₄, filtered, and the solvent removed in vacuo. The residue was purified by column chromatography (silica gel (100 g), eluting with 800 mL of 10% EtOAc/hexanes to remove the triethylsilane (Et₃SiH) (collected as a single fraction), then eluting with 1.5 L of 40% EtOAc/hexanes to elute the product) to give the title compound (1.93 g, 40%) as an off-white amorphous solid. Due to the low mass recovery, the initial column wash was examined and determined to contain more of the product. The initial column wash was concentrated in vacuo to give a mixture of solid and liquid. The liquid was decanted, and the solid washed and decanted twice

with hexanes. The solid was dried under vacuum to give more of the title compound (1.82 g, 38%) as an off-white amorphous solid: ^1H NMR (300 MHz, CDCl_3) δ 8.46 (br s, 1H), 7.17 (s, 1H), 6.84 (s, 1H), 3.72 (t, J = 7.3 Hz, 2H), 3.15 (t, J = 7.3 Hz, 2H), 2.49 (s, 2H), 1.32 (s, 6H); ESI MS m/z 272 [$\text{C}_{13}\text{H}_{15}\text{Cl}_2\text{NO} + \text{H}$] $^+$.

B. 7-Chloro-6-(2-chloroethyl)-4,4-dimethyl-1,2,3,4-tetrahydroquinoline

Borane (25 mL, 38 mmol, 1.5 M in THF) was added portionwise over 5 min to a stirred solution of lactam from step A (1.93 g, 7.09 mmol) in anhydrous THF (40 mL) under N_2 . The mixture was heated to reflux for 3 h, then allowed to cool. The mixture was quenched by adding (slowly at first) 6 M HCl (25 mL) with stirring. The mixture was heated to reflux for 30 min, then allowed to cool. The mixture was diluted with H_2O (100 mL), then NaOH pellets were added until the mixture was strongly alkaline. The organic phase was separated, and the aqueous phase extracted twice with chloroform (CHCl_3) (75 mL). The organic phases were combined, dried over Na_2SO_4 , filtered, and the solvent removed in vacuo. The residue was purified by column chromatography (silica gel (100 g), 10% EtOAc/hexanes) to give the title compound (1.92 g, 1.83 g theoretical) as a clear, light yellow oil: ^1H NMR (300 MHz, CDCl_3) δ 7.02 (s, 1H), 6.46 (s, 1H), 3.92 (br s, 1H), 3.65 (t, J = 7.7 Hz, 2H), 3.27–3.32 (m, 2H), 3.04 (t, J = 7.7 Hz, 2H), 1.68–1.73 (m, 2H), 1.27 (s, 6H); ESI MS m/z 258 [$\text{C}_{13}\text{H}_{17}\text{Cl}_2\text{N} + \text{H}$] $^+$.

C. 1-[7-Chloro-6-(2-chloroethyl)-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone

Acetic anhydride (1.0 mL, 11 mmol) was added to a stirred solution of the amine from step B (918 mg, 3.56 mmol) and Et_3N (1.5 mL, 11 mmol) in anhyd CH_2Cl_2 (10 mL) under N_2 . After stirring for 23 h, MeOH (1 mL) was added to quench the excess reagent. After stirring for 1.25 h, the solvents were removed in vacuo. The residue was purified by column

chromatography (silica gel (50 g), 10–30% EtOAc/hexanes) to give the title compound (934 mg, 87% from the product of step A) as a pale yellow oil:

¹H NMR (300 MHz, CDCl₃) δ 7.33 (br s, 1H), 7.20 (s, 1H), 3.79 (t, *J* = 6.4 Hz, 2H), 3.73 (t, *J* = 7.3 Hz, 2H), 3.16 (t, *J* = 7.3 Hz, 2H), 2.27 (s, 3H), 1.77 (t, *J* = 6.3 Hz, 2H), 1.29 (s, 6H); ESI MS *m/z* 300 [C₁₅H₁₉Cl₂NO + H]⁺.

D. 1-{6-[2-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl}-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}ethanone methanesulfonate


Anhydrous acetonitrile (15 mL) was added to a flask containing the title compound from step C (929 mg, 3.09 mmol), 3-piperazin-1-yl-benzo[d]isoxazole hydrochloride (821 mg, 3.43 mmol), potassium carbonate (K₂CO₃) (883 mg, 6.39 mmol), and sodium iodide (NaI) (486 mg, 3.24 mmol) under N₂. The mixture was stirred, giving a suspension.

The mixture was heated to reflux overnight (16 h). TLC analysis indicated low conversion, so tetrabutylammonium iodide (Bu₄NI) (3.34 g, 9.04 mmol) was added and the mixture heated to reflux for 4 d, then allowed to cool. TLC analysis indicated moderate conversion. The mixture was diluted with EtOAc (200 mL), then washed twice with H₂O (200 mL) and saturated (sat'd) NaCl (75 mL). The combined aqueous phases were reextracted with EtOAc (100 mL), and the extract was washed with H₂O (100 mL) and sat'd NaCl (50 mL). The organic phases were combined, dried over Na₂SO₄, filtered, and the solvent removed in vacuo. The residue was purified by column chromatography (silica gel (50 g), 30–50% EtOAc/hexanes containing 1% Et₃N) to give the title compound as a free base (945 mg, 65%) as a colorless sticky oil. The product was dissolved in EtOAc (20 mL), then CH₃SO₃H (120 μL, 1.85 mmol) was added dropwise with stirring to give a clear solution. After stirring a couple more minutes, a white precipitate began to form. After stirring for 2 h, the precipitate was collected by suction filtration washing with EtOAc, then dried in a vacuum oven at 50°C for 20 h to give the title compound (772 mg, 68%) as a white amorphous solid: mp 174–177 °C; ¹H NMR (300

MHz, DMSO- d_6) δ 9.95 (br s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.75 (br s, 1H), 7.60–7.68 (m, 2H), 7.44 (s, 1H), 7.31–7.41 (m, 1H), 4.21 (br d, J = 10.8 Hz, 2H), 3.68–3.79 (m, 4H), 3.27–3.50 (m + H_2O), 3.09–3.19 (m, 2H), 2.34 (s, 3H), 2.22 (s, 3H), 1.70–1.78 (m, 2H), 1.26 (s, 6H); ESI MS m/z 467 [$C_{26}H_{31}ClN_4O_2 + H$] $^+$; HPLC >99% (AUC), t_R = 13.71 min. Anal. Calc'd for $C_{26}H_{31}ClN_4O_2 \cdot CH_3SO_3H$: C, 57.59; H, 6.26; N, 9.95. Found: C, 57.68; H, 6.20; N, 9.74.

EXAMPLE 92

1-[6-[2-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]-2-methylpropan-1-one
methanesulfonate



A. 1-[7-Chloro-6-(2-chloroethyl)-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]-2-methylpropan-1-one

Isobutyric anhydride (1.7 mL, 10 mmol) was added to a stirred solution of the title compound of step B of Example 91 (1.00 g, 3.87 mmol) and triethylamine (Et_3N) (2.0 mL, 14 mmol) in anhydrous CH_2Cl_2 (10 mL) under N_2 . After stirring for 13 h, TLC analysis indicated only starting material, so the acylation catalyst 4-dimethylaminopyridine (353 mg, 2.89 mmol) was added. After stirring for 17 h, TLC and HPLC analysis indicated low (15%) conversion. The mixture was heated to reflux overnight (21 h), at which point HPLC analysis indicated 50% conversion. The mixture was heated to reflux for another 3 days, during which time most of the solvent evaporated, then allowed to cool. The residue was partitioned between EtOAc (200 mL) and H_2O (200 mL). The organic phase was washed with 0.5 M HCl (100 mL), H_2O (100 mL), sat'd $NaHCO_3$ (50 mL), and sat'd NaCl

(50 mL). The aqueous phase was reextracted with EtOAc (100 mL) and the extract washed as before. (Note: All the extractions and washings were slowed by emulsions.) The organic phases were combined, dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by column chromatography (silica gel (50 g), 5–15% EtOAc/hexanes) to give the title compound (298 mg, 23%) as a dark yellow, viscous oil: ¹H NMR (300 MHz, CDCl₃) δ 7.31 (br s, 1H), 7.21 (s, 1H), 3.78 (t, *J* = 6.3 Hz, 2H), 3.73 (t, *J* = 7.3 Hz, 2H), 3.16 (t, *J* = 7.3 Hz, 2H), 3.06–3.17 (m, 1H), 1.76 (t, *J* = 6.3 Hz, 2H), 1.29 (s, 6H), 1.21 (d, *J* = 7.0 Hz, 3H), 1.17 (d, *J* = 6.7 Hz, 3H); ESI MS *m/z* 328 [C₁₇H₂₃Cl₂NO + H]⁺.


B. 1-{6-[2-(4-Benzo[*d*]isoxazol-3-yl)piperazin-1-yl]ethyl}-7-chloro-4,4-dimethyl-3,4-dihydro-2*H*-quinolin-1-yl}-2-methylpropan-1-one methanesulfonate

Anhydrous acetonitrile (10 mL) was added to a flask containing the product from step A (293 mg, 0.893 mmol), 3-piperazin-1-yl-benzo[*d*]isoxazole hydrochloride (243 mg, 1.01 mmol), K₂CO₃ (271 mg, 1.96 mmol), and sodium iodide (NaI) (459 mg, 3.06 mmol) under N₂. The mixture was stirred to give a suspension, then heated to reflux. After 2 d at reflux, HPLC analyses indicated approximately 50% conversion. More anhydrous acetonitrile (10 mL) was added to replace solvent that had escaped, then the mixture was heated to reflux overnight (23 h). HPLC analysis indicated approximately 1:2 SM/Pdt. After heating to reflux overnight (total reaction time = 4 d), the mixture was allowed to cool. HPLC analysis indicated approximately 1:3 SM/Pdt. The mixture was diluted with EtOAc, washed twice with H₂O, once with sat'd NaCl, dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by column chromatography (silica gel (18 g), 30–50% EtOAc/hexanes containing 1% Et₃N) to give the free base of the title compound (234 mg, 53%) as a dark yellow oil. The product was dissolved in EtOAc (10 mL), then methanesulfonic acid (CH₃SO₃H) (30 μL, 1.0 equiv.) was added dropwise with stirring. After stirring for 5 min, hexanes

(5 mL) was added to the stirred solution. After stirring another 5 min, a precipitate began to form. After stirring for 2 h, the precipitate was collected by suction filtration washing with EtOAc, then dried in a vacuum oven at 50°C for 22 h to give the title compound (134 mg, 48%) as a light brown amorphous solid: mp 153–157 °C dec; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.91 (br s, 1H), 8.08 (d, *J* = 8.1 Hz, 1H), 7.56–7.68 (m, 3H), 7.45 (s, 1H), 7.33–7.39 (m, 1H), 4.12–4.27 (m, 2H), 3.69–3.80 (m, 4H), 3.24–3.48 (m + H₂O), 3.02–3.19 (m, 2H), 2.32 (s, 3H), 1.69–1.77 (m, 2H), 1.27 (s, 6H), 1.06 (d, *J* = 6.6 Hz, 6H); ESI MS *m/z* 495 [C₂₈H₃₅ClN₄O₂ + H]⁺; HPLC >99% (AUC), *t*_R = 15.37 min. Anal. Calc'd for C₂₈H₃₅ClN₄O₂ • CH₃SO₃H: C, 58.92; H, 6.65; N, 9.48. Found: C, 58.92; H, 6.76; N, 9.33.

EXAMPLE 93

1-{7-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone methanesulfonate



A. 7-(2-Chloro-ethyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepine

A solution of 7-(2-chloroethyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one (784 mg, 3.50 mmol) in THF (15 mL) was added dropwise to a solution of BH₃ in THF (15.0 mL, 1.5 M, 22.5 mmol). The mixture was heated to reflux for 3 h, then allowed to cool. The reaction was quenched with 6N HCl until gas evolution subsided. The mixture was heated to reflux for 1 h, allowed to cool, and then made basic with solid NaOH. The biphasic mixture was extracted with CH₂Cl₂ (3 x 50 mL), and the combined organic layers were dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 9:1 hexanes/EtOAc) to give the title compound (0.55 g, 75%) as a

colorless oil: ^1H NMR (300 MHz, CDCl_3) δ 6.95 (d, J = 1.9 Hz, 1H), 6.88 (dd, J = 7.8, 2.1 Hz, 1H), 6.68 (d, J = 7.8 Hz, 1H), 3.76 (bs, 1H), 3.66 (t, J = 7.7 Hz, 2H), 3.01-3.04 (m, 2H), 2.96 (t, J = 7.7 Hz, 2H), 2.72-2.76 (m, 2H), 1.75-1.83 (m, 2H), 1.59-1.67 (m, 2H); ESI MS m/z 210 [$\text{C}_{12}\text{H}_{16}\text{ClN} + \text{H}$] $^+$; R_f 0.62 (silica gel, 2:1 hexanes/EtOAc).

B. 1-[7-(2-Chloro-ethyl)-2,3,4,5-tetrahydro-benzo[*b*]azepin-1-yl]-ethanone

A solution of the title compound from step A (0.55 g, 2.6 mmol) in CH_2Cl_2 (20 mL) was treated with acetic anhydride (Ac_2O) (0.25 mL, 2.6 mmol). After stirring at room temperature under N_2 for 7.5 h, the reaction was quenched with saturated sodium bicarbonate (NaHCO_3) (50 mL) and extracted with CH_2Cl_2 (4 x 50 mL). The combined organic layers were dried over Na_2SO_4 , decanted, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (silica gel, 2:1 hexanes/EtOAc) to give the title compound (602 mg, 91%) as a white solid: ^1H NMR (300 MHz, CDCl_3) δ 7.09 (s, 1H), 7.08 (s, 2H), 4.66-4.71 (m, 1H), 3.73 (t, J = 7.3 Hz, 2H), 3.06 (t, J = 7.3 Hz, 2H), 2.58-2.76 (m, 3H), 1.79-1.97 (m, 3H), 1.86 (s, 3H), 1.30-1.45 (m, 1H); ESI MS m/z 252 [$\text{C}_{14}\text{H}_{18}\text{ClNO} + \text{H}$] $^+$; R_f 0.30 (silica gel, 2:1 hexanes/EtOAc).


C. 1-[7-[2-(4-Benzo[*d*]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[*b*]azepin-1-yl]-ethanone methanesulfonate

A solution of the title compound from step B (602 mg, 2.39 mmol) in CH_3CN (20 mL) was treated with 3-piperazin-1-yl-benzo[*d*]isothiazole \cdot HCl (683 mg, 2.67 mmol), NaI (406 mg, 2.71 mmol), and K_2CO_3 (1.09 g, 7.86 mmol). The mixture was heated to reflux under N_2 for 43 h, then allowed to cool. The mixture was diluted with H_2O (100 mL) and extracted with CH_2Cl_2 (3 x 100 mL). The combined organic layers were dried over Na_2SO_4 , decanted, and the solvent was removed in vacuo. The residue was purified by flash column chromatography (Silica gel, EtOAc) to give a white solid residue (430 mg, 0.99 mmol, 41%). The residue was dissolved

in EtOAc (10 mL) and treated with a solution of $\text{CH}_3\text{SO}_3\text{H}$ in Et_2O (0.5 mL, 2M, 1 mmol). After stirring for 5 min, the resulting precipitate was isolated by filtration, washed with Et_2O (3 x 10 mL), and dried in a vacuum oven at 50 °C for 3 d to give the title compound (465 mg, 89%) as a white powder: mp 189-190 °C (dec); ^1H NMR (300 MHz, CDCl_3) δ 11.76 (s, 1H), 7.85 (t, J = 7.8 Hz, 2H), 7.51-7.56 (m, 1H), 7.39-7.45 (m, 1H), 7.14-7.18 (m, 2H), 7.08 (d, J = 7.8 Hz, 1H), 4.66-4.70 (m, 1H), 4.11-4.20 (m, 2H), 3.95-4.03 (m, 2H), 3.68 (d, J = 11.3 Hz, 2H), 3.13-3.34 (m, 6H), 2.91 (s, 3H), 2.68-2.78 (m, 2H), 2.51-2.59 (m, 1H), 1.74-2.00 (m, 3H), 1.83 (s, 3H), 1.32-1.40 (m, 1H); ESI MS m/z 435 [$\text{C}_{25}\text{H}_{30}\text{N}_4\text{OS} + \text{H}$] $^+$; R_f 0.35 (silica gel, 95:5 EtOAc/MeOH); HPLC >99% (AUC), t_R = 12.68 min. Anal. Calc'd for $\text{C}_{25}\text{H}_{30}\text{N}_4\text{OS} \cdot \text{CH}_3\text{SO}_3\text{H}$: C, 58.84; H, 6.46; N, 10.56. Found: C, 58.56; H, 6.49; N, 10.31.

EXAMPLE 94


5-(3-Chloro-propionyl)-3,3-dimethyl-1,3-dihydro-indol-2-one



The title compound was prepared using a procedure similar to that described in Example 86 using chloro propionyl chloride as the acylating agent. Yield = 3.05 g (98%); MS (APCI), $(M + 1)^+ = 252$.

EXAMPLE 95


5-(3-Chloro-propyl)-3,3-dimethyl-1,3-dihydro-indol-2-one



The title compound was prepared using a procedure similar to that described in Example 87. Yield = 2.87g (100%); MS (APCI), $(M + 1)^+ = 238$.

EXAMPLE 96


5-(3-Chloro-propyl)-3,3-dimethyl-2,3-dihydro-1H-indol



The title compound was prepared using a procedure similar to that described in Example 88. Yield = 0.172g (7%); MS (APCI), $(M + 1)^+ = 224$.

EXAMPLE 97


1-[5-(3-Chloro-propyl)-3,3-dimethyl-2,3-dihydro-indol-1-yl]-ethanone



A solution of 5-(3-Chloro-propyl)-3,3-dimethyl-2,3-dihydro-1H-indole (172 mg) in THF (2.0ml) with triethylamine (0.145 ml) was treated with acetic anhydride (0.145 ml) and stirred for 14 hours at reflux. The reaction was quenched with water, extracted with ethyl acetate and filter and concentrated in vacuo. Yield: 159 mg (78%) MS (APCI), $(M+1)^+ = 266$.

EXAMPLE 98

1-{5-[3-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-propyl}-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone



To a stirring solution of 1-[5-(3-Chloro-propyl)-3,3-dimethyl-2,3-dihydro-indol-1-yl]-ethanone (159 mg) in acetonitrile (20 ml) was added 3-piperazin-1-yl-benzo[d]isothiazole (263 mg), potassium carbonate (332 mg) and water (20 ml) the reaction was warmed to reflux for 72 hours. The reaction cooled and precipitate was filtered off. Yield: 114 mg (45%) MS (APCI), $(M+1)^+ = 449.1$.

EXAMPLE 99

2,3-Dihydro-1H-isoindole

Beilstein Registry Number 111921; CAS Registry Number 496-12-8

EXAMPLE 100

1-(1,3-dihydroisoindol-2-yl)ethanone

Beilstein Registry Number 131840; CAS Registry Number 18913-38-7

EXAMPLE 101

1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-2-chloroethanone

Anhydrous CS_2 (15 mL) and chloroacetyl chloride (0.75 mL, 9.4 mmol) were added to a stirred (mechanical stirrer) mixture of the title compound of Example 100 (1.00 g, 6.20 mmol) and $AlCl_3$ (3.3 g, 4.0 mmol) under N_2 . The mixture was heated to reflux for 3 h, then allowed to cool, to give a dark oil with very little CS_2 remaining over it due to evaporation/leakage. Some ice was added to the stirred oil to quench the excess reagent. After stirring for 5 min, 6M HCl (25 mL) was added. After stirring for 1 h, the solid precipitate was collected by suction filtration washing with water, then dried in vacuo at 55 °C for 15 h to give the title compound (1.19 g, 81%) as a brown amorphous solid: 1H NMR (500 MHz, C_6D_6 ; low solubility, but this solvent gave the best spectral dispersion of the aromatic signals; Note: The spectrum shows two sets of signals due to rotational isomers) δ 7.58 (d, $J = 7.7$ Hz, 0.5H), 7.37 (s, 0.5H), 7.29 (d, $J = 7.9$ Hz, 0.5H), 7.25 (s, 0.5H), 6.55 (d, $J = 7.9$ Hz, 1H), 4.53 (br s, 2H), 3.91 (s, 1H), 3.89 (s, 1H), 3.65 (br s, 2H), 1.654 (s, 1.5H), 1.646 (s, 1.5H); 1H NMR (300 MHz,

CDCl₃; Note: The spectrum shows two sets of signals due to rotational isomers) δ 7.88–7.95 (m, 2H), 7.44 (d, J = 8.6 Hz, 0.5H), 7.40 (d, J = 8.0 Hz, 0.5H), 4.88 (br s, 2H), 4.86 (br s, 2H), 4.71 (s, 1H), 4.70 (s, 1H), 2.20 (s, 1.5H), 2.19 (s, 1.5H); Variable Temperature ¹H NMR (500 MHz, DMSO-*d*₆) spectra at 25°C and 90°C showed differences consistent with rotational isomerization; ESI MS m/z 238 [C₁₂H₁₂ClNO₂ + H]⁺; HPLC 98.5% (AUC), t_R = 13.09 min.

EXAMPLE 102

1-(2-Acetyl-2,3-dihydro-1*H*-isoindol-5-yl)-2-(4-benzo[*d*]isothiazol-3-yl)piperazin-1-yl)ethanone

A mixture (suspension) of the title compound of Example 101 (2.10 g, 8.84 mmol), 3-piperazin-1-yl-benzo[*d*]isothiazole hydrochloride (2.49 g, 9.72 mmol), K₂CO₃ (3.63 g, 26.3 mmol), and NaI (1.40 g, 9.34 mmol) in anhyd CH₃CN (90 mL) under N₂ was stirred at 25°C for 20 h, then the solvent was removed in vacuo. The residue was suspended in H₂O, then extracted twice with EtOAc, however a solid remained undissolved in the aqueous phase. The solid was collected by suction filtration, washing and triturating with H₂O, then dried in a vacuum oven at 50°C for 3 d to give the title compound (2.68 g, 72%) as a light brown amorphous solid. Both TLC and ¹H NMR analyses indicated that the product was of high purity: ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J = 8.1 Hz, 1H), 7.98 (br s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.32–7.43 (m, 2H), 4.87 (br s, 2H), 4.85 (br s, 2H), 3.91 (s, 1H), 3.90 (s, 1H), 3.59–3.67 (m, 4H), 2.81–2.89 (m, 4H), 2.20 (s, 1.5H), 2.19 (s, 1.5H); ESI MS m/z 421 [C₂₃H₂₄N₄O₂S + H]⁺.

EXAMPLE 103

1-(2-Acetyl-2,3-dihydro-1*H*-isoindol-5-yl)-2-(4-benzo[*d*]isoxazol-3-yl)piperazin-1-yl)ethanone

The title compound was prepared from the title compound of Example 101 (2.18 g, 9.17 mmol) and 3-piperazin-1-yl-benzo[*d*]isoxazole hydrochloride

(2.40 g, 10.0 mmol) by the procedure used to prepare the title compound of Example 102 (3.03 g, 82%) as an off-white amorphous solid: ^1H NMR (300 MHz, CDCl_3) δ 7.99 (d, J = 8.1 Hz, 1H), 7.95 (br s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.35–7.53 (m, 3H), 7.18–7.26 (m, 1H), 4.87 (br s, 2H), 4.85 (br s, 2H), 3.91 (s, 1H), 3.90 (s, 1H), 3.62–3.70 (m, 4H), 2.80–2.87 (m, 4H), 2.20 (s, 1.5H), 2.19 (s, 1.5H); ESI MS m/z 405 [$\text{C}_{23}\text{H}_{24}\text{N}_4\text{O}_3 + \text{H}$] $^+$.

EXAMPLE 104

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-hydroxyethyl}-1,3-dihydroisoindol-2-yl}ethanone

Sodium borohydride (0.20 g, 5.3 mmol) was added to a stirred solution of the title compound of Example 102 (2.67 g, 6.35 mmol) in 1:1 MeOH/ CHCl_3 (130 mL) at 0°C. The mixture was allowed to warm to room temperature while stirring overnight. The solvents were removed in vacuo, and the residue was partitioned between CHCl_3 (200 mL) and H_2O (100 mL). The aqueous phase was reextracted with CHCl_3 (50 mL). The combined organic phases were washed with sat'd NaCl (50 mL), dried over Na_2SO_4 , filtered, and the solvent removed in vacuo to give the title compound (2.92 g crude; 2.68 g theoretical) as a light brown amorphous solid (foam): ^1H NMR (300 MHz, CDCl_3) δ 7.91 (d, J = 8.1 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.49 (t, J = 7.4 Hz, 1H), 7.22–7.41 (m, 4H), 4.77–4.87 (m, 5H), 4.05 (d, J = 1.9 Hz, 1H), 3.54–3.69 (m, 4H), 2.96–3.06 (m, 2H), 2.49–2.77 (m, 4H), 2.18 (s, 3H); ESI MS m/z 423 [$\text{C}_{23}\text{H}_{26}\text{N}_4\text{O}_2\text{S} + \text{H}$] $^+$.

EXAMPLE 105

1-{5-[2-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl]-1-hydroxyethyl}-1,3-dihydroisoindol-2-yl}ethanone

The title compound was prepared from the title compound of Example 103 (2.97 g, 7.34 mmol) using the procedure used to prepare the title compound of Example 104 (3.18 g crude; 2.98 g theoretical) as a light brown amorphous solid (foam): ^1H NMR (300 MHz, CDCl_3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.44–7.54 (m, 2H), 7.20–7.38 (m, 4H), 4.77–4.87 (m, 5H),

3.96 (br s, 1H), 3.58–3.72 (m, 4H), 2.92–3.02 (m, 2H), 2.48–2.74 (m, 4H), 2.18 (s, 3H); ESI MS m/z 407 [$C_{23}H_{26}N_4O_3 + H$]⁺.

EXAMPLE 106

5 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-chloroethyl}-1,3-dihydroisoindol-2-yl}ethanone**

Methanesulfonyl chloride (0.80 mL, 10 mmol) was added to a stirred solution of the title compound of Example 104 (2.92 g crude, 6.35 mmol theoretical) and triethylamine (2.0 mL, 14 mmol) in anhydrous CH_2Cl_2 (200 mL) at 0°C under N_2 . After stirring for 10 min, the ice-water bath was removed. After stirring for 2 h, TLC analysis indicated that no starting material was remaining. The solution was washed twice with H_2O , once with sat'd NaCl, dried over Na_2SO_4 , filtered, and the solvent removed in vacuo to give the title compound (2.75 g, 98% from the ketone product of Example 102) as a light brown amorphous solid (foam): 1H NMR (300 MHz, $CDCl_3$) δ 7.87 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.22–7.39 (m, 4H), 5.02 (t, J = 7.0 Hz, 1H), 4.77–4.85 (m, 4H), 3.47–3.53 (m, 4H), 3.13 (ddd, J = 13.5, 7.4, 1.5 Hz, 1H), 2.94 (dd, J = 13.5, 6.8 Hz, 1H), 2.66–2.82 (m, 4H), 2.180 (s, 1.5H), 2.178 (s, 1.5 H); ESI MS m/z 441 [$C_{23}H_{25}ClN_4OS + H$]⁺.

EXAMPLE 107

25 **1-{5-[2-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl]-1-chloroethyl}-1,3-dihydroisoindol-2-yl}ethanone**

The title compound was prepared from the title compound of Example 105 (3.18 g crude, 7.34 mmol theoretical) using the procedure used to prepare the title compound of Example 106 (2.96 g, 95% from the ketone product of Example 103) as a light brown amorphous solid (foam): 1H NMR (300 MHz, $CDCl_3$) δ 7.66 (d, J = 8.0 Hz, 1H), 7.41–7.52 (m, 2H), 7.17–7.38 (m, 4H), 5.01 (t, J = 7.0 Hz, 1H), 4.78–4.86 (m, 4H), 3.49–3.58 (m, 4H), 3.10 (ddd, J = 13.5, 7.4, 1.4 Hz, 1H), 2.93 (dd, J = 13.5, 6.6 Hz, 1H), 2.63–2.80 (m, 4H), 2.18 (s, 3H); ESI MS m/z 425 [$C_{23}H_{25}ClN_4O_2 + H$]⁺.

EXAMPLE 108

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)pyrazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}ethanone methanesulfonate

5 A stirred solution of the title compound of Example 106 (2.74 g, 6.21 mmol) and tributyl tin hydride (Bu_3SnH) (2.5 mL, 9.3 mmol) in anhydrous toluene (170 mL) was degassed by bubbling argon through the solution for 30 min. 2,2'-Azobisisobutyronitrile (AIBN) (0.15 g, 0.91 mmol) was added and the flask was heated with a preheated 80°C oil bath for 1 h. After
10 allowing to cool, H_2O (10 mL) was added. After stirring for 20 min, the solvents were removed in vacuo. The residue was dissolved in CHCl_3 (250 mL), then washed with H_2O (100 mL) and sat'd NaCl (50 mL), dried over Na_2SO_4 , filtered, and the solvent removed in vacuo. The residue was purified by column chromatography (silica gel (100 g), 1:1:98
15 MeOH/ Et_3N / CHCl_3) to give the free base of the title compound (1.28 g, 51%; plus slightly impure fractions: 0.69 g, 27%). The free base was dissolved in warm EtOAc-MeOH, then $\text{CH}_3\text{SO}_3\text{H}$ (0.20 mL, 3.1 mmol, 1.0 equiv.) was added dropwise with stirring. After stirring for 15 min, the solution was diluted with hexanes to precipitate the salt, which was
20 collected by suction filtration washing with hexanes, then dried overnight (18 h) in a vacuum oven at 50°C to give the title compound (1.36 g, 87% yield for salt formation, 44% yield from the title compound of Example 106) as a light brown amorphous solid: mp 219–222°C dec; ^1H NMR (300 MHz, DMSO- d_6) δ 9.81 (br s, 1H), 8.16 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.61 (t, J = 7.2 Hz, 1H), 7.49 (t, J = 7.2 Hz, 1H), 7.22–7.38 (m, 3H),
25 4.81 (br s, 2H), 4.60 (br d, J = 5.3 Hz, 2H), 4.14 (br d, J = 9.2 Hz, 2H), 3.68–3.75 (m, 2H), 3.02–3.12 (m, 2H), 2.34 (s, 3H); 2.072 (s, 1.5H), 2.066 (s, 1.5H); IR (KBr) 3437, 2959, 2920, 1643, 1448, 1423, 1207, 1035, 973, 774, 558 cm^{-1} ; ESI MS m/z 407 [$\text{C}_{23}\text{H}_{26}\text{N}_4\text{OS} + \text{H}$] $^+$; HPLC 95.7% (AUC), t_R = 11.78 min. Anal. Calc'd for $\text{C}_{23}\text{H}_{26}\text{N}_4\text{OS} \cdot \text{CH}_3\text{SO}_3\text{H} \cdot 0.1 \text{CH}_3\text{OH} \cdot 0.25 \text{H}_2\text{O}$: C, 56.81; H, 6.07; N, 11.03. Found: C, 56.65; H, 6.22; N, 10.71.

EXAMPLE 109


1-[5-[2-(4-Benzo[d]isoxazol-3-yl)piperazin-1-yl)ethyl]-1,3-dihydroisoindol-2-yl]ethanone methanesulfonate

5 The title compound was prepared from the title compound of Example 107 (2.95 g, 6.94 mmol) using the procedure used to prepare the title compound of Example 108 (1.44 g, 43%) as a white amorphous solid: mp 217–220°C dec; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.87 (br s, 1H), 8.07 (d, *J* = 8.1 Hz, 1H), 7.59–7.67 (m, 2H), 7.22–7.39 (m, 4H), 4.81 (br s, 2H), 4.60 (br d, *J* = 4.8 Hz, 2H), 4.19 (br d, *J* = 11.5 Hz, 2H), 3.71 (br d, *J* = 10.3 Hz, 2H), 3.01–3.11 (m, 2H), 2.34 (s, 3H), 2.07 (s, 1.5H), 2.06 (s, 1.5H); IR (KBr) 3438, 1631, 1529, 1449, 1198, 1058 cm⁻¹; ESI MS *m/z* 391 [C₂₃H₂₆N₄O₂ + H]⁺; HPLC 96.3% (AUC), *t*_R = 11.16 min. Anal. Calc'd for C₂₃H₂₆N₄O₂ • CH₃SO₃H • 0.1 CH₃OH • H₂O: C, 57.00; H, 6.43; N, 11.03. Found: C, 57.17; H, 6.49; N, 10.92.

EXAMPLE 110

5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl]-1,3-dihydroisoindole dihydrochloride


20



25 1-[5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl]-1,3-dihydroisoindol-2-yl] ethanone (6.6 g, 1.60 mmol) was dissolved in 630 mL of EtOH and 630 mL of conc. HCl and refluxed for 77 h. After reaction, the solvent was removed to afford the title compound (7.4 g) as a light brown solid. Mp: 112–121 °C. ¹H NMR (400 MHz, CD₃OD): δ 8.12–7.93 (dd, 2H), 7.60–7.40 (m, 5H), 4.60 (d, 4H), 4.20 (d, 2H), 3.80 (d, 2H), 3.62–3.40 (m, 6H), 3.30–3.20 (m, 2H). MS *m/z* 365 [M+1].

EXAMPLE 111

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]thyl}-1,3-dihydroisoindol-2-yl}acetic acid methyl ester




To a solution of the title compound from Example 110 (4.0 g, 0.91 mmol) in 200 mL of chloroform were slowly added methyl bromoacetate (1.67 g, 1.09 mmol) and triethylamine (7.6 mL, 5.47 mmol). The reaction mixture was stirred at room temperature overnight, washed with water, dried over sodium sulphate and concentrated. The crude residue was subjected to chromatography (silica gel, EtOAc/MeOH/Et₃N, 98/1/1) to afford the title compound (2.5 g, 63%) as yellow oil, which darkens in the air. ¹H NMR (400 MHz, CDCl₃): δ 7.94-7.79 (dd, 2H), 7.50-7.32 (dt, 2H), 7.16-7.04 (m, 3 H), 4.08 (s, 4H), 3.78 (s, 2H), 3.62-3.58 (m, 6H), 2.88-2.60 (m, 8H). MS *m/z* 437 [M+1].

10

15

EXAMPLE 112

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}acetic acid




A solution of the title compound from Example 111 (2.5 g, 0.57 mmol) in THF/H₂O (100/10 mL) was treated with LiOH·H₂O (0.36 g, 0.86 mmol). The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure. The crude product was diluted with water, and neutralized with 0.5 N HCl to pH = 7. The solution was extracted with DCM, dried over sodium sulphate and concentrated to

25

give the title compound (2.49 g) as green solid. The crude product is pure in NMR spectrum, but is 75 % purity in HPLC analysis. The title compound was further purified by chromatography (silica gel, MeOH/DCM/acetic acid, 40/60/0.1). Yellow oil was obtained, but it darkens quickly. It is 85 % purity in HPLC analysis. ¹H NMR (400 MHz, CDCl₃): δ 7.95-7.79 (dd, 2H), 7.50-7.30 (dt, 2H), 7.16-7.10 (m, 3 H), 4.70-4.50 (br s, 4H), 3.80 (s, 2H), 3.62-3.58 (br s, 4H), 2.90-2.60 (m, 8H). MS *m/z* 423 [M+1].

EXAMPLE 113

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl]-1,3-dihydroisoindol-2-yl}-1-[(3-amino)pyrrolidin-1-yl]ethanone




Oxalyl chloride (0.42 g, 3.30 mmol) was added dropwise to a stirred solution of the title compound from Example 112 (0.70 g, 1.65 mmol) and DMF (2 drops) in DCM (20 mL). The reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the residue was suspended in DCM (15 mL), which was added dropwise to a stirred solution of 3-(dimethylamino)pyrrolidine (0.28 g, 2.47 mmol) and triethylamine (1.8 mL, 13.25 mmol). The reaction mixture was stirred at room temperature for 3 h, 100 mL of DCM was added. The solution was washed with water, dried over sodium sulphate and concentrated. The crude residue was subjected to chromatography (MeOH/DCM/Et₃N, 2/98/0.5) to provide the title compound (0.27 g, 31 %) as a light brown oil, which was treated with 4 mL of 2M solution of hydrogen chloride in ether to provide the title compound as hydrochloride

salt. mp: 181-188°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.90-11.50 (m, 3H), 8.10 (m, 2H), 7.60-7.23 (m, 5H), 4.90 (m, 2H), 4.60 (m, 4H), 4.10 (d, 2H), 4.00-3.00 (m, 15H), 2.72 (br s, 6H), 2.40-2.20 (m, 2 H). MS *m/z* 519 [M+1]. Anal. Calcd for C₂₉H₃₈N₆OS·3HCl·4H₂O: C, 49.75; H, 7.05; N, 12.00. Found: C, 49.06; H, 6.32; N, 11.01.

EXAMPLE 114

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}-1-[methyl(dimethylaminoethyl)]aminoethanone




Oxalyl chloride (0.42 g, 3.30 mmol) was added dropwise to a stirred solution of the title compound from Example 112 (0.70 g, 1.65 mmol) and DMF (2 drops) in DCM (20 mL). The reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the residue was suspended in DCM (15 mL), which was added dropwise to a stirred solution of amine (0.25 g, 2.47 mmol) and triethylamine (1.8 mL, 13.25 mmol). The reaction mixture was stirred at room temperature for 3 h, 100 mL of DCM was added. The solution was washed with water, dried over sodium sulphate and concentrated. The crude residue was subjected to chromatography (MeOH/DCM/Et₃N, 2/98/0.5) to provide the title compound (0.28 g, 34 %) as a light brown oil, which was treated with 4 mL of 2M solution of hydrogen chloride in ether to provide the title compound as hydrochloride salt. mp: 152-160°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.79 (br s, 1H), 11.35 (br s, 1H), 10.86 (br

s, 1H), 8.15 (m, 2H), 7.62-7.28 (m, 5H), 5.00-4.30 (m, 10H), 4.10 (d, 2H), 3.80-3.10 (m, 11H), 2.99 (s, 2H), 2.75 (d, 6H). MS m/z 507 [M+1]. Anal. Calcd for $C_{27}H_{36}N_6OS \cdot 3HCl \cdot 5H_2O$: C, 47.62; H, 7.28; N, 11.90. Found: C, 47.28; H, 6.86; N, 11.06.

5

EXAMPLE 115

N-chloroacetyl-morpholine



10


To a solution of chloroacetyl chloride (2.0 mL, 2.5 mmol) in 20 mL DCM was slowly added a solution of morpholine (2.2 mL, 5.0 mmol) in 20 mL DCM at -78°C . The reaction mixture was warmed to room temperature and stirred for 3 h. A white suspension solution resulted. The white precipitate was filtered off. The filtrate was washed with 1 N HCl, dried over sodium sulphate and concentrated to give the title compound (3.11 g, 78 %) as colorless oil. ^1H NMR (400 MHz, CDCl_3): δ 4.12 (s, 2H), 3.74 (br s, 4H), 3.61 (br s, 2H), 3.50 (br s, 2H). MS m/z 164 [M+1].

15

EXAMPLE 116

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}-1-(N-morpholino)ethanone


20



A mixture of the title compound from Example 110 (0.40 g, 0.091 mmol), the title compound from Example 115 (0.15 g, 0.092 mmol), potassium carbonate (0.38 g, 0.28 mmol) and sodium iodide (0.15 g, 0.10 mmol) was suspended in 40 mL of acetonitrile and stirred under reflux overnight, cooled to room temperature, solvent was removed, and water was added. The mixture was extracted with DCM, dried over sodium sulphate and concentrated. The crude residue was subjected to chromatography (MeOH/DCM/acetic acid, 3/97/0.1) to provide the title compound (0.27 g, 60 %) as light yellow oil, which darkens quickly in the air. ¹H NMR (400 MHz, CDCl₃): δ 7.93-7.80 (dd, 2H), 7.50-7.37 (dt, 2H), 7.12-7.06 (m, 3H), 4.01 (s, 4H), 3.71-3.58 (m, 14H), 2.90-2.65 (m, 8H). MS *m/z* 292 [M+1]. Anal. Calcd for C₂₇H₃₃N₅O₂S·1.5 H₂O: C, 62.52; H, 7.00; N, 13.50. Found: C, 62.63; H, 6.48; N, 13.03.

EXAMPLE 117

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]thyl}-1,3-dihydroisoindol-2-yl}-1-(methoxyethylamino)ethanon






5

A mixture of the title compound from Example 110 (1.00 g, 2.28 mmol), 2-chloro-1-(methoxyethylamino)ethanone (0.34 g, 2.28 mmol), potassium carbonate (0.94 g, 6.84 mmol) and sodium iodide (0.37 g, 2.50 mmol) was suspended in 100 mL of acetonitrile and stirred under reflux overnight, cooled to room temperature. The solvent was removed, and water was added. The mixture was extracted with DCM, dried over sodium sulphate and concentrated. The crude residue was subjected to chromatography (MeOH/DCM, 3/97) to provide the title compound (0.53 g, 49 %) as a light brown oil, which was treated with 4 mL of 2M solution of hydrogen chloride in ether to provide the title compound as a hydrochloride salt. mp: 149-154°C. 1H NMR (400 MHz, $DMSO-d_6$): δ 11.70 (br s, 1H), 11.40 (br s, 1H), 8.68 (br s, 1H), 8.13 (m, 2H), 7.62-7.20 (m, 5H), 4.90-4.80 (m, 2H), 4.50 (br s, 2H), 4.13 (br s, 2H), 4.10 (d, 2H), 3.65-3.43 (m, 4H), 3.46-3.05 (m, 13 H). MS m/z 480 $[M+1]$. Anal. Calcd for $C_{26}H_{33}N_5O_2S \cdot 2HCl \cdot 2H_2O$: C, 53.06; H, 6.68; N, 11.90. Found: C, 53.01; H, 5.80; N, 11.34.

25

EXAMPLE 118


1-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}-2-(N-morpholino)ethanon



EXAMPLE 119


1-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}-2-(N-morpholino)ethanone

Step 1. Preparation of compound 6




To a solution of morpholine (5.46 mL, 39.2 mmol) and triethylamine (1.71 mL, 19.6 mmol) in THF (100 mL), methyl bromoacetate (1.86 mL, 19.6 mmol) was added. The reaction mixture was stirred at room temperature for 5 h. The solvent was removed under reduced pressure. Sodium bicarbonate solution was added. The mixture was extracted with EtOAc, dried over sodium sulphate and concentrated to provide compound

5



10

15




20

(MeOH/DCM/EtOAc/Et₃N, 1/20/20/0.1) to provide the title compound (0.12 g, 23 %) as a light yellow oil, which was treated with 4 mL of 2M solution of hydrogen chloride in ether to provide the title compound as hydrochloride salt. mp: 183-187°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.42 (br s, 1H), 10.42 (br s, 1H), 8.15 (m, 2H), 7.60 (m, 1H), 7.45 (m, 1H), 7.40-7.28 (m, 3H), 4.83-4.70 (dd, 4H), 4.39 (br s, 2H), 4.10 (d, 2H), 4.00-3.15 (m, 18H). MS *m/z* 492 [M+1]. Anal. Calcd for C₂₇H₃₃N₅O₂S·2HCl·3H₂O: C, 52.42; H, 6.68; N, 11.32. Found: C, 52.84; H, 6.36; N, 10.96.

EXAMPLE 120

3-{4-[2-(1-Methanesulfonyl-2,3-dihydro-1H-isoindol-4-yl)-ethyl]-piperizin-1-yl}-benzo[d]isithiazole hydrochloride




Compound 1 (0.55 g, 1.25 mmol) and triethylamine (0.35 ml, 2.50 mmol) were dissolved in 10 mL of DCM at 0°C. Methanesulfonyl chloride (0.17 g, 1.50 mmol) was added slowly. The reaction mixture was warmed to room temperature and stirred for 2 h, 50 mL of DCM was added. The solution was washed with water, dried over sodium sulphate and concentrated. The crude residue was subjected to chromatography (MeOH/DCM, 2/98) to provide compound 10 (0.32 g, 58 %) as a light yellow oil, which was treated with 5 mL of 2M solution of hydrogen chloride

in ether to provide compound **10** as hydrochloride salt. mp: 179°C (dec).
¹H NMR (400 MHz, DMSO-*d*₆): δ 11.00 (br s, 1H), 8.10 (m, 2H), 7.62 (dt, 1H), 7.45 (dt, 1H), 7.30 (m, 3H), 4.60 (br s, 4H), 4.10 (d, 2H), 3.61 (d, 2H), 3.59-3.10 (m, 8H), 2.98 (s, 3H). MS *m/z* 443 [M+1]. Anal. Calcd for C₂₂H₂₆N₄O₂S₂·HCl: C, 55.16; H, 5.68; N, 11.69. Found: C, 54.52; H, 5.43; N, 11.13.

EXAMPLE 121

1-(5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl]-1,3-dihydroisoindol-2-yl}-ethanone




Acetic anhydride (0.62 mL, 6.6 mmol) was added to a solution containing **1** (02-029-218; 1.0 g, 2.6 mmol), triethylamine (1.62 mL, 11.6 mmol), 4-dimethylamino-pyridine (0.08 g, 0.65 mmol), and anhydrous dichloromethane (40 mL) at room temperature. The reaction mixture was stirred overnight at room temperature. The resulting solution was washed with NaHCO₃, dried over Na₂SO₄, and evaporated. The residue thus obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 12 cm), using ethyl acetate:methanol:acetic acid (88:10:2) solvent mixture as eluent to obtain the acetylated amine product. The product was dissolved in 40 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (5.0 mL, 5 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (2 x 10 mL), and dried under vacuum. Yield: 0.884 g, 73.2 %. M.p. 130.0 – 133.0 °C. HPLC: Purity 98.10% (retention time: 9.918; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6

x 150 mm). ^1H NMR (400 MHz, DMSO): δ 10.9 (b.s, 1H), 7.88 (d, 1H), 7.83 (d, 1H), 7.48 (t, 1H), 7.36 (t, 1H), 7.21 (t, 1H), 7.14 (m, 2H), 4.79 (m, 4H), 3.67 (m, 4H), 2.89 (m, 4H), 2.67 (t, 2H), 2.63 (t, 2H), 2.18 (s, 3H), 1.93 (t, 2H). ES-MS m/z 420.58 ($\text{C}_{24}\text{H}_{28}\text{N}_4\text{OS} + 1$) $^+$. Analysis calculated for $\text{C}_{24}\text{H}_{28}\text{N}_4\text{OS} \cdot \text{HCl}$: % C 63.07; % H 6.40; % N 12.26. Found % C 63.03; % H 6.51; % N 12.08.

EXAMPLE 122

2-{5-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-1,3-dihydroisoindol-2-yl}acetic acid



Preparation of compound 2

Methyl bromoacetate (0.28 mL, 2.9 mmol) was added to a suspension containing **1** (02-029-218; 1.0 g, 2.6 mmol), potassium carbonate (0.44 g, 3.2 mmol) and anhydrous acetonitrile (50 mL) at rt and stirred overnight. Solvent was evaporated and the residue was distributed between chloroform (50 mL) and water (30 mL). The organic layer was separated, dried over Na_2SO_4 , and evaporated. The residue was purified over silica gel column (230 - 400 mesh, 2.5 x 18 cm) using methanol:ethyl acetate (1.5:98.5) solvent mixture as eluent to obtain pure compound **2**. Yield: 0.12 g, 10.08%. Using triethylamine as a base, the yield was improved to 67.8%; Reference: 02-029-224). ^1H NMR (400 MHz, CDCl_3): δ 7.91 (d, 1H), 7.80 (d, 1H), 7.47 (t, 1H), 7.36 (t, 1H), 7.11 (d, 1H), 7.08 (d, 1H), 4.09

(s, 4H), 3.76 (s, 2H), 3.62 (s, 3H), 3.56 (m, 4H), 2.67 (m, 4H), 2.64 (m, 2H), 2.44 (t, 2H), 1.85 (m, 2H). ES-MS m/z 451.08 ($C_{25}H_{30}N_4O_2S + 1$)⁺.


Preparation of compound 3

5 Lithium hydroxide monohydrate (0.1 g, 2.4 mmol) was added to a solution containing **2** (0.6 g, 1.3 mmol), tetrahydrofuran (30 mL), and water (4 mL), and stirred overnight. The solution was evaporated to dryness and the residue was dissolved in 3 mL of water, and pH was adjusted to 6 using 1M HCl. The resulting solution was evaporated to dryness, and washed
10 with ether (2 x 10 mL) and tetrahydrofuran (2 x 10 mL). As the elemental analysis results were not satisfactory, the product was further purified using HP20 Diaion column (Supelco product). The impure product was treated with 1 mL of triethylamine and then loaded over HP20 column. After washing the column with methanol:water (1:1), elution with
15 acetonitrile yielded pure product containing fractions, which were evaporated, and dried under vacuum. Yield: 0.44 g, 72.7 %. M.p. 78.0 – 80.0 °C. HPLC: Purity 94.45% (retention time: 11.601; mobile phase: 0.1% H_3PO_4 /MeCN gradient; column: ACE_C18_5 μ m_4-6 x 150 mm). ¹H NMR (400 MHz, $CDCl_3$): δ 7.90 (d, 1H), 7.79 (d, 2H), 7.46 (t, 1H), 7.37 (t, 1H), 7.13 (m, 2H), 7.07 (s, 1H), 4.58 (s, 4H), 3.77 (s, 2H), 3.58 (m, 4H),
20 2.70 (m, 4H), 2.67 (m, 2H), 2.47 (m, 2H), 1.86 (m, 2H). ES-MS m/z 437.09 ($C_{24}H_{28}N_4O_2S + 1$)⁺. Analysis calculated for $C_{24}H_{28}N_4O_2S \cdot 0.5Et_3N \cdot H_2O$: % C 64.19; %H 7.50; %N 12.48. Found: %C 65.26; %H 6.94; %N 12.41.

25

EXAMPLE 123

1-[5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1,3-dihydroisoindol-2-yl]-2-(dimethylamino)-ethanone




Preparation of compound 3

Chloroacetylchloride (0.15 mL, 1.9 mmol) was added to a solution containing 1 (02-029-218; 0.5 g, 1.1 mmol), 4-dimethylaminopyridine (0.014 g, 0.01 mmol), triethylamine (0.7 mL, 5.0 mmol) and dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight at room temperature and later an aliquot was examined by NMR, which indicated the absence of starting material and formation of 2. The resultant solution was washed with NaHCO_3 , brine, dried over Na_2SO_4 , and evaporated to obtain crude 2. This was dissolved in acetonitrile (50 mL), and to which was added dimethylamine (1.11 mL of 2M MeOH solution, 2.2 mmol), potassium carbonate (0.18 g, 1.3 mmol), and sodium bromide (0.028 g, 0.30 mmol) at room temperature, and stirred overnight. The resulting suspension was filtered and the precipitate was washed with chloroform. The filtrate was evaporated, and the residue obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 12 cm), using triethylamine:ethyl acetate:methanol (1:94:5) solvent mixture as eluent to obtain compound 3. The product was dissolved in 5 mL of anhydrous diethylether and to which was added 1M hydrogen chloride

solution in ether (2.0 mL, 2.0 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (3 x 15 mL), and dried under vacuum. Yield: 0.40 g, 66.9 %. M.p. 90.0 C turned brown. HPLC: Purity 97.59% (retention time: 11.683; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.62 (b.s, 1H), 10.02 (b.s, 1H), 8.12 (m, 2H), 7.60 (M, 1H), 7.49 (m, 1H), 7.36 (m, 1H), 7.32 (m, 1H), 7.23 (m, 1H), 4.81 (m, 2H), 4.73 (m, 2H), 4.33 (s, 2H), 4.05 (m, 2H), 3.57 (m, 4H), 3.30 (m, 2H), 3.15 (m, 2H), 2.88 (s, 6H), 2.72 (m, 2H), 2.11 (m, 2H). ES-MS m/z 464.18 (C₂₆H₃₃N₅OS + 1)⁺. Analysis calculated for C₂₆H₃₃N₅OS.2HCl.H₂O: % C 56.31; %H 6.72; %N 12.63. Found: %C 56.25; %H 6.70; %N 12.32.

EXAMPLE 124

1-{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-2-(piperidin-1-yl)-ethanone




Preparation of compound 3

Chloroacetylchloride (0.15 mL, 1.9 mmol) was added to a solution containing **1** (02-029-218; 0.6 g, 1.6 mmol), 4-dimethylaminopyridine (0.020 g, 0.02 mmol), triethylamine (0.97 mL, 6.9 mmol) and acetonitrile

(40 mL) at room temperature. The reaction mixture was stirred overnight at room temperature and later an aliquot was examined by NMR, which indicated the absence of starting material and formation of **2**. Solvent was evaporated to afford an oil, which was diluted with 50 mL of chloroform, washed with NaHCO₃, brine, dried over Na₂SO₄, and evaporated to obtain crude **2**. This was dissolved in acetonitrile (50 mL), and to which was added piperidine (0.33 mL, 3.3 mmol), potassium carbonate (0.26 g, 1.9 mmol), and sodium bromide (0.040 g, 0.39 mmol) at room temperature, and stirred overnight. The resulting suspension was filtered and the precipitate was washed with chloroform. The filtrate was evaporated, and the residue obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 12 cm), using triethylamine:ethyl acetate:methanol (1:93:6) solvent mixture as eluent to obtain compound **3**. The product was dissolved in 5 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (2.1 mL, 2.1 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (3 x 5 mL), and dried under vacuum. Yield: 0.39 g, 43.6 %. M.p. 98.0 C turned brown. HPLC: Purity 94.40% (retention time: 11.987; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.58 (b.s, 1H), 9.78 (b.s, 1H), 8.12 (m, 2H), 7.60 (m, 1H), 7.49 (m, 1H), 7.36 (m, 1H), 7.30 (m, 1H), 7.25 (m, 1H), 4.83 (m, 2H), 4.72 (m, 2H), 4.31 (s, 2H), 4.02 (m, 4H), 3.60 (m, 4H), 3.47 (m, 2H), 3.30 (m, 2H), 3.19 (m, 2H), 3.15 (m, 2H), 2.70 (b.s, 2H), 2.11 (b.s, 2H), 1.81 (b.s, 2H), 1.68 (b.s, 2H). ES-MS m/z 504.17 (C₂₉H₃₇N₅OS + 1)⁺. Analysis calculated for C₂₉H₃₇N₅OS.2HCl.0.5H₂O: % C 59.47; %H 6.90; %N 11.96. Found: %C 59.64; %H 6.89; %N 11.49.

EXAMPLE 125

1-{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-2-(morpholin-1-yl)-ethanone




Preparation of compound 3

Chloroacetylchloride (0.14 mL, 1.7 mmol) was added to a solution containing **1** (02-029-218; 0.6 g, 1.6 mmol), potassium carbonate (0.26 g, 1.9 mmol), 4-dimethylaminopyridine (0.050 g, 0.04 mmol), and acetonitrile (40 mL) at room temperature. The reaction mixture was stirred overnight at room temperature and later an aliquot was examined by NMR, which indicated the absence of starting material and formation of compound **2**. To the same pot was added morpholine (0.28 mL, 3.2 mmol), potassium carbonate (0.4 g, 2.9 mmol), and sodium bromide (0.048 g, 0.47 mmol) at room temperature, and stirred overnight. The resulting suspension was diluted with 100 mL of chloroform, washed with brine, dried over Na_2SO_4 , and evaporated. The residue thus obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 14 cm), using ethyl acetate:methanol:acetic acid (88:10:2) solvent mixture as eluent to obtain compound **3**. The product was dissolved in 20 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (5.0 mL, 5 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which

was filtered off, washed with ether (2 x 10 mL), and dried under vacuum. Yield: 0.66 g, 71.9 %. M.p. 179.0 – 183.0 °C. HPLC: Purity 94.29% (retention time: 11.665; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5µm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.58 (b.s, 1H), 10.58 (b.s, 1H), 8.12 (m, 2H), 7.62 (m, 1H), 7.48 (m, 1H), 7.30 (m, 3H), 4.83 (m, 2H), 4.72 (m, 2H), 4.42 (s, 2H), 4.03 (m, 4H), 3.84 (m, 2H), 3.6 (m, 4H), 3.54 (m, 2H), 3.30 (m, 4H), 3.16 (m, 2H), 2.70 (m, 2H), 2.11 (m, 2H). ES-MS m/z 379.08 (C₂₈H₃₅N₅O₂S + 1)⁺. Analysis calculated for C₂₈H₃₅N₅O₂S.2HCl: % C 58.12; %H 6.45; %N 12.10. Found: %C 58.18; %H 6.51; %N 11.84.

EXAMPLE 126

1-{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-2-[methyl(dimethylaminoethyl)amino]-ethanone



Preparation of compound 3

Chloroacetylchloride (0.23 mL, 2.9 mmol) was added to a solution containing **1** (02-029-218; 1.0 g, 2.2 mmol), 4-dimethylaminopyridine (0.010 g, 0.002 mmol), triethylamine (1.4 mL, 9.9 mmol) and dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight at room temperature and later an aliquot was examined by NMR, which indicated the absence of starting material and formation of

2. The resultant solution was washed with NaHCO_3 , brine, dried over Na_2SO_4 , and evaporated to obtain crude **2** (Ref: 02-029-239). About half of the crude **2** was dissolved in acetonitrile (50 mL), and to which was added NNN-trimethylethylenediamine (0.29 mL, 2.2 mmol), potassium carbonate (0.18 g, 1.3 mmol), and sodium bromide (0.028 g, 0.27 mmol) at room temperature, and stirred overnight. The resulting suspension was filtered and the precipitate was washed with chloroform (2 x 10 mL). The filtrate was evaporated and the residue obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 11 cm), using triethylamine:ethyl acetate:methanol (1:94:5) solvent mixture as eluent to obtain target **A**. The product was dissolved in 5 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (4.4 mL, 4.4 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (2 x 10 mL), and dried under vacuum. Yield: 0.33 g, 42.9 %. M.p. 85.1 – 87.3 C. HPLC: Purity 95.42% (retention time: 11.097; mobile phase: 0.1% $\text{H}_3\text{PO}_4/\text{MeCN}$ gradient; column: ACE_C18_5 μm _4-6 x 150 mm). ^1H NMR (400 MHz, DMSO): δ 11.64 (b.s, 1H), 11.16 (b.s, 1H), 8.14 (m, 2H), 7.61 (m, 1H), 7.49 (m, 1H), 7.36 (m, 1H), 7.33 (m, 1H), 7.26 (m, 1H), 4.84 (m, 2H), 4.73 (m, 2H), 4.49 (b.s, 2H), 4.21 (b.s, 4H), 4.05 (m, 2H), 3.74 (m, 2H), 3.41 (m, 4H), 3.28 (m, 2H), 3.07 (m, 2H), 2.98 (s, 3H), 2.85 (s, 6H), 2.70 (b.s, 2H), 2.11 (b.s, 2H). ES-MS m/z 521.26 ($\text{C}_{29}\text{H}_{40}\text{N}_6\text{OS} + 1$) $^+$. Analysis calculated for $\text{C}_{29}\text{H}_{40}\text{N}_6\text{OS} \cdot 4\text{HCl} \cdot \text{H}_2\text{O}$: % C 50.88; %H 6.77; %N 12.28. Found: %C 50.50; %H 7.17; %N 11.67.

EXAMPLE 127


1-(5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl)-1,3-dihydroisoindol-2-yl]-2-(diethylamino)-ethanone

5 Chloroacetylchloride (0.23 mL, 2.9 mmol) was added to a solution containing **1** (02-029-218; 1.0 g, 2.2 mmol), 4-dimethylaminopyridine (0.010 g, 0.002 mmol), triethylamine (1.4 mL, 9.9 mmol) and dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight at room temperature and later an aliquot was examined by NMR, which indicated the absence of starting material and formation of **2**. The resultant solution was washed with NaHCO₃, brine, dried over Na₂SO₄, and evaporated to obtain crude **2** (Ref: 02-029-239). About half of the crude **2** was dissolved in acetonitrile (50 mL), and to which was added diethylamine (0.6 mL, 5.7 mmol), potassium carbonate (0.18 g, 1.3 mmol), and sodium bromide (0.025 g, 0.28 mmol) at room temperature, and stirred overnight. The resulting suspension was filtered and the precipitate was washed with chloroform (2 x 10 mL). The filtrate was evaporated, and the residue obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 11 cm), using triethylamine:ethyl acetate:methanol (1:93:6) solvent mixture as eluent to obtain compound **3**. The product was dissolved in 5 mL of anhydrous diethylether and to which was added 1M hydrogen chloride solution in ether (3.3 mL, 3.3 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (3 x 10 mL), and dried under vacuum. Yield: 0.40

g, 58.3 %. M.p. 90.0 C turned waxy. HPLC: Purity 95.82% (retention time: 11.936; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.76 (b.s, 1H), 9.66 (b.s, 1H), 8.18 (m, 2H), 7.66 (m, 1H), 7.55 (m, 1H), 7.39 (m, 1H), 7.36 (m, 1H), 7.31 (m, 1H), 4.94 (m, 2H), 4.78 (m, 2H), 4.36 (s, 2H), 4.10 (m, 2H), 3.64 (m, 4H), 3.36 (m, 4H), 3.24 (m, 4H), 2.76 (b.s, 2H), 2.18 (b.s, 2H), 1.29 (m, 6H). ES-MS m/z 492.22 (C₂₈H₃₇N₅OS + 1)⁺. Analysis calculated for C₂₈H₃₇N₅OS.3HCl.H₂O: % C 54.32; %H 6.84; %N 11.31. Found: %C 54.45; %H 7.25; %N 11.11.

EXAMPLE 128

{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-[(3-dimethylamino)pyrrolidin-1-yl]-methanone




Preparation of compound 3

Chloroacetylchloride (0.14 mL, 1.7 mmol) was added to a solution containing 1 (02-029-218; 0.6 g, 1.6 mmol), potassium carbonate (0.26 g, 1.9 mmol), 4-dimethylaminopyridine (0.050 g, 0.04 mmol), and acetonitrile (40 mL) at room temperature. The reaction mixture was stirred overnight

at room temperature and later an aliquot was examined by NMR, which indicated the presence of starting material. Hence, added triethylamine (1.0 mL, 7.2 mmol) and stirred for an hour. Now, the starting material completely disappeared. The resulting suspension was diluted with 100 mL of chloroform, washed with NaHCO₃, brine, dried over Na₂SO₄, and evaporated to obtain crude **2**. This was dissolved in acetonitrile (50 mL), and to which was added 2-dimethylaminopyrrolidine(S-) (0.36 g, 3.2 mmol), potassium carbonate (0.4 g, 2.9 mmol), and sodium bromide (0.048 g, 0.47 mmol) at room temperature, and stirred overnight. The resulting suspension was diluted with 100 mL of chloroform, washed with brine, dried over Na₂SO₄, and evaporated. The residue thus obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 12 cm), using chloroform:methanol (88:12) solvent mixture as eluent to obtain compound **3**. The product was dissolved in 20 mL of anhydrous tetrahydrofuran and to which was added 1M hydrogen chloride solution in ether (6.8 mL, 6.8 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (3 x 10 mL), and dried under vacuum. Yield: 0.73 g, 68.8 %. M.p. 166.0 – 170.0 °C. HPLC: Purity 94.60% (retention time: 11.032; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5µm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.99 (b.d, 1H), 11.66 (b.s, 1H), 11.09 (b.s, 1H), 8.10 (m, 2H), 7.59 (m, 1H), 7.47 (m, 1H), 7.34 (m, 2H), 7.23 (m, 1H), 4.82 (b.s, 2H), 4.71 (b.s, 2H), 4.57 (b.m, 2H), 4.43 (b.m, 4H), 4.04 (m, 4H), 3.72 (m, 2H), 3.60 (m, 4H), 3.28 (m, 2H), 3.14 (m, 2H), 2.79 (b.s, 6H), 2.40 (b.m, 1H), 2.12 (m, 2H). ES-MS m/z 533.22 (C₃₀H₄₀N₆OS + 1)⁺. Analysis calculated for C₃₀H₄₀N₆OS.3HCl.1.5H₂O: % C 53.84; %H 6.94; %N 12.56. Found: %C 53.84; %H 7.39; %N 11.85.

EXAMPLE 129

{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-4-fluorophenylamide




Preparation of compound 3

4-Fluorophenylisocyanate (0.15 mL, 1.3 mmol) was added to a solution containing **1** (02-029-218; 0.5 g, 1.1 mmol), triethylamine (0.46 mL, 3.3 mmol) and tetrahydrofuran (40 mL) at room temperature. The reaction mixture was stirred for 2 h at room temperature and later evaporated. The residue was dissolved in 30 mL of dichloromethane, washed with NaHCO₃, dried over Na₂SO₄, and evaporated to obtain crude product. Purification over silica gel column (230 - 400 mesh, 2.5 x 12 cm), using triethylamine:ethyl acetate (1:99) solvent mixture as eluent yielded pure compound **3**. The product was dissolved in 5 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (2.0 mL, 2.0 mmol) with stirring. A white precipitate of hydrogen chloride salt of **A** was obtained, which was filtered off, washed with ether (3 x 15 mL), and dried under vacuum. Yield: 0.46 g, 75.2 %. M.p. 145.0 – 150.0 °C. HPLC: Purity 96.34% (retention time: 15.080; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.71 (b.s, 1H), 8.46 (s, 1H), 8.10 (m, 2H), 7.59 (m, 3H), 7.45 (m, 1H), 7.30 (m, 1H), 7.26 (m, 1H), 7.20 (m, 1H), 7.12 (m, 2H), 4.74 (s, 4H), 4.02 (m, 2H), 3.56 (m, 2H), 3.49 (m, 2H), 3.31 (m, 2H), 3.16 (m, 2H), 2.71 (m, 2H), 2.12 (m, 2H). ES-MS m/z 516.20 (C₂₉H₃₀FN₅OS + 1)⁺. Analysis calculated for C₂₉H₃₀FN₅OS.HCl.0.5H₂O: % C 62.07; %H 5.76; %N 12.48. Found: %C 61.83; %H 5.61; %N 12.23.

EXAMPLE 130

{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-(cyclohexylamino)-methylsulfide



Preparation of compound 3

5 Cyclohexylisothiocyanate (0.31 mL, 2.2 mmol) was added to a solution containing **1** (02-029-218; 0.5 g, 1.1 mmol), triethylamine (0.46 mL, 3.3 mmol) and tetrahydrofuran (40 mL) at room temperature. The reaction mixture was stirred for 2 h at room temperature and later evaporated. The residue was washed with hexane to remove CyNCS. Purification over

10 silica gel column (230 - 400 mesh, 2.5 x 10 cm) using ethyl acetate as eluent yielded pure compound **3** as an oil, which was washed with dry ether (2 x 10 mL) to obtain white solid. Yield: 0.35 g, 60.8 %. M.p. 194.2 – 195.3 °C. HPLC: Purity 98.95% (retention time: 16.571; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6 x 150 mm). ¹H


15 NMR (400 MHz, CDCl₃): δ 7.91 (m, 1H), 7.82 (m, 1H), 7.47 (m, 1H), 7.37 (m, 1H), 7.19 (m, 1H), 7.15 (m, 2H), 5.14 (m, 2H), 4.82 (b.s, 2H), 4.37 (m, 1H), 3.58 (b.s, 4H), 2.68 (m, 4H), 2.67 (b.s, 2H), 2.45 (m, 2H), 2.17 (m, 2H), 1.88 (m, 2H), 1.76 (m, 2H), 1.68 (m, 2H), 1.50 (m, 2H), 1.44 (m, 2H), 1.24 (m, 2H). ES-MS m/z 520.20 (C₂₉H₃₇N₅S₂ + 1)⁺. Analysis calculated for C₂₉H₃₇N₅S₂: % C 67.01; %H 7.18; %N 13.47. Found: %C 66.54; %H 7.00; %N 13.18.

20

EXAMPLE 131

5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-2-methanesulfonyl-1,3-dihydroisoindole

25



Preparation of compound 3


5 Methanesulfonylchloride (0.16 mL, 2.2 mmol) was added to a solution containing **1** (02-029-218; 0.8 g, 1.8 mmol), triethylamine (4.0 mL, 28.7 mmol) and anhydrous chloroform (50 mL) at 5°C. After 2 h stirring at rt, the reaction mixture was washed with NaHCO_3 , dried over Na_2SO_4 , and evaporated to obtain crude product. Purification over silica gel column

10 (230 - 400 mesh, 2.5 x 12 cm) using ethyl acetate as eluent yielded pure compound **3**. The product was dissolved in 20 mL of anhydrous tetrahydrofuran and to which was added 1M hydrogen chloride solution in ether (4.3 mL, 4.3 mmol) with stirring. A white precipitate of hydrogen chloride salt of compound **3** was obtained, which was filtered off, washed with ether (3 x 6 mL), and dried under vacuum. Yield: 0.79 g, 90.4 %.

15 M.p. 201.0- 203.0 °C. HPLC: Purity 97.50% (retention time: 14.072; mobile phase: 0.1% $\text{H}_3\text{PO}_4/\text{MeCN}$ gradient; column: ACE_C18_5 μm _4-6 x 150 mm). ^1H NMR (400 MHz, DMSO): δ 11.48 (b.s, 1H), 8.14 (m, sH), 7.60 (m, 1H), 7.47 (m, 1H), 7.29 (m, 1H), 7.27 (m, 1H), 7.20 (m, 1H), 4.61 (s, 4H), 4.03 (d, 2H), 3.59 (m, 4H), 3.30 (m, 2H), 3.25 (m, 2H), 2.98 (s, 3H), 2.69 (m, 2H), 2.09 (m, 2H). ES-MS m/z 457.06 ($\text{C}_{23}\text{H}_{28}\text{N}_4\text{O}_2\text{S}_2 + 1$) $^+$. Analysis calculated for $\text{C}_{23}\text{H}_{28}\text{N}_4\text{O}_2\text{S}_2 \cdot \text{HCl} \cdot 1.5\text{H}_2\text{O}$: % C 53.12; %H 6.21; %N 10.78. Found: %C 53.38; %H 5.61; %N 10.33.

EXAMPLE 132

5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl-2-phenylsulfonyl-1,3-dihydroisoindole



Preparation of compound 3

Benzenesulfonylchloride (0.14 mL, 1.06 mmol) was added to a solution containing **1** (02-029-218; 0.4 g, 0.88 mmol), triethylamine (0.43 mL, 3.1 mmol) and anhydrous dichloromethane (40 mL) at 5°C. After 2 h stirring at rt, the reaction mixture was evaporated to obtain a residue, which was washed with hexane (3 x 10 mL), and dried. The residue was purified over silica gel column (230 - 400 mesh, 2.5 x 12 cm) using ethyl acetate as eluent to obtain pure compound **3**. The product was dissolved in 10 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (2.0 mL, 2.0 mmol) with stirring. A white precipitate of hydrogen chloride salt of compound **3** was obtained, which was filtered off, washed with ether (3 x 5 mL), and dried under vacuum. Yield: 0.286 g, 62.2 %. M.p. 130.2 – 133.9 °C. HPLC: Purity 96.92% (retention time: 11.078; mobile phase: 0.1% $\text{H}_3\text{PO}_4/\text{MeCN}$ gradient; column: ACE_C18_5 μm _4-6 x 150 mm). ^1H NMR (400 MHz, DMSO): δ 10.68 (b.s, 1H), 8.11 (m, 2H), 7.88 (m, 2H), 7.69 (m, 1H), 7.65 (m, 3H), 7.59 (m, 1H), 7.45 (m, 1H), 7.19 (m, 2H), 4.55 (s, 4H), 4.05 (d, 2H), 3.56 (d, 2H), 3.44 (m, 2H), 3.26 (m, 2H), 3.12 (m, 2H), 2.63 (m, 2H), 2.02 (m, 2H). ES-MS m/z 519.23 ($\text{C}_{28}\text{H}_{30}\text{N}_4\text{O}_2\text{S}_2 + 1$) $^+$. Analysis calculated for $\text{C}_{28}\text{H}_{30}\text{N}_4\text{O}_2\text{S}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$: % C 58.67; %H 5.80; %N 9.77. Found: %C 58.84; %H 5.54; %N 9.60.


EXAMPLE 133

{5-[3-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl}-1,3-dihydroisoindol-2-yl}-phenyl-methanone

Benzoic anhydride (0.50 g, 2.2 mmol) was added to a solution containing 1 (02-029-218; 0.4 g, 0.88 mmol), triethylamine (0.43 mL, 3.1 mmol), 4-dimethyl-aminopyridine (0.001 g, 0.008 mmol), and anhydrous dichloromethane (40 mL) at room temperature. The reaction mixture was stirred overnight at room temperature. The resulting solution was washed with NaHCO₃, dried over Na₂SO₄, and evaporated. The residue thus obtained was purified over silica gel column (230 - 400 mesh, 2.5 x 12 cm), using ethyl acetate:methanol solvent mixture (95:5) as eluent to obtain the acylated amine product. The product was dissolved in 10 mL of anhydrous ethyl acetate and to which was added 1M hydrogen chloride solution in ether (2.0 mL, 2 mmol) with stirring. A white precipitate of hydrogen chloride salt was obtained, which was filtered off, washed with ether (2 x 6 mL), and dried under vacuum. Yield: 0.342 g, 74.4 %. M.p. 120.1 – 123.2°C. HPLC: Purity 97.45% (retention time: 14.707; mobile phase: 0.1% H₃PO₄/MeCN gradient; column: ACE_C18_5μm_4-6 x 150 mm). ¹H NMR (400 MHz, DMSO): δ 11.27 (b.s, 1H), 8.13 (m, 2H), 7.58 (m, 3H), 7.49 (m, 4H), 7.34 (m, 1H), 7.19 (m, 2H), 4.84 (m, 2H), 4.74 (m, 2H), 4.02 (m, 2H), 3.86 (b.s, 1H), 3.59 (m, 4H), 3.15 (m, 4H), 2.68 (m, 2H), 2.08 (m, 2H). ES-MS m/z 482.65 (C₂₉H₃₀N₄OS + 1)⁺. Analysis calculated for C₂₉H₃₀N₄OS.HCl.H₂O: % C 64.85; % H 6.19; % N 10.43. Found % C 64.39; % H 5.96; % N 10.07.

EXAMPLE 134

1-(3,4-Dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoro thanone




5

To a stirred solution of 1,2,3,4-tetrahydroisoquinoline (10.0 mL, 79.886 mmol) in anhydrous CH_2Cl_2 (200 mL) and pyridine (7.2 mL, 89.021 mmol) under a nitrogen atmosphere was added trifluoroacetic anhydride (12.4 mL, 87.791 mmol). The reaction was stirred overnight at ambient temperature. The reaction was quenched by slow addition of sat. NaHCO_3 solution (50 mL) and transferred to a separatory funnel. The layers were separated and the organic layer was extracted with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. The resulting yellow oil was eluted through a flash column (silica gel 60, 230-400 mesh, 0-3% MeOH in CH_2Cl_2 gradient over 1 h) to give a yellow oil. Yield: 17.1459 g (74.808, 94%). MS (APCI), $(\text{M}+1)^+ = 230$. $^1\text{H-NMR}$ (400 MHz, CDCl_3 , δ): 7.22 (m, 2 H), 7.15 (m, 2 H), 4.78 (s, 1.3 H), 4.73 (s, 0.7 H), 3.88 (t, $J=6.0$ Hz, 0.7 H), 3.83 (m, 1.3 H), 2.95 (q, $J=6.0$ Hz, 2 H).

20

EXAMPLE 135

1-[7-(2-Chloro-acetyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoroethanone



25

To a stirred solution of 1-(3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (16.7121 g, 72.915 mmol) in anhydrous CH_2Cl_2 (182 mL) was added chloroacetyl chloride (7.0 mL, 87.515 mmol). The reaction was heated to 40 $^\circ\text{C}$ (oil bath). Aluminum chloride (38.90 g, 291.735 mmol) was slowly added in portions. The process was slightly exothermic. A reflux

30

condenser was attached and the reaction was heated to reflux. After 2.5 h, the reaction was cooled to ambient temperature and slowly poured into an ice bath and stirred vigorously. The mixture was transferred to a separatory funnel and the aqueous layer extracted with additional CH₂Cl₂.
5 The organic portions were combined and extracted with sat. NaHCO₃ solution, passed through a phase separator and then concentrated *in vacuo* to a yellow solid. The solid was eluted through a flash column (silica gel 60, 230-400 mesh, 2% MeOH in CH₂Cl₂) to give an impure yellow solid. The solid was repurified by flash column under the same condition
10 and then recrystallized from EtOAc/hexanes to give pure product as a yellow solid. Yield: 10.5912 g (34.648 mmol, 48%). MS (APCI, (M-1)⁺ = 304. ¹H-NMR (400 MHz, CDCl₃, δ): 7.78 (m, 2 H), 7.30 (m, 1 H), 4.85 (s, 1.3 H), 4.80 (s, 0.7 H), 4.66 (d, J=2.69 Hz, 2 H), 3.89 (m, 2 H), 3.02 (m, 2 H).

EXAMPLE 136

1-[7-(2-Chloro-ethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone




To a stirred solution of 1-[7-(2-chloro-acetyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoroethanone (10.5851 g, 34.628 mmol) in boron trifluoride etherate (BF₃•Et₂O, 26.4 mL, 0.208 mol) in a sealed tube was
25 added triethylsilane (33.2 mL, 0.208 mol). The tube was sealed and then placed into a preheated 80 °C oil bath. After 4 h, the reaction was cooled to ambient temperature and poured into an ice bath and extracted with CH₂Cl₂ (3 x 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to give a brown oil.
30 The oil was eluted through a flash column (silica gel 60, 230-400 mesh, 10-25% EtOAc in hexanes gradient over 1 h) to give a brown oil. Yield:

3.5199 g (12.067 mmol, 35%). MS (APCI), $(M+1)^+ = 292$. $^1\text{H-NMR}$ (400 MHz, CDCl_3 , δ): 7.09 (m, 2 H), 6.99 (m, 1 H), 4.77 (s, 1.3 H), 4.72 (s, 0.7 H), 3.85 (m, 2 H), 3.70 (m, 2 H), 3.03 (m, 2 H), 2.93 (m, 2 H).

5

EXAMPLE 137

1-[7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoroethanone methane sulfonate



10

A mixture of 3-piperazin-1-yl-benzo[d]isothiazole hydrochloride (0.4056 g, 1.417 mmol), 1-[7-(2-chloro-ethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone (0.3755 g, 1.287 mmol), anhydrous sodium carbonate (0.3019 g, 2.848 mmol) and potassium iodide (0.0259 g, 0.156 mmol) in acetonitrile (10 mL) was allowed to react at 175 °C for 0.5 h in a microwave reactor. The reaction was cooled to ambient temperature. CH_2Cl_2 and H_2O were added and the solution was mixed well then poured into a phase separator. The organic layer was concentrated *in vacuo* to give an oil. The oil was eluted through a flash column (silica gel 60, 230-400 mesh, 30-100% EtOAc in CH_2Cl_2 gradient over 1 h) to give a white waxy/gummy solid. Yield: 0.4106 g (0.865 mmol, 67 %). The solid (0.405 g, 0.853 mmol) was taken up in THF (8.5 mL) and heated to 40 °C. Methanesulfonic acid (55.5 μL , 0.855 mmol) was added and after 5 min, the reaction was allowed to cool to ambient temperature. The product was allowed to crystallize overnight. Hexanes were added to the reaction mixture and the solid was filtered and washed with hexanes. The wet solid was dried in a vacuum oven at 50 ° to give a white/off-white crystalline solid as the mesylate salt. CHN: Calculated for $\text{C}_{24}\text{H}_{25}\text{F}_3\text{N}_4\text{OS}\cdot\text{CH}_4\text{O}_3\text{S}$: C, 52.62; H, 5.12; N, 9.82. Found: C, 52.36, H, 4.98; N, 9.69. $^1\text{H-NMR}$ (400 MHz, CDCl_3 , δ): 11.66 (s, 1 H), 7.84 (d, $J=7.42$ Hz, 2 H), 7.52 (m, 2 H),

15

20


25

30

7.41 (m, 1 H), 7.12 (m, 2 H), 4.76 (m, 4 H), 4.17 (m, 2 H), 4.00 (m, 4 H),
3.82 (m, 2 H), 3.27 (m, 3 H), 2.91 (m, 6 H).

EXAMPLE 138

5



1,2,3,4-Tetrahydroquinoline (77).

Beilstein Registry Number 116149; CAS Registry Number 635-46-1

10

(3,4-Dihydro-2H-quinolin-1-yl)(4-fluorophenyl)methanone (78).

CAS Registry Number 313276-23-2

2-Chloro-1-[1-(4-fluorobenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl]ethanon (79).

Carbon disulfide (100 mL) and chloroacetyl chloride (6.0 mL, 75 mmol) were added sequentially to a mechanically stirred mixture of compound **78** (13 g crude, 48 mmol theoretical) and AlCl₃ (24 g, 180 mmol) under N₂. The mixture was heated to reflux for 3 h, then allowed to cool. After sitting at room temperature overnight, the clear liquid top phase was decanted (by pipet) off of the dark oil lower phase. Ice water (250 mL) was added cautiously to the stirred dark oil. Then, 6 M HCl (150 mL) was added to the stirred mixture. After stirring for 30 min, the solid was collected by suction filtration washing several times with H₂O. The solid was dried in a vacuum oven at 50 °C for 3 d to give ketone **79** (14.9 g, 93% from **77**) as a brown amorphous solid: ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 1.8 Hz, 1H), 7.49 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.37–7.46 (m, 2H), 6.96–7.06 (m, 2H), 6.83 (d, *J* = 8.6 Hz, 1H), 4.63 (s, 2H), 3.92 (t, *J* = 6.4 Hz, 2H), 2.93 (t, *J* = 6.6 Hz, 2H), 2.01–2.13 (m, 2H); ESI MS *m/z* 332 [C₁₈H₁₅ClFNO₂ + H]⁺.

[6-(2-Chloroethyl)-3,4-dihydro-2H-quinolin-1-yl](4-fluorophenyl)methanone (80).

Triethylsilane (7.0 mL, 44 mmol) was added portionwise over 10 min to a stirred solution of ketone **79** (5.03 g, 15.2 mmol) in trifluoroacetic acid (20 mL) under N₂. The mixture was heated to 50 °C for 17 h, then allowed to cool. The mixture (a dark brown solution) was poured into a stirred mixture of 1M NaOH (300 mL) and ice (100 mL). The two-phase mixture was stirred for 1 h, during which time the dark oil turned into a brown solid. The mixture was extracted with EtOAc (200 mL), which dissolved the brown solid. The organic phase was washed with H₂O (200 mL) and sat'd NaCl (100 mL), dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue (brown solid and clear, colorless oil) was purified by column chromatography (silica gel (120 g), 10–40% EtOAc/hexanes) to give compound **80** (4.35 g, 90%) as a yellow waxy solid: ¹H NMR (300 MHz, CDCl₃) δ 7.32–7.41 (m, 2H), 7.01 (br s, 1H),

6.91–7.00 (m, 2H), 6.74 (dd, $J = 8.2, 1.7$ Hz, 1H), 6.63 (d, $J = 8.1$ Hz, 1H), 3.89 (t, $J = 6.5$ Hz, 2H), 3.66 (t, $J = 7.4$ Hz, 2H), 2.97 (t, $J = 7.4$ Hz, 2H), 2.83 (t, $J = 6.6$ Hz, 2H), 1.98–2.10 (m, 2H); ESI MS m/z 318 [$C_{18}H_{17}ClFNO + H$]⁺.

5

{6-[2-(4-Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-3,4-dihydro-2H-quinolin-1-yl}(4-fluorophenyl)methanone (81).

A stirred mixture of chloride **80** (2.00 g, 6.29 mmol), 3-piperazin-1-yl-benzo[d]isothiazole hydrochloride (**9**, 1.82 g, 7.12 mmol), K_2CO_3 (2.34 g, 16.9 mmol), and NaI (1.00 g, 6.67 mmol) in anhyd CH_3CN (60 mL) under N_2 was heated to reflux for 3 d, then allowed to cool. The mixture was diluted with EtOAc (300 mL), then washed twice with H_2O (300 mL), once with sat'd NaCl (100 mL), dried over Na_2SO_4 , filtered, and the solvent was removed in vacuo. The residue was purified by column chromatography (silica gel (150 g), 40–60% EtOAc/hexanes containing 1% Et_3N) to give compound **81** (2.75 g, 87%) as a sticky oil and solid mixture. The product was dissolved in warm EtOAc (60 mL), then allowed to cool with stirring. A small amount of precipitate was observed after 30 min. The mixture was diluted with hexanes (120 mL) portionwise over 2 h. After stirring an additional hour, the precipitate was collected by suction filtration washing with hexanes, then dried in vacuo at 46 °C for 3 d to give compound **81** (1.71 g, 54%) as a white amorphous solid: mp 126–129 °C; 1H NMR (300 MHz, $CDCl_3$) δ 7.91 (d, $J = 8.1$ Hz, 1H), 7.82 (d, $J = 8.1$ Hz, 1H), 7.47 (td, $J = 7.6, 1.0$ Hz, 1H), 7.32–7.41 (m, 3H), 7.02 (br s, 1H), 6.91–7.00 (m, 2H), 6.76 (dd, $J = 8.2, 1.5$ Hz, 1H), 6.60 (br d, $J = 7.7$ Hz, 1H), 3.89 (t, $J = 6.5$ Hz, 2H), 3.54–3.63 (m, 4H), 2.60–2.87 (m, 10H), 2.05 (p, $J = 6.6$ Hz, 2H); IR (ATR) 2947, 2835, 1634, 1600, 1504, 1374, 1271, 1227 cm^{-1} ; ESI MS m/z 501 [$C_{29}H_{29}FN_4OS + H$]⁺; HPLC >99% (AUC), $t_R = 14.77$ min. Anal. calcd. for $C_{29}H_{29}FN_4OS$: C, 69.57; H, 5.84; N, 11.19. Found: C, 69.36; H, 5.86; N, 11.03.


30

{6-[2-(4-Benzo[d]isoxazol-3-ylpiperazin-1-yl)thyl]-3,4-dihydro-2H-quinolin-1-yl}(4-fluorophenyl)methanon (82).

A stirred mixture of chloride **80** (2.30 g, 7.24 mmol), 3-piperazin-1-yl-benzo[d]isoxazole hydrochloride (**11**, 2.03 g, 8.47 mmol), K₂CO₃ (2.66 g, 19.2 mmol), and NaI (1.24 g, 8.27 mmol) in anhyd CH₃CN (75 mL) under N₂ was heated to reflux for 3 d, then allowed to cool. The mixture was diluted with EtOAc (300 mL), then washed twice with H₂O (300 mL). The organic phase was diluted with more EtOAc (200 mL) to dissolve some solid particles, then washed with sat'd NaCl (100 mL), dried over Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was dissolved in hot 10% MeOH/EtOAc (220 mL), then allowed to cool with stirring. After stirring for 4 h, no precipitate had formed. The mixture was diluted portionwise with hexanes (200 mL) over the next 2 h to promote precipitation of the product. After stirring overnight, the precipitate was collected by suction filtration washing with 50% EtOAc/hexanes, then hexanes, then dried in vacuo at 49 °C for 20 h to give compound **82** (1.65 g, 47%) as a white amorphous solid: mp 170–172 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, *J* = 8.1 Hz, 1H), 7.43–7.53 (m, 2H), 7.33–7.41 (m, 2H), 7.18–7.26 (m, 1H), 7.01 (br s, 1H), 6.96 (t, *J* = 8.7 Hz, 2H), 6.75 (dd, *J* = 8.2, 1.5 Hz, 1H), 6.60 (br d, *J* = 7.8 Hz, 1H), 3.89 (t, *J* = 6.5 Hz, 2H), 3.58–3.65 (m, 4H), 2.58–2.86 (m, 10H), 2.05 (p, *J* = 6.5 Hz, 2H); IR (ATR) 1630, 1602, 1527, 1498, 1445, 1385, 1230 cm⁻¹; ESI MS *m/z* 485 [C₂₉H₂₉FN₄O₂ + H]⁺; HPLC 98.8% (AUC), *t*_R = 14.16 min. Anal. calcd. for C₂₉H₂₉FN₄O₂: C, 71.88; H, 6.03; N, 11.56. Found: C, 71.75; H, 6.08; N, 11.38.

EXAMPLE 139


1-(4-Fluoro-2,3-dihydro-indol-1-yl)-ethanone



A 10 mL flask equipped with a magnetic stir bar was charged with 4-Fluoro-1H-indole (1.0g, 7.4 mmol). The solid was dissolved in glacial acetic acid (10mL). Sodium cyanoborohydride (932 mg, 14.8 mmol) was added portion-wise, and the reaction stirred at ambient temperature while being monitored by TLC. After 72 hours, the reaction was quenched by drop-wise addition of H₂O and the pH was adjusted to ~8 with 1N NaOH. The aqueous layer was extracted with CH₂Cl₂ (3x). The organic extracts were combined, dried over MgSO₄, filtered, and concentrated *in vacuo*. A yellow oil weighing 1.14g was obtained. The yellow oil was dissolved in THF (50 mL). Triethylamine (1.7 mL, 12.5 mmol) was added with stirring, followed by acetyl chloride (688 μ L, 9.9 mmol). The reaction stirred overnight for 15 hours and was then quenched by drop-wise addition of H₂O. The aqueous phase was extracted with CH₂Cl₂ (3x), the combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo* to yield 1.58 g of a light yellow solid. The yellow solid was recrystallized from 2-propanol to yield 1-(4-Fluoro-2,3-dihydro-indol-1-yl)-ethanone (3) as white needle crystals weighing 858 mg (65%, 2 steps).

EXAMPLE 140

1-(1-Acetyl-4-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone




A 50 mL flask was equipped with a magnetic stir bar, charged with 1-(4-Fluoro-2,3-dihydro-indol-1-yl)-ethanone (358 mg, 2.0 mmol) and aluminum chloride (400 mg, 3 mmol). The flask was fitted with a nitrogen bubbler, purged with nitrogen gas and cooled to 0°C in an ice water bath. Chloro-acetyl chloride (242 μ L, 3.0 mmol) was added drop-wise to the stirring solution, and the reaction was allowed to gradually warm to ambient temperature. The reaction stirred at room temperature for two

hours, and was then fitted with a condenser and heated to reflux. After an additional two hours, an additional 1.5 equivalents of AlCl_3 (400 mg) were added and the reaction stirred overnight at reflux. When all starting material had disappeared by TLC, the reaction was quenched by drop-wise addition of H_2O . The contents of the flask were extracted with CH_2Cl_2 (3x) and the combined organic extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo* to yield 368 mg of a brown solid that was shown to be the desired product 1-(1-Acetyl-4-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone (66%).

EXAMPLE 141


1-[5-(2-Chloro-ethyl)-4-fluoro-2,3-dihydro-indol-1-yl]-ethanone



A 25 mL flask equipped with a magnetic stir bar was charged with 1-(1-Acetyl-4-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone (368 mg, 1.44 mmol), and the contents were dissolved in trifluoroacetic acid (3.2 mL). The flask was fitted with a rubber septum and purged with nitrogen gas. After drop-wise addition of triethylsilane (690 μL , 4.32 mmol), the reaction was heated to 50°C in an oil bath. Stirring continued for 4 hours, after which time no starting material was visible by TLC. The contents of the flask were poured into a separatory funnel containing water and extracted with dichloromethane (3x). The organic extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo* to yield 334 mg of a brown solid shown to be the desired 1-[5-(2-Chloro-ethyl)-4-fluoro-2,3-dihydro-indol-1-yl]-ethanone (89%).

EXAMPLE 142


1-[5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone



A microwave vessel equipped with a magnetic stir bar was charged with 1-[5-(2-Chloro-ethyl)-4-fluoro-2,3-dihydro-indol-1-yl]-ethanone (121 mg, 0.5 mmol), 3-Piperazin-1-yl-benzo[d]isoxazole (180 mg as the HCl salt, 0.75 mmol), and sodium carbonate (106 mg, 1 mmol). The contents of the vessel were diluted with 2.5 mL H₂O, the vessel was sealed, placed in a CEM Discover microwave, and heated to 175°C for a duration of 10 minutes. After cooling to room temperature, the contents were diluted with 2 mL of an 8:1 solution of ethanol:NH₄OH and extracted three times with dichloromethane. The combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo* to yield 367 mg of a crude brown solid. The solid was purified on a column of silica gel (15g) using a slow elution gradient of CH₂Cl₂ to 100:8:1 CH₂Cl₂:ethanol:NH₄OH over the course of an hour. The isolated brown solid weighed 148 mg (73%).

EXAMPLE 143

1-[5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone




1-[5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone was prepared in a similar fashion as described above for 1-[5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone starting with 1-[5-(2-Chloro-ethyl)-4-

(t, $J=8.55$ Hz, 2 H) 6.97 (d, $J=8.06$ Hz, 1 H) 7.11 (d, $J=8.06$ Hz, 1 H) 8.08 (d, $J=8.06$ Hz, 1 H)

EXAMPLE 146


1-(1-Acetyl-4-chloro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone



1-(1-Acetyl-4-chloro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone was prepared in a similar fashion as described above for 1-(1-Acetyl-4-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone starting with 1-(4-Chloro-2,3-dihydro-indol-1-yl)-ethanone] yield: 180 mg (26%) ^1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.24 (s, 3 H) 3.25 (t, $J=8.67$ Hz, 2 H) 4.14 (m, 2 H) 4.68 (s, 2 H) 7.57 (d, $J=8.30$ Hz, 1 H) 8.14 (d, $J=8.30$ Hz, 1 H)

EXAMPLE 147

1-[4-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone




1-[4-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone was prepared in a similar fashion as described above for 1-[5-(2-Chloro-ethyl)-4-fluoro-2,3-dihydro-indol-1-yl]-ethanone starting with 1-(1-Acetyl-4-chloro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone yield: 168g (84%) ^1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.20 (s, 3 H) 3.17 (m, 4 H)

3.68 (t, $J=7.45$ Hz, 2 H) 4.09 (t, $J=8.55$ Hz, 2 H) 7.09 (d, $J=8.06$ Hz, 1 H)
8.03 (m, $J=8.06$ Hz, 1 H).

EXAMPLE 148


5 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-4-chloro-2,3-**
dihydro-indol-1-yl}-ethanone



10 1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-4-chloro-2,3-
dihydro-indol-1-yl}-ethanone was prepared in a similar fashion as described
above for 1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-4-fluoro-
2,3-dihydro-indol-1-yl}-ethanone starting with 1-[5-(2-Chloro-ethyl)-4-
chloro-2,3-dihydro-indol-1-yl]-ethanone and 3-Piperazin-1-yl-
15 benzo[d]isothiazole. Yield: 117 mg (83%), Isolated in 100% purity @ 254
nm; LCMS (APCI) 441.1 [M+H]⁺.

EXAMPLE 149


20 **1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-4-chloro-2,3-**
dihydro-indol-1-yl}-ethanone



25 1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-4-chloro-2,3-
dihydro-indol-1-yl}-ethanone was prepared in a similar fashion as described
above for 1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-4-fluoro-
2,3-dihydro-indol-1-yl}-ethanone starting with 1-[5-(2-Chloro-ethyl)-4-
chloro-2,3-dihydro-indol-1-yl]-ethanone and 3-Piperazin-1-yl-
benzo[d]isoxazole. Yield: 75 mg (59%), Isolated in 100% purity @ 254 nm;
30 LCMS (APCI) 425.0 [M+H]⁺.

EXAMPLE 150

1-(6-Fluoro-2,3-dihydro-indol-1-yl)-ethanone




5

1-(6-Fluoro-2,3-dihydro-indol-1-yl)-ethanone was prepared in a similar fashion as described above for 1-(4-Fluoro-2,3-dihydro-indol-1-yl)-ethanone starting with 6-fluoroindole yield: 1.85 g (70%) ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.20 (s, 3 H) 3.14 (t, $J=8.55$ Hz, 2 H) 4.08 (m, 2 H) 6.68 (t, $J=8.55$ Hz, 1H) 7.05 (m, 1H) 7.94 (d, $J=10.75$ Hz, 1 H).

10

EXAMPLE 151

1-(1-Acetyl-6-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone




15

1-(1-Acetyl-6-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone was prepared in a similar fashion as described above for 1-(1-Acetyl-4-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone starting with 1-(6-Fluoro-2,3-dihydro-indol-1-yl)-ethanone yield: 665 mg (52%) ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.25 (s, 3 H) 3.20 (t, $J=8.43$ Hz, 2 H) 4.15 (t, $J=8.43$ Hz, 2 H) 4.70 (d, $J=2.93$ Hz, 2 H) 7.76 (d, $J=6.84$ Hz, 1 H) 7.97 (d, $J=13.19$ Hz, 1 H).

20

EXAMPLE 152

1-[5-(2-Chloro-ethyl)-6-fluoro-2,3-dihydro-indol-1-yl]-ethanone



5


1-[5-(2-Chloro-ethyl)-6-fluoro-2,3-dihydro-indol-1-yl]-ethanone was prepared in a similar fashion as described above for starting with 1-(1-Acetyl-6-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone yield: 168g (84%) ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.20 (s, 3 H) 3.01 (t, $J=7.08$ Hz, 2 H) 3.14 (t, $J=8.30$ Hz, 2 H) 3.67 (t, $J=7.08$ Hz, 2 H) 4.07 (t, $J=8.55$ Hz, 2 H) 6.98 (d, $J=7.33$ Hz, 1 H) 7.92 (d, $J=11.72$ Hz, 1 H).

10

EXAMPLE 153

1-[5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-fluoro-2,3-dihydro-indol-1-yl]-ethanone

15




20

1-[5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-fluoro-2,3-dihydro-indol-1-yl]-ethanone was prepared in a similar fashion as described above for 1-[4-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone starting with 1-[5-(2-Chloro-ethyl)-6-fluoro-2,3-dihydro-indol-1-yl]-ethanone and 3-Piperazin-1-yl-benzo[d]isothiazole. Yield: 146 mg (57%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 425.1 $[M+H]^+$.

25

EXAMPLE 154


1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-6-fluoro-2,3-dihydro-indol-1-yl}-ethanone



1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-6-fluoro-2,3-dihydro-indol-1-yl}-ethanone was prepared in a similar fashion as described above for 1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone starting with 1-[5-(2-Chloro-ethyl)-6-fluoro-2,3-dihydro-indol-1-yl]-ethanone and 3-Piperazin-1-yl-benzo[d]isoxazole. Yield: 123mg (50%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 409.1 [M+H]⁺.

EXAMPLE 155


1-(6-Chloro-2,3-dihydro-indol-1-yl)-ethanone



1-(6-Chloro-2,3-dihydro-indol-1-yl)-ethanone] was prepared in a similar fashion as described above for 1-(4-Fluoro-2,3-dihydro-indol-1-yl)-ethanone starting with 6-chloroindole yield: 2.05 g (80%) ¹H NMR (400 MHz, DMSO-D₆) δ ppm 2.10 (s, 3 H) 3.06 (t, *J*=8.42 Hz, 2 H) 4.06 (m, 2 H) 6.97 (dd, *J*=7.93, 2.07 Hz, 1 H) 7.18 (d, *J*=8.05 Hz, 1 H) 7.99 (d, *J*=2.20 Hz, 1 H).

EXAMPLE 156


1-(1-Acetyl-6-chloro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone



1-(1-Acetyl-6-chloro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone was prepared in a similar fashion as described above for 1-(1-Acetyl-4-fluoro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone starting with 1-(6-Chloro-2,3-dihydro-indol-1-yl)-ethanone] yield: 2.8 g (100%) ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.25 (s, 3 H) 3.21 (t, $J=8.54$ Hz, 2 H) 4.14 (t, $J=8.54$ Hz, 3 H) 4.75 (s, 2 H) 7.49 (s, 1 H) 8.29 (s, 1 H).

EXAMPLE 157


1-[6-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone



1-[6-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone was prepared in a similar fashion as described above for 1-[5-(2-Chloro-ethyl)-4-fluoro-2,3-dihydro-indol-1-yl]-ethanone starting with 1-(1-Acetyl-6-chloro-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone yield: 1.87g (96%) ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.10 (s, 3 H) 3.03 (m, 4 H) 3.74 (t, $J=7.08$ Hz, 2 H) 4.06 (t, $J=8.54$ Hz, 2 H) 7.22 (s, 1 H) 8.00 (s, 1 H).

EXAMPLE 158

1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone was prepared in a similar fashion as described above for 1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone starting with 1-[6-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone and 6-Fluoro-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 47 mg (51%). ¹H NMR (400 MHz, DMSO-D₆) δ ppm 2.12 (s, 3 H) 2.52 (m, 2 H) 2.65 (m, 4 H) 2.81 (m, 2 H) 3.07 (m, 2 H) 3.41 (m, 4 H) 4.07 (t, J=8.55 Hz, 2 H) 7.22 (s, 1 H) 7.27 (m, 1 H) 7.93 (m, 1 H) 8.00 (s, 1 H) 8.07 (m, 1 H), Isolated in 97% purity @ 254 nm; LCMS (APCI) 459 [M+H]⁺.

The following compounds were prepared from 1-[6-Chloro-5-(2-chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone and the appropriate piperazine or piperidine in a fashion similar to that reported above.

EXAMPLE 159

1-(6-Chloro-5-{2-[4-(5-methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




Starting with 5-Methoxy-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 52 mg (55%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 471 [M+H]⁺.

5

EXAMPLE 160

1-(6-Chloro-5-{2-[4-(7-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




10

Starting with 7-Fluoro-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 64 mg (70%), Isolated in 94% purity @ 254 nm; LCMS (APCI) 459 [M+H]⁺.

EXAMPLE 161

15

1-(6-Chloro-5-{2-[4-(7-methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




20

Starting with 7-Methoxy-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 49 mg (52%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 471 [M+H]⁺.

EXAMPLE 162

25

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperidin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone




Starting with 3-Piperidin-4-yl-benzo[d]isothiazole. Yield: 54 mg (61%), Isolated in 95% purity @ 254 nm; LCMS (APCI) 440 [M+H]⁺.

5

EXAMPLE 163

1-(6-Chloro-5-{2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




10

Starting with 5-Fluoro-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 52 mg (57%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 459 [M+H]⁺.

EXAMPLE 164

15

1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




20

Starting with 6-Fluoro-3-piperidin-4-yl-benzo[d]isoxazole. Yield: 29 mg (31%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 458 [M+H]⁺.

EXAMPLE 165

25

1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-6-chloro-2,3-dihydro-indol-1-yl)-ethanone




Starting with 3-Piperazin-1-yl-benzo[d]isoxazole. Yield: 14 mg (16%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 425 [M+H]⁺.

5

EXAMPLE 166

1-(6-Chloro-5-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




10

Starting with 5-Fluoro-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 40 mg (45%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 443 [M+H]⁺.

EXAMPLE 167

15

1-(6-Chloro-5-{2-[4-(5-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




20

Starting with 5-Chloro-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 38 mg (41%), Isolated in 91% purity @ 254 nm; LCMS (APCI) 459 [M+H]⁺.

EXAMPLE 168

25

1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




Starting with 6-Fluoro-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 40 mg (44%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 443 [M+H]⁺.

5

EXAMPLE 169

1-(6-Chloro-5-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




10

Starting with 6-Methyl-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 40 mg (46%), Isolated in 91% purity @ 254 nm; LCMS (APCI) 439 [M+H]⁺.

EXAMPLE 170

15

1-(6-Chloro-5-{2-[4-(7-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




20

Starting with 7-Methyl-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 43 mg (49%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 439 [M+H]⁺.

EXAMPLE 171

25

1-{5-[2-(4-Benzo[b]thiophen-3-yl)-piperazin-1-yl]-ethyl}-6-chloro-2,3-dihydro-indol-1-yl)-ethanone




-174-

Starting with 1-Benzo[b]thiophen-3-yl-piperazine. Yield: 79 mg (86%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 458 [M+H]⁺.

EXAMPLE 172


1-(6-Chloro-5-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone



Starting with 3-Piperazin-1-yl-1H-indazole. Yield: 35 mg (41%), Isolated in 100% purity @ 254 nm; LCMS (APCI) 424 [M+H]⁺.

EXAMPLE 173

1-(2,3-Dihydro-indol-1-yl)-ethanone




A solution of 11.2 ml (0.1 mol) of indoline (commercially available from Aldrich Chemical company) in THF (200ml) was treated with triethyl amine (15.33 ml, 0.11 mol) followed by dropwise addition of acetyl chloride (7.82 ml, 0.11 mol). The reaction was stirred at room temperature for 20 hours, quenched with water (50 ml) followed by concentration in vacuo. White solid was collected and washed with water. Yield: 15.7 g (97.5%)
1H NMR (400 MHz, DMSO-D6) δ ppm 2.11 (s, 3 H) 3.09 (t, J=8.55 Hz, 2 H) 4.03 (m, 2 H) 6.95 (m, 1 H) 7.10 (s, 1 H) 7.19 (d, J=6.84 Hz, 1 H) 8.01 (d, J=7.82 Hz, 1 H).

EXAMPLE 174

1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-2-chloro- thanone


-175-



1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone was prepared in a similar fashion as described above for (5) starting with 1-(2,3-dihydro-indol-1-yl)-ethanone] yield: 11.85 g (100%) ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.26 (d, $J=3.90$ Hz, 3 H) 3.25 (t, $J=8.42$ Hz, 2 H) 4.13 (t, $J=8.54$ Hz, 2 H) 4.67 (s, 2 H) 7.80 (m, 2 H) 8.26 (d, $J=8.30$ Hz, 1 H).

EXAMPLE 175

1-[5-(2-Chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone




1-[5-(2-Chloro-ethyl)-2,3-dihydro-indol-1-yl]-ethanone was prepared in a similar fashion as described above for (6) starting with 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-2-chloro-ethanone yield: 2.85 g (85%) ¹H NMR (400 MHz, DMSO-D₆) δ ppm 2.11 (s, 3 H) 2.92 (t, $J=7.08$ Hz, 2 H) 3.08 (t, $J=8.55$ Hz, 2 H) 3.76 (t, $J=7.20$ Hz, 2 H) 4.04 (t, $J=8.55$ Hz, 2 H) 7.00 (d, $J=8.30$ Hz, 1 H) 7.11 (s, 1 H) 7.92 (d, $J=8.30$ Hz, 1 H).

EXAMPLE 176

1-(5-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2,3-dihydro-indol-1-yl)-ethanone

-176-




1-(5-{2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3-dihydro-indol-1-yl)-ethanone was prepared in a similar fashion as
described above for **(8)** starting with 1-[5-(2-Chloro-ethyl)-2,3-dihydro-indol-
1-yl]-ethanone and 6-Fluoro-3-piperazin-1-yl-benzo[d]isothiazole. The
crude products were purified by HPLC (30x100 mm ODS-A C(18) 5u
column). Yield: 20 mg (24%). R_t (min) reported is for the following HPLC
conditions: 70:30 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA
C₁₈.

Isolated in 100% purity @ 254 nm HPLC: R_t = 9.693; MS (APCI), $(M+1)^+ = 425.1$.

The following compounds were prepared from 1-[5-(2-Chloro-ethyl)-
2,3-dihydro-indol-1-yl]-ethanone and the appropriate Piperazine or
piperidine in a fashion similar to that reported above. The crude products
were purified by HPLC (30x100 mm ODS-A C(18) 5u column).

EXAMPLE 177


1-(5-{2-[4-(5-Methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}- 2,3-dihydro-indol-1-yl)-ethanone



Starting with 5-Methoxy-3-piperazin-1-yl-benzo[d]isothiazole. Yield:
37 mg (42%), Isolated in 95% purity @ 254 nm HPLC: R_t = 16.04; MS
(APCI), $(M+1)^+ = 437.3$.

EXAMPLE 178

1-(5-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanon




5

Starting with 7-Fluoro-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 23 mg (27%), R_t (min) reported is for the following HPLC conditions: 60:40 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 5.725; MS (APCI), (M+1)⁺ = 425.2.

10

EXAMPLE 179

1-(5-{2-[4-(7-Methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




15

Starting with 7-Methoxy-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 23 mg (26%), R_t (min) reported is for the following HPLC conditions: 60:40 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 5.275; MS (APCI), (M+1)⁺ = 437.1.

20

EXAMPLE 180

1-(5-{2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




25

Starting with 5-Fluoro-3-piperazin-1-yl-benzo[d]isothiazole. Yield: 52 mg (57%), R_t (min) reported is for the following HPLC conditions: 70:30 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 14.59; MS (APCI), (M+1)⁺ = 425.2.

5

EXAMPLE 181

1-{5-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-ethanone




10

Starting with 3-Piperazin-1-yl-benzo[d]isoxazole. Yield: 21 mg (27%), R_t (min) reported is for the following HPLC conditions: 70:30 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 7.87; MS (APCI), (M+1)⁺ = 391.1.

15

EXAMPLE 182

1-(5-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




20

Starting with 5-Fluoro-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 15 mg (18%), R_t (min) reported is for the following HPLC conditions: 70:30 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 9.699; MS (APCI), (M+1)⁺ = 409.2.

25

EXAMPLE 183

1-(5-{2-[4-(5-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-thyl}-2,3-dihydro-indol-1-yl)-ethanon




5

Starting with 5-Chloro-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 18 mg (21%), R_t (min) reported is for the following HPLC conditions: 70:30 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 15.722; MS (APCI), (M+1)⁺ = 425.1.

10

EXAMPLE 184

1-(5-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




15

Starting with 6-Fluoro-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 19 mg (23%), R_t (min) reported is for the following HPLC conditions: 60:40 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 9.971; MS (APCI), (M+1)⁺ = 409.2.

20

EXAMPLE 185

1-(5-{2-[4-(7-Methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone




25

Starting with 7-Methyl-3-piperazin-1-yl-benzo[d]isoxazole. Yield: 18 mg (22%), R_t (min) reported is for the following HPLC conditions: 70:30 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 12.705; MS (APCI), (M+1)⁺ = 405.2.

5

EXAMPLE 186

1-{5-[2-(4-Benzo[b]thiophen-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-ethanone




10

Starting with 1-Benzo[b]thiophen-3-yl-piperazine. Yield: 24 mg (30%), R_t (min) reported is for the following HPLC conditions: 60:40 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 5.760; MS (APCI), (M+1)⁺ = 406.1.

15

EXAMPLE 187

1-(5-{2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone



20

Starting with 3-Piperazin-1-yl-1H-indazole. Yield: 32 mg (41%), R_t (min) reported is for the following HPLC conditions: 60:40 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 2.902; MS (APCI), (M+1)⁺ = 391.


25

EXAMPLE 188

5-(2-Chloro-ethyl)-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester

30


-181-



To a suspension 30 g (0.286 mol) of known 5-(2-Chloro-ethyl)-1,3-dihydro-indol-2-one (Lowe, John A., III; Seeger, Thomas F.; Nagel, Arthur A.; Howard, Harry R.; Seymour, Patricia A.; Heym, James H.; Ewing, Frank E.; Newman, Michael E.; Schmidt, Anne W.; et al. **1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents.** Journal of Medicinal Chemistry (1991), 34(6), 1860-6) in anhydrous toluene (600 ml) was added Borane methyl sulfide complex (2.0 M in toluene, 230 ml) and the resulting mixture was refluxed for 5 hours. The mixture was cooled and saturated sodium bicarbonate (300 ml) was added. The mixture was then heated to reflux for an additional 5 hours. The organic solvent was removed in vacuo. To the aqueous residue was added 1,4 dioxane (300 ml), Di-tert-butyl dicarbonate (42 g, 0.192 mol) and the resulting mixture was stirred for 60 hours at room temperature. The reaction was diluted with water, extracted with ethyl acetate, dried, concentrated and the residue was purified via flash chromatography (heptane-ethyl acetate/4:1) to afford solid. Yield: 41.6 g (96%). MS (APCI), $(M+1)^+ = 225.9$.

EXAMPLE 189

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester




A mixture of 5-(2-Chloro-ethyl)-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester (27.7 g, 0.098 mol), 3-piperazin-1-yl-benzo[d]isothiazole hydrochloride (20.2g, 0.079 mol) and sodium carbonate (18.6 g, 0.175

mol) in 1,4-dioxane-water (320 + 560 ml) was stirred at reflux for 48 hours. Additional cesium carbonate (18 g, 0.055mol) was added and the mixture was heated at reflux for an additional 6 hours. Mixture was cooled, diluted with water and extracted with ethyl acetate (2 x 1 L), dried and concentrated, purified via flash chromatography (heptane-ethyl acetate-triethyl amine/2:1:0.01) to provide a white powder. Yield: 26.2 g (67%). MS (APCI), (M+1)⁺ = 465.2

EXAMPLE 190


3-{4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole



5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester was dissolved in 1,4-dioxane (300 ml) and cooled to 10°C before 1,4-dioxane-HCl (4.0N, 700ml) was added and the resulting mixture was stirred at room temperature overnight. The resulting white precipitate was collected via filtration. Yield: 29.5 g (95%)
1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 3.02 (m, 2 H) 3.14 (t, $J=7.69$ Hz, 2 H) 3.25 (d, $J=10.01$ Hz, 4 H) 3.33 (m, 2 H) 3.56 (m, 2 H) 3.71 (t, $J=7.69$ Hz, 2 H) 3.96 (d, $J=10.75$ Hz, 2 H) 7.19 (m, 1 H) 7.28 (m, 3 H) 7.42 (t, $J=7.69$ Hz, 1 H) 7.80 (dd, $J=16.97, 8.18$ Hz, 2 H).

EXAMPLE 191

1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-ethanone




A solution of 3-{4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole (364 mg, 1.0 mmols) in THF (4.0ml) with triethylamine (0.200 ml, 1.5 mmols) was treated with Acetyl chloride (0.078 ml, 1.1 mmols) and stirred for 16 hours at room temperature. The reaction was quenched with sodium hydroxide (1N, 5 ml), extracted with methylene chloride and filtered through 5 μ m PTFE (phase-separating filter), and concentrated in vacuo, followed by a crystallization from isopropyl alcohol to yield: 253 mg (62%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 406.9 [M+H]⁺.

The title compounds of Examples 192 through 220 were prepared from 3-{4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole in a parallel fashion to that reported above using the appropriate commercially available acid chloride.

EXAMPLE 192


1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-propan-1-one



Treating with propionyl chloride. Yield: 301 mg (72%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 420.9 [M+H]⁺.

EXAMPLE 193

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-butan-1-one




-184-

Treating with butyryl chloride. Yield: 240 mg (55%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 435.0 [M+H]⁺.

EXAMPLE 194


5 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one**



10 Treating with isobutyryl chloride. Yield: 165 mg (38%) Isolated in 98.4% purity @ 254 nm; LCMS (APCI) 435.0 [M+H]⁺.

EXAMPLE 195


15 **{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-cyclopropyl-methanone**



20 Treating with cyclopropane carbonyl chloride. Yield: 311 mg (72%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 432.9 [M+H]⁺.

EXAMPLE 196


25 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-pentan-1-one**



Treating with valeryl chloride. Yield: 158 mg (35%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 448.9 [M+H]⁺.

EXAMPLE 197


5 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one**



10 Treating with isovaleryl chloride. Yield: 270 mg (60%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 448.9 [M+H]⁺.

EXAMPLE 198


15 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2,2-dimethyl-propan-1-one**



20 Treating with trimethyl acetyl chloride. Yield: 142 mg (32%) Isolated in 96% purity @ 254 nm; LCMS (APCI) 448.9 [M+H]⁺.

EXAMPLE 199


25 **{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone**



Treating with cyclopentane carbonyl chloride. Yield: 320 mg (70%)
Isolated in 100% purity @ 254 nm; LCMS (APCI) 460.9 [M+H]⁺.

EXAMPLE 200


5 **{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-cyclohexyl-methanone**



10 Treating with cyclohexane carbonyl chloride. Yield: 358 mg (76%)
Isolated in 100% purity @ 254 nm; LCMS (APCI) 474.9 [M+H]⁺.

EXAMPLE 201


15 **{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-phenyl-methanone**



20 Treating with benzoyl chloride. Yield: 352 mg (75.2%) Isolated in
100% purity @ 254 nm; LCMS (APCI) 468.9 [M+H]⁺.

EXAMPLE 202


25 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl}-propan-1-one**



Treating with methane sulfonyl chloride. Yield: 321 mg (73%)
Isolated in 100% purity @ 254 nm; LCMS (APCI) 442.9 [M+H]⁺.

EXAMPLE 203

5 **5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid methylamide**




10 A solution of 3-[4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl]-benzo[d]isothiazole (150 mg, 0.4 mmols in THF (5ml) was treated by dropwise addition with above methyl isocyanate(0.03 ml) at room temperature and allowed to stir for 72 hours. The reaction was concentrated to dryness, diluted with H₂O and extracted with methylene
15 chloride and filtered through 5 µm PTFE (phase-separating filter), and concentrated in vacuo, followed by a crystallization from acetonitrile to yield: 124 mg (74%). R_t (min) reported is for the following HPLC conditions: 65:35 [H₂O:MeCN]+0.1% TFA, 1.5 mL/min, 250x4.6 mm LUNA C₁₈. Isolated in 100% purity @ 254 nm HPLC: R_t = 3.70; MS (APCI), (M+1)⁺ =
20 422.2.

The following compounds were prepared from 3-[4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl]-benzo[d]isothiazole in a fashion similar to that reported above using the appropriate commercially available isocyanate.

25

EXAMPLE 204

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid ethylamide




30

Treating with ethyl isocyanate; yield: 120 mg (69%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 4.474$; MS (APCI), $(M+1)^+ = 436.3$.

5

EXAMPLE 205

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid propylamide




10

Treating with n-propyl isocyanate; yield: 118 mg (66%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 5.864$; MS (APCI), $(M+1)^+ = 450.3$.

EXAMPLE 206

15

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid isopropylamide




20

Treating with isopropyl isocyanate; yield: 128 mg (71%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 5.834$; MS (APCI), $(M+1)^+ = 450.2$.

EXAMPLE 207

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid tert-butylamide

25




-189-

Treating with t-butyl isocyanate; yield: 109 mg (59%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 9.459$; MS (APCI), $(M+1)^+ = 464.3$.

EXAMPLE 208


5 **5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid cyclopentylamide**



10 Treating with cyclopentyl isocyanate; yield: 179 mg (94%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 8.975$; MS (APCI), $(M+1)^+ = 476.2$.

EXAMPLE 209


15 **5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid phenylamide**



20 Treating with phenyl isocyanate; yield: 63 mg (32%) Isolated in 100% purity @ 254 nm HPLC: $R_t = 13.091$; MS (APCI), $(M+1)^+ = 484.1$.

EXAMPLE 210


25 **1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-chloro-ethanone**



Chloroacetyl chloride was added dropwise to a solution of 3-{4-[2-(2,3-Dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole in THF at 0°C and allowed to warm to RT with stirring. The reaction was allowed to stir for 16 hours. The reaction was quenched with water and concentrated to dryness. The crude was suspended in CH₂Cl₂ (500ml) and washed with Brine (2X 100ml). The organics were dried with MgSO₄ and filtered. The sample was concentrated to dryness resulting in an off white solid Yield: 4.2 g (95%) MS (APCI), (M+1)⁺ = 441.1.

EXAMPLE 211

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-pyrrolidin-1-yl-ethanone




To a solution of 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-chloro-ethanone (475 mg, 1.1 mmol) in DMF (8 ml) was added sodium carbonate (200 mg, 2.0 mmol) and pyrrolidine (0.125 ml, 1.5 mmol) and the reaction was warmed to 65°C for 4.5 hours. The reaction was poured into water and extracted with methylene chloride, dried, concentrated and purified via medium pressure chromatography (15g silica cartridge) elution with methylene chloride to methylene chloride:ethanol:ammonium hydroxide (100:8:1 over 1 hour). Recrystallization from acetonitrile yielded 181 mg (35%). ¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.67 (s, 4 H) 2.54 (m, 4 H) 2.64 (m, 4 H) 2.70 (m, 2 H) 3.07 (t, J=8.43 Hz, 2 H) 3.31 (m, 4 H) 3.42 (m, 4 H) 4.10 (t, J=8.55 Hz, 2 H) 6.99 (d, J=8.55 Hz, 1 H) 7.09 (s, 1 H) 7.41 (t, J=7.69 Hz, 1 H) 7.53 (t, J=7.57 Hz, 1 H) 7.93 (d, J=8.06 Hz, 1 H) 8.03 (d, J=8.06 Hz, 2 H), MS (APCI), (M+1)⁺ = 476.2.

The following compounds were prepared from 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-chloro-ethanone in a fashion similar to that reported above using the appropriate commercially available amine.

5

EXAMPLE 212

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-diethylamino-ethanone




10

Treating with diethyl amine; Yield: 137 mg (29%) Isolated in 97% purity @ 254 nm; LCMS (APCI) 478.1 [M+H]⁺.

15

EXAMPLE 213

11-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-dimethylamino-ethanone



20


Treating with dimethyl amine; Yield: 158 mg (35%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 450.1 [M+H]⁺.

EXAMPLE 214

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-morpholin-4-yl-ethanone

25

-192-




Treating with Morpholine; Yield: 380 mg (77%) Isolated in 100%
purity @ 254 nm; LCMS (APCI) 492.1 [M+H]⁺.

5

EXAMPLE 215

**1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-
indol-1-yl}-2-piperidin-1-yl-ethanone**




10

Treating with Piperidine; Yield: 150 mg (31%) Isolated in 100%
purity @ 254 nm; LCMS (APCI) 490.2 [M+H]⁺.

15

EXAMPLE 216

**1-{5-[2-(4-Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-
indol-1-yl}-3-chloro-propan-1-one**



20


Sample prepared in a same fashion to example above (1-{5-[2-(4-
Benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-2-
chloro-ethanone) treating with chloro propionyl Chloride. Yield: 4.5 g (99%)
MS (APCI), (M+1)⁺ = 450.0.

The following compounds were prepared from 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-chloro-propan-1-one in a fashion similar to that reported above using the appropriate commercially available amine.

5

EXAMPLE 217

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-pyrrolidin-1-yl-propan-1-one




10

Treating with Pyrrolidine; Yield: 224 mg (42%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 490.1 [M+H]⁺.

15

EXAMPLE 218

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-diethylamino-propan-1-one




20

Treating with diethyl amine; Yield: 220 mg (45%) Isolated in 100% purity @ 254 nm; LCMS (APCI) 492.1 [M+H]⁺.

25

EXAMPLE 219

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-dimethylamino-propan-1-one




Treating with dimethyl amine; Yield: 114 mg (18%) Isolated in 100% purity
@ 254 nm; LCMS (APCI) 464.1 [M+H]⁺

5

EXAMPLE 220

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-morpholin-4-yl-propan-1-one




10

Treating with Morpholine; Yield: 257 mg (51%) Isolated in 100% purity @
254 nm; LCMS (APCI) 506.1 [M+H]⁺

15

EXAMPLE 221

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-piperidin-1-yl-propan-1-one




20

Treating with Piperidine; Yield: 205 mg (41%) Isolated in 100% purity @
254 nm; LCMS (APCI) 504.4 [M+H]⁺

-195-
CLAIMS

1. A compound of the formula 1



5 wherein U is sulfur, oxygen, SO, SO₂, CH₂ or NR³;

 V is nitrogen or carbon;

 Z is nitrogen or carbon;

 A is -(CH₂)_mCH₂-; -(CH₂)_mO-; -(CH₂)_mNR⁴-; or -(CH₂)_mC(R⁵R⁶)-
 10 wherein R⁵ and R⁶ can independently be (C₁-C₄) alkyl optionally
 substituted with from one to three fluorine atoms, (C₁-C₄) alkoxy optionally
 substituted with from one to three fluorine atoms, hydroxy, aminoalkyl or
 R⁵ and R⁶ can together form a carbonyl, and wherein m is an integer from
 one to four;

 R¹ and R² are independently selected from hydrogen, (C₁-C₄) alkyl
 15 optionally substituted with from one to three fluorine atoms, (C₁-C₄) alkoxy
 optionally substituted with from one to three fluorine atoms, halogen, nitro,
 cyano, amino, (C₁-C₄) alkylamino and di-(C₁-C₄) alkylamino;

 R³ and R⁴ are independently selected from hydrogen, (C₁-C₄) alkyl
 20 optionally substituted with from one to three fluorine atoms or (C₁-C₄)
 alkoxy optionally substituted with from one to three fluorine atoms;

 or, when U is NR³, one of R¹ and R² can form, together with the
 carbon to which it is attached, and together with R³ and the nitrogen to
 which it is attached, a heterocyclic ring containing from 4 to 7 ring
 25 members of which from 1 to 3 ring members can be heteroatoms selected
 from nitrogen, oxygen and sulfur, and of which the remaining ring

members are carbon, with the proviso that when R^3 forms a ring with one of R^1 and R^2 , the other of R^1 and R^2 is absent.

X is $(CH_2)_m$ wherein m is an integer from zero to three, with the proviso that when W is absent, m must be greater than or equal to 2;

5 W is $(CH_2)_p$ wherein p is an integer from zero to three, with the proviso that when X is absent, p is greater than or equal to 2;

R^7 and R^8 are selected, independently, from halo (e.g., chloro, fluoro, bromo or iodo), R^1 and $-OR^1$;

10 or R^7 , when attached to a carbon adjacent to one of the carbon atoms shared by both the phenyl ring to which R^7 is attached and the ring containing W, N and X forms, together with a carbon atom of X or a carbon atom of W, a saturated carbocyclic ring containing from three to six carbon atoms;

15 R^9 is selected from phenyl, phenoxy and phenylamino, wherein the phenyl moieties of said phenyl, phenoxy and phenylamino are optionally substituted with from 1-3 substituents independently selected from halo, (C_1-C_3) alkyl optionally substituted with from 1 to 3 fluorine atoms, (C_1-C_3) alkoxy optionally substituted with from 1 to 3 fluorine atoms, nitro, cyano, amino, and (C_1-C_3) alkylamino; or

20 R^9 is a pyrrolidine, piperidine or morpholine ring wherein the point of attachment to D, T or E is the ring nitrogen, and wherein said pyrrolidine, piperidine or morpholine ring can be optionally substituted with one or two substituents selected, independently, from methyl and amino; or

25 R^9 is (C_1-C_6) straight or branched alkyl or (C_3-C_6) cycloalkyl, wherein said straight, branched and cyclic alkyl moieties can be optionally substituted with from one to three halo atoms, (C_1-C_4) alkoxy optionally substituted with from one to three fluorine atoms; or

30 R^9 is halogen, nitro, cyano, amino, (C_1-C_4) alkylamino, di- (C_1-C_4) alkylamino or OR^1 , wherein the alkyl moieties of (C_1-C_4) alkylamino and di- (C_1-C_4) alkylamino can be optionally substituted with an amino group;

E is $-C(O)-$, $-S(O)-$ or $-SO_2-$;

T is $-C(O)-$, $-CO_2-$;

L is $-(CH_2)_n$ wherein n is an integer from 0-3;

D is $-(CH_2)_n$ wherein n is an integer from 1-3, or NR^{10} ;
 R^{10} is hydrogen or straight or branched (C_1 - C_3) alkyl;
and the pharmaceutically acceptable salts of such compounds.

- 5 2. A compound according to claim 1 wherein R^1 is 1,2-benzisothiazoyl.
3. A compound according to claim 1 wherein U is carbon.
4. A compound according to claim 1 wherein U is nitrogen.
- 10 5. A compound according to claim 1 wherein A is CH_2CH_2 .
6. A compound according to claim 1 wherein W is $-S(O)_2N(CH_3)-$.
- 15 7. A compound according to claim 1 wherein W is $-C(O)-$ or $-C(O)NH-$.
8. A compound according to claim 1 wherein R^2 is hydrogen, methyl or ethyl.
- 20 9. A compound according to claim 1 wherein X^1 and X^2 is hydrogen.
10. A compound according to claim 1 wherein W is $-CO-$ and R^3 is (C_1 - C_3)alkyl.
11. A compound according to claim 1 wherein Z is nitrogen.
- 25 12. A compound according to claim 1 wherein X is absent.
13. A compound according to claim 1 wherein R^8 is chloro or methyl.
- 30 14. A compound according to claim 1 wherein W is ethylene or propylene.

15. A compound according to claim 1 wherein M is C(O)R⁹ and R⁹ is (C₁ - C₄)alkyl.
16. A compound according to claim 1 that is selected from the following compounds and their pharmaceutically acceptable salts:
- 1-5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;
- 1-5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;
- 1-7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;
- 1-7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;
- 1-6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;
- 1-7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;
- 1-6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}-2-methyl-propan-1-one;
- 7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-(4-fluoro-phenyl)-methanone;
- 1-7-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-5,5-dimethyl-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-propan-1-one;
- 6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl)-(4-fluoro-phenyl)-methanone;
- 6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl)-(4-fluoro-phenyl)-methanone;
- 1-7-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl]-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl}-ethanone;
- 1-5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-ethanone;
- 1-5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-ethanone;

1-(7-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-ethanone;

1-(7-{2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl}-2,3,4,5-
tetrahydro-benzo[b]azepin-1-yl)-propan-1-one;

5 1-(7-{2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl}-2,3,4,5-
tetrahydro-benzo[b]azepin-1-yl)-2-methyl-propan-1-one;

{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-
2H-quinolin-1-yl}-(4-fluoro-phenyl)-methanone;

10 {6-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-
quinolin-1-yl}-(4-fluoro-phenyl)-methanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-
isoindol-2-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-
isoindol-2-yl}-ethanone;

15 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-diethyl-
2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-
2,3-dihydro-indol-1-yl}-ethanone;

20 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-
2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-6-chloro-
3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

1-{6-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-
dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

25 1-{6-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-7-fluoro-
4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-3,3-
dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

30 1-{6-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-4,4-
dimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-(7-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-
2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-ethanone;

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline;

1-{7-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-2,2,2-trifluoro-ethanone;

5 {6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-cyclopropyl-methanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

10 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-propan-1-one;

{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-(4-fluoro-phenyl)-methanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(3-methoxy-phenyl)-ethanone;

15 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-thiophen-2-yl-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-phenoxy-propan-1-one;

20 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-(2,5-dimethyl-2H-pyrazol-3-yl)-methanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-butan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one;

25 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-m-tolyl-methanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(4-chloro-phenoxy)-ethanone;

30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-3-phenyl-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(3,4-dimethoxy-phenyl)-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(4-chloro-phenyl)-ethanone;

{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-(4-methoxy-phenyl)-methanone;

5 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-phenyl-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-(2,5-dimethoxy-phenyl)-ethanone;

10 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indole-1-carboxylic acid phenyl ester;

{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-furan-2-yl-methanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one;

15 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-benzyloxy-ethanone;

20 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-phenyl-methanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-2-cyclopentyl-ethanone;

6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-1,2,3,4-tetrahydro-quinoline;

25 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4,4,8-trimethyl-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-propan-1-one;
- 5 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-butan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one;
- 10 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-pentan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone;
- 15 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-cyclohexyl-methanone;
- 3-{4-[2-(6-Chloro-1-methanesulfonyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-ethanone;
- 20 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-propan-1-one;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-butan-1-one;
- 25 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-methyl-propan-1-one;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclopropyl-methanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-pentan-1-one;
- 30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-methyl-butan-1-one;

- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2,2-dimethyl-propan-1-one;
- 5 {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclopentyl-methanone;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-cyclohexyl-methanone;
- {5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-phenyl-methanone;
- 10 3-{4-[2-(1-Methanesulfonyl-2,3-dihydro-1H-indol-5-yl)-ethyl]-piperazin-1-yl}-benzo[d]isothiazole;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;
- 1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 15 1-(6-Chloro-5-{2-[4-(5-methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 1-(6-Chloro-5-{2-[4-(7-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 20 1-(6-Chloro-5-{2-[4-(7-methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperidin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;
- 1-(6-Chloro-5-{2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 25 1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;
- 30 1-(6-Chloro-5-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;
- 1-(6-Chloro-5-{2-[4-(5-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(6-Chloro-5-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(6-Chloro-5-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

5 1-(6-Chloro-5-{2-[4-(7-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[b]thiophen-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

10 1-(6-Chloro-5-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(5-Methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

15 1-(5-{2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(7-Methoxy-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

20 1-(5-{2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-ethanone;

1-(5-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

25 1-(5-{2-[4-(5-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-(5-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

30 1-(5-{2-[4-(7-Methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[b]thiophen-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-ethanone;

1-(5-[2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]-ethyl]-2,3-dihydro-indol-1-yl)-ethanone;

1-[5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl]-2-pyrrolidin-1-yl-ethanone;

5 3-(4-[2-[1-(4,5-Dihydro-oxazol-2-yl)-2,3-dihydro-1H-indol-5-yl]-ethyl]-piperazin-1-yl)-benzo[d]isothiazole;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid methylamide;

10 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid ethylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid propylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid isopropylamide;

15 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid tert-butylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid cyclopentylamide;

20 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indole-1-carboxylic acid phenylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid methylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid ethylamide;

25 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid propylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid isopropylamide;

30 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid tert-butylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid cyclopentylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indole-1-carboxylic acid phenylamide;

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indole-1-carboxylic acid isopropylamide;

5 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone;

1-(6-{2-[4-(1H-Indazol-3-yl)-piperazin-1-yl]-ethyl}-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone;

10 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-propan-1-one;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2,2-dimethyl-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-1,3-dihydro-isoindol-2-yl}-2-morpholin-4-yl-ethanone;

15 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-morpholin-4-yl-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-ethanone;

20 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-(3-dimethylamino-pyrrolidin-1-yl)-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-piperidin-1-yl-ethanone;

5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindole-2-carboxylic acid (4-fluoro-phenyl)-amide;

25 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-dimethylamino-ethanone;

{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-phenyl-methanone;

30 1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-[(2-dimethylamino-ethyl)-methyl-amino]-ethanone;

1-{5-[3-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-propyl]-1,3-dihydro-isoindol-2-yl}-2-diethylamino-ethanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-3,4-dihydro-2H-quinolin-1-yl}-ethanone;

5 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-pyrrolidin-1-yl-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-pyrrolidin-1-yl-propan-1-one;

10 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-diethylamino-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-diethylamino-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-dimethylamino-ethanone;

15 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-dimethylamino-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-morpholin-4-yl-ethanone;

20 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-morpholin-4-yl-propan-1-one;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-2-piperidin-1-yl-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2,3-dihydro-indol-1-yl}-3-piperidin-1-yl-propan-1-one;

25 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4-fluoro-2,3-dihydro-indol-1-yl}-ethanone;

30 1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-4-chloro-2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-fluoro-2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-6-fluoro-2,3-dihydro-indol-1-yl}-ethanone;

1-{5-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-ethyl]-4-chloro-2,3-dihydro-indol-1-yl}-ethanone;

5 1-(4-Fluoro-5-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-2,3-dihydro-indol-1-yl)-ethanone;

1-{5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2,3-dihydro-indol-1-yl}-ethanone;

10 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-ethanone;

{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-cyclopropyl-methanone;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-propan-1-one;

15 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-2,2-dimethyl-propan-1-one;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-pentan-1-one;

20 1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-3-methyl-butan-1-one;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-2-methyl-propan-1-one;

1-{6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-butan-1-one; and

25 {6-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl}-phenyl-methanone.

17. A pharmaceutical composition for treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersonia

psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnesic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine,

benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

18. A method for treating a disorder or condition selected from selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD),

Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple
5 aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant
10 syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbitol) and behavioral addictions
15 such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

20 19. A method according to claim 18, wherein the disorder or condition that is being treated is selected from major depression, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthymia, cyclothymia and bipolar disorder.

25 20. A method according to claim 18, wherein the disorder or condition that is being treated is selected from schizophrenia, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a
30 general medical condition, and schizophreniform disorder.

21. A method according to claim 18, wherein the disorder or condition that is being treated is selected from autism, pervasive development disorder, and attention deficit hyperactivity disorder.

5 22. A method according to claim 18, wherein the disorder or condition that is being treated is selected from generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and phobias, including social phobia, agoraphobia, and specific phobias.

10 23. A method according to claim 18, wherein the disorder or condition being treated is schizophrenia with concomitant depression.

24. A method according to claim 18, wherein the disorder or condition being treated is schizophrenia with concomitant anxiety.

15

25. A method of treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or
20 psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior
25 disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders
30 including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional

disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising administering to said mammal:

(a) a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and

(b) another pharmaceutically active compound that is an antidepressant or an anti-anxiety agent, or a pharmaceutically acceptable salt thereof;

wherein the active agents "a" and "b" are present in amounts that render the combination effective in treating such disorder or condition.

26. A pharmaceutical composition for treating a disorder or condition selected from single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal

movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbital) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, comprising:

- (a) a compound according to claim 1 or a pharmaceutically acceptable salt thereof;
- (b) another pharmaceutically active agent that is an antidepressant or an anti-anxiety agent; and
- (c) a pharmaceutically acceptable carrier.

27. A method according to claim 25, wherein the disorder or condition being treated is schizophrenia.

28. A method according to claim 25, wherein the disorder or condition that is being treated is selected from schizophrenia, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, and schizophreniform disorder.

30. A method according to claim 25, wherein the disorder or condition that is being treated is selected from autism, pervasive development disorder, and attention deficit hyperactivity disorder.

31. A method according to claim 25, wherein the disorder or condition that is being treated is selected from generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and phobias, including social phobia, agoraphobia, and specific phobias.


32. A method according to claim 25, wherein the disorder or condition being treated is schizophrenia with concomitant depression.

5 33. A method according to claim 25, wherein the disorder or condition being treated is schizophrenia with concomitant anxiety.

EXOCYCLIC N-SUBSTITUTED HETEROCYCLIC ANALOGS FOR THE TREATMENT OF SCHIZOPHRENIA

ABSTRACT

This invention relates to compounds of the formula 1



wherein R¹ through R⁴, n, U, V, L, Y, Z and X are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.